SUPPLEMENTARY MATERIAL

SUPPLEMENTARY METHODS

Section A. List of codes/keywords used in the systematic search of Phase 1 ...................................................... 2
Section B. Methodology for calculating prevalence, incidence and relative percentages in Phase 1 ................................................................. 33
Section C. Sample size calculations ............................................................................................................................... 37
Section D. Exceptions to the general methodology for PPV calculation in Phase 2 .................................................. 38
Section E. Sensitivity analyses ................................................................................................................................. 38

SUPPLEMENTARY FIGURES

sFigure 1. Algorithm for the systematic search in Phase 1 ...................................................................................... 40
sFigure 2. Annual prevalence (per 10^5 persons) of SSc-ILD in the participating countries during the study period (2014-2018) ................................................................. 41

SUPPLEMENTARY TABLES

sTable 1. PPVs by centre and country .......................................................................................................................... 42
sTable 2. Incidence per 10^5 person-years (95%CI) of ILDs, F-ILDs, IPF, non-IPF F-ILDs, and SSc-ILD in each country and overall, annually and for the whole study period ......................... 43
sTable 3. Prevalence per 10^5 persons (95%CI) of ILD, F-ILD, IPF, non-IPF F-ILD, and SSc-ILD in each country and overall, annually and for the whole study period ........................................ 47
sTable 4. Incidence per 10^5 person-years (95%CI) of non-IPF F-ILD subtypes in each country and overall, annually and for the whole study period ...................................................... 51
sTable 5. Prevalence per 10^5 persons (95%CI) of non-IPF F-ILD subtypes in each country and overall, annually and for the whole study period ........................................................................... 57
sTable 6. Relative percentage (95%CI) of each non-IPF F-ILD subtype in each country, annually and for the whole study period ........................................................................................................ 63
sTable 7. Incidence per 10^5 person-years and prevalence per 10^5 persons (95%CI) of non-F-ILDs in each country and overall, annually and for the whole study period .................................................. 67
sTable 8. Relative percentage (95% CI) of PF behaviour only, UIP-like pattern only, both or none among total non-IPF F-ILD cases and by subtype (all countries) ..................................................... 69
sTable 9. Exploratory p-values for pairwise comparisons of PF behaviour percentage between non-IPF F-ILD subtypes (all countries) .................................................................................. 70
sTable 10. Incidence per 10^5 person-years (95%CI) of PF-ILDs in each country and overall, annually and for the whole study period. Primary analysis (Method 1) and sensitivity analyses (Methods 1b-3) ........................................................................................................ 71
sTable 11. Prevalence per 10^5 persons (95%CI) of PF-ILDs in each country and overall, annually and for the whole study period. Primary analysis (Method 1) and sensitivity analyses (Methods 1b-3) ........................................................................................................ 75
SUPPLEMENTARY METHODS

Section A. List of codes/keywords used in the systematic search of Phase 1

Codes

ICD-10¹

| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|-------------------------------|--------------|-----------------------------|
| ILD     | Non-Autoimmune                | ILD-INSIP    | J84.113 Idiopathic non-specific interstitial pneumonitis |
|         |                               | ILD-IPF      | J84.112 Idiopathic pulmonary fibrosis |
|         |                               | ILD-Unclassifiable IIP | J84.111 Idiopathic interstitial pneumonia, not otherwise specified |
|         |                               | ILD-Hypersensitivity Pneumonitis | J67.x Hypersensitivity pneumonitis due to organic dust |
|         |                               | ILD-Exposure-related ILD | J60 Coal Workers’ Pneumoconiosis |
|         |                               |              | J61 Asbestosis               |
|         |                               |              | J62.8 Pneumoconiosis due to other dust containing silica |
|         |                               |              | J63.x Pneumoconiosis due to other inorganic dusts |
|         |                               |              | J64 Unspecified pneumoconiosis |
|         |                               |              | J66.0 Byssinosis             |

¹ Some subtypes without a specific ICD-10 code were defined by the corresponding ICD-10CM, which contains more granularity, to account for variability in coding practices.
| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|--------------------------------|--------------|-----------------------------|
|         |                                | ILD-Sarcoidosis | D86.0 Sarcoidosis of the lung |
|         |                                |               | D86.2 Sarcoidosis of the lung and lymph nodes |
|         |                                | ILD-Other fibrosing | J84.10 Pulmonary fibrosis, unspecified |
|         |                                |               | J84.89 Other specified interstitial pulmonary diseases |
|         |                                |               | J84.9 Interstitial pulmonary disease, unspecified |
|         |                                | ILD-Other (non-fibrotic) | J84.114 Acute interstitial pneumonitis |
|         |                                |               | J84.116 Cryptogenic organizing pneumonia |
|         |                                |               | J84.117 Desquamative interstitial pneumonia |
|         |                                |               | D76.x Langerhans ’cell histiocytosis |
|         |                                |               | J84.82 Adult Pulmonary Langerhans histiocytosis |
|         |                                |               | J84.83 Surfactant mutations of the lung |
|         |                                |               | J84.115 Respiratory bronchiolitis interstitial lung disease |
| Autoimmune/CTD-ILD | ILD-Rheumatoid Arthritis associated ILD | M05.1 Rheumatoid lung disease with rheumatoid arthritis |
|         | ILD-SSc-ILD | M34.81 Systemic sclerosis with lung involvement |
|         |         | M34.x at any time within the last 10 years + any fibrotic code (J84.10/J84.89/J84.9) |
|         | ILD-Mixed Connective Tissue Disease | M35.1 Other overlap syndromes |
| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|-------------------------------|--------------|------------------------------|
|        |                               |              | M32.13 Lung involvement in SLE |
|        |                               | ILD-Other diffuse CTD | M33.01 Juvenile dermatopolymyositis w lung involvement |
|        |                               |              | M33.11 Other dermatopolymyositis w lung involvement |
|        |                               |              | M33.91 Dermatopolyositis unsp w lung involvement |
|        |                               |              | M33.21 Polymyositis with respiratory involvement |
|        |                               |              | M35.02 Sicca syndrome with lung involvement |

**NOTE:** ".x" in a code denotes that all numeric subcodes are included

**ICD-9**

| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|-------------------------------|--------------|------------------------------|
| ILD     | Non-Autoimmune                | ILD-INSIP    | 516.32 Idiopathic non-specific interstitial pneumonitis |
|         |                               | ILD-IPF      | 516.31 Idiopathic pulmonary fibrosis |
|         |                               | ILD-Unclassifiable IIP | 516.30 Idiopathic interstitial pneumonia, not otherwise specified |
|         |                               | ILD-Hypersensitivity Pneumonitis | 495.x Hypersensitivity pneumonia |
|         |                               | ILD-Exposure-related ILD | 500 Coal Workers' Pneumoconiosis |
|         |                               |              | 501 Asbestosis |
|         |                               |              | 502 Pneumoconiosis due to other silica or silicates |
| Disease              | Underlying autoimmune disease | ILD Category                                      | Underlying medical condition                                      |
|---------------------|-------------------------------|--------------------------------------------------|-------------------------------------------------------------------|
|                     |                               | 503 Pneumoconiosis due to other inorganic dust    | 135 Sarcoïdosis                                                   |
|                     |                               | 504 Pneumonopathy due to inhalation of other dust | 505 Pneumoconiosis, unspecified                                   |
| ILD-Sarcoidosis     |                               |                                                  | 515 Postinflammatory pulmonary fibrosis                           |
|                      |                               |                                                  | 516.9 Unspecified alveolar and parietoalveolar pneumonopathy      |
| ILD-Other fibrosing |                               | 516.33 Acute interstitial pneumonitis             | 516.36 Cryptogenic organizing pneumonia                           |
|                      |                               | 516.37 Desquamative interstitial pneumonia        | 516.5 Adult Pulmonary Langerhans histiocytosis                     |
|                      |                               | 516.63 Surfactant mutations of the lung           | 516.34 Respiratory bronchiolitis interstitial lung disease        |
| ILD-Other (non-fibrotic) |                               |                                                  | 710.1 at any time within the last 10 years + any fibrotic code   |
| Autoimmune/CTD-ILD  | ILD-Rheumatoid Arthritis      | 714.81 Rheumatoid lung                            | 517.2 Lung involvement in systemic sclerosis                      |
|                     | associated ILD                |                                                  | 710.1 at any time within the last 10 years + any fibrotic code   |
|                     | ILD-SSc-ILD                   | 515/516.9                                        |                                                                   |
| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|-------------------------------|--------------|-----------------------------|
| ILD-Mixed Connective Tissue Disease | ILD-Mixed Connective Tissue Disease | 710.8 Other specified diffuse diseases of connective tissue |
| ILD-Other diffuse CTD | 710.0 Systemic lupus erythematosus + 517.8 Lung involvement in other diseases classified elsewhere |
| | 710.3 Dermatomyositis + 517.8 Lung involvement in other diseases classified elsewhere |
| | 710.4 Polymyositis + 517.8 Lung involvement in other diseases classified elsewhere |
| | 710.2 Sicca syndrome + 517.8 Lung involvement in other diseases classified elsewhere |

NOTE: ".x" in a code denotes that all numeric subcodes are included

**Keywords**

**English transliteration**

| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|-------------------------------|--------------|-----------------------------|
| ILD | Non-Autoimmune | ILD-NSIP | Idiopathic non-specific interstitial pneumonitis |
| | | | NSIP |
| | | | Fibrotic NSIP |
| | | | Fibrotic non-specific interstitial pneumonia |
| | | | Fibrotic non specific interstitial pneumonia |
| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|--------------------------------|---------------|-----------------------------|
|         |                                | ILD-IPF       | Idiopathic pulmonary fibrosis |
|         |                                |               | IPF                         |
|         |                                | ILD-Unclassifiable IIP | Idiopathic interstitial pneumonia, not otherwise specified |
|         |                                |               | Unclassifiable IIP          |
|         |                                | ILD-Hypersensitivity Pneumonitis | Hypersensitivity pneumonitis |
|         |                                |               | Hypersensitivity pneumonia  |
|         |                                |               | Extrinsic allergic alveolitis|
|         |                                | ILD-Exposure-related ILD | Coal Workers |
|         |                                |               | Asbestosis                  |
|         |                                |               | Pneumoconiosis              |
|         |                                |               | Byssinosis                  |
|         |                                | ILD-Sarcoidosis | Sarcoidosis of the lung     |
|         |                                |               | Sarcoidosis + any ILD-other fibrosing keyword |
|         |                                | ILD-Other fibrosing | Interstitial pulmonary disease |
|         |                                |               | Interstitial pulmonary diseases |
|         |                                |               | Interstitial lung disease   |
|         |                                |               | Pulmonary fibrosis          |
|         |                                |               | Fibrotic interstitial lung disease |
| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|--------------------------------|--------------|------------------------------|
|         |                                | Pulmonary fibrosis |                              |
|         |                                | Lung fibrosis    |                              |
|         |                                | Fibrosing alveolitis |                           |
|         |                                | Interstitial pneumonia |                        |
|         |                                | Interstitial pneumonias |                      |
|         |                                | Interstitial pneumonitis |                    |
|         |                                | Fibrotic lung     |                              |
|         |                                | IIP              |                              |
|         |                                | Idiopathic interstitial pneumonia |                 |
|         |                                | Fibrotic interstitial pneumonia |             |
|         |                                | ILD              |                              |
|         |                                | Idiopathic lung disease |              |
|         |                                | Pulmonary fibrotic |                              |
|         |                                | Restrictive lung disease |                      |
|         |                                | UIP              |                              |
|         |                                | Usual interstitial pneumonia |                    |
|         |                                | Diffuse parenchymal lung disease |              |
|         |                                | Interstitial alveolitis |                         |
| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|-----------------------------|--------------|------------------------------|
|        |                             | ILD-Other (non-fibrotic) | Acute interstitial pneumonitis |
|        |                             |               | AIP |
|        |                             |               | Cryptogenic organizing pneumonia |
|        |                             |               | Desquamative interstitial pneumonia |
|        |                             |               | Langerhans 'cell histiocytosis |
|        |                             |               | Langerhans histiocytosis |
|        | Autoimmune/CTD-ILD          |               | Surfactant mutations of the lung |
|        |                             |               | Respiratory bronchiolitis |
|        | ILD-Rheumatoid Arthritis associated ILD | ILD-Rheumatoid Arthritis associated ILD | Rheumatoid lung disease |
|        |                             |               | RA-ILD |
|        |                             |               | RA with lung involvement |
|        | ILD-SSc-ILD                 | ILD-SSc-ILD   | Systemic sclerosis with lung involvement |
|        |                             |               | Any ILD-other fibrosing keyword + any SSc keyword at any time within the last 10 years |
|        | ILD-Mixed Connective Tissue Disease | ILD-Mixed Connective Tissue Disease | Mixed CTD-ILD |
|        |                             |               | MCTD-ILD |
|        | ILD-Other diffuse CTD       | ILD-Other diffuse CTD | SLE |
|        |                             |               | Juvenile dermatopolymyositis w lung involvement |
| Disease | Underlying autoimmune disease | ILD Category | Underlying medical condition |
|---------|-------------------------------|--------------|-------------------------------|
|         |                               |              | Other dermatopolymyositis w lung involvement |
|         |                               |              | Dermatopolymyositis unsp w lung involvement |
|         |                               |              | Polymyositis with respiratory involvement |
|         |                               |              | Sicca syndrome with lung involvement |
|         |                               |              | Sjogren |

Belgium - French

| Maladie | Maladie auto-immune sous-jacente | MPI Catégorie | Condition médicale sous-jacente |
|---------|---------------------------------|---------------|--------------------------------|
| MPI     | Non auto-immune                 | MPI-PINS      | Pneumopathie interstitielle non spécifique |
|         |                                 |               | PINS |
|         |                                 |               | PINS fibrotique |
|         |                                 |               | Fibrotic pneumopathie interstitielle non spécifique |
|         |                                 | MPI -FPI      | Fibrose pulmonaire idiopathique |
|         |                                 |               | FPI |
|         |                                 | MPI -Inclassable IIP | Pneumonie interstitielle idiopathique, non spécifiée |
|         |                                 |               | Inclassable IIP |
| Maladie | Maladie auto-immune sous-jacente | MPI Catégorie | Condition médicale sous-jacente |
|---------|---------------------------------|--------------|--------------------------------|
|         |                                 | MIP- Pneumopathie d'hypersensibilité | Pneumopathie d'hypersensibilité  |
|         |                                 |              | Alvéolite allergique extrinsèque |
|         |                                 | MPI- MPI liée à l'exposition | Charbonniers / pneumoconiose du charbon |
|         |                                 |              | Asbestose                     |
|         |                                 |              | Pneumoconiose                 |
|         |                                 |              | Byssinose                     |
|         |                                 | MPI- Sarcoïdone | Sarcoïdose du poumon          |
|         |                                 |              | Sarcoïdose + n'importe quel mot clé relative à MPI- autres fibroses |
|         |                                 | MPI- autres fibroses | Maladie pulmonaire interstitielle / Maladies pulmonaires interstitielles |
|         |                                 |              | Fibrose pulmonaire            |
|         |                                 |              | Maladie pulmonaire interstitielle fibrotique |
|         |                                 |              | Alvéolite fibrosante          |
|         |                                 |              | Pneumonie interstitielle      |
|         |                                 |              | Pneumonies interstitielles    |
|         |                                 |              | Pneumopathie interstitielle   |
|         |                                 |              | Poumon fibrotique             |
| Maladie | Maladie auto-immune sous-jacente | MPI Catégorie | Condition médicale sous-jacente |
|---------|----------------------------------|---------------|--------------------------------|
|         |                                  |               | PII                            |
|         |                                  |               | Pneumonie interstitielle idiopathique |
|         |                                  |               | Pneumonie interstitielle fibrotique |
|         |                                  |               | MPI                            |
|         |                                  |               | Maladie pulmonaire idiopathique |
|         |                                  |               | Fibrotique pulmonaire           |
|         |                                  |               | Maladie pulmonaire restrictive  |
|         |                                  |               | UIP                            |
|         |                                  |               | Pneumonie interstitielle usuelle |
|         |                                  |               | Maladie pulmonaire diffuse du parenchyme |
|         |                                  |               | Alvéolite interstitielle        |
|         | MPI- Autre (non fibrotique)      |               | Pneumopathie interstitielle aiguë |
|         |                                  |               | PIA                            |
|         |                                  |               | Pneumonie organisatrice cryptogène |
|         |                                  |               | Pneumonie interstitielle desquamative |
|         |                                  |               | Histiocytose à cellules de Langerhans |
|         |                                  |               | Histiocytose de Langerhans      |
|         |                                  |               | Mutations du surfactant du poumon |
| Maladie | Maladie auto-immune sous-jacente | MPI Catégorie | Condition médicale sous-jacente |
|---------|---------------------------------|---------------|--------------------------------|
| Auto-immune/MPI - Maladie du tissu conjonctif | MPI - Maladie pulmonaire interstitielle associée à la polyarthrite rhumatoïde | Maladie pulmonaire rhumatoïde | Bronchiolite respiratoire |
| MPI-SSc-MPI | | PR-MPI | |
| | | Polyarthrite rhumatoïde avec atteinte pulmonaire | |
| MPI - Maladie mixte du tissu conjonctif | | | |
| MPI- autres maladies diffuses du tissu conjonctif | | | |
| | | Sclérose systémique avec atteinte pulmonaire | |
| | | N’importe quel mot clé relative à MPI ou autre “fibrosing” + autre mot clé relative à SSc à tout moment au cours des 10 dernières années | |
| | | Maladie mixte du tissu conjonctif | |
| | | Lupus érythémateux disséminé LED | |
| | | Dermatopolymyosite juvénile avec atteinte pulmonaire | |
| | | Autres dermatopolymyosites à atteinte pulmonaire | |
| | | Dermatopolymyosite non précisée avec atteinte pulmonaire | |
| | | Polymyosite avec atteinte respiratoire | |
| | | Syndrome de Sicca avec atteinte pulmonaire | |
| | | Sjogren / syndrome de Sjogren | |
| Ziekte                  | Onderliggende auto-immuunziekte | Categorie ILD                                                                 | Onderliggende medische aandoening                                      |
|------------------------|---------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Interstitiële longziekte | Niet auto-immuun                | ILD-NSIP                                                                     | Idiopathische niet-specifieke interstitiële pneumonitis                |
|                        |                                 |                                                                              | NSIP                                                                   |
|                        |                                 |                                                                              | Fibrotische nsip                                                       |
|                        |                                 |                                                                              | Fibrotische niet-specifieke interstitiële pneumonie                   |
|                        |                                 | ILD-IPF                                                                      | Idiopathische pulmonale fibrose                                       |
|                        |                                 |                                                                              | IPF                                                                    |
|                        |                                 | ILD-Niet-classificeerbare IIP                                                | Idiopathische interstitiële pneumonie, niet anders gespecificeerd      |
|                        |                                 |                                                                              | Niet-classificeerbare IIP                                             |
|                        |                                 | ILD-Overgevoeligheids pneumonitis                                             | Overgevoeligheids pneumonitis                                          |
|                        |                                 |                                                                              | Overgevoeligheids pneumonie                                            |
|                        |                                 |                                                                              | Extrinsiche allergische alveolitis                                   |
|                        |                                 | ILD- Blootstelling Gerelateerde ILD                                          | Kolenarbeiders                                                        |
|                        |                                 |                                                                              | Asbestose                                                             |
| Ziekte         | Onderliggende auto-immuunziekte | Categorie ILD                       | Onderliggende medische aandoening                  |
|---------------|---------------------------------|-------------------------------------|--------------------------------------------------|
|               |                                 | Pneumoconiose                        |                                                  |
|               |                                 | Byssinosis                           |                                                  |
| ILD- Sarcoïdose|                                 | Sarcoïdose van de long               |                                                  |
|               |                                 | Sarcoïdose + een ander ILD-fibrosing-sleutelwoord |                                                  |
| ILD-Ander fibrosing |                                | Interstitiële longziekte              |                                                  |
|               |                                 | Interstitiële longziekten            |                                                  |
|               |                                 | Pulmonaire fibrose                   |                                                  |
|               |                                 | Fibrotische interstitiële longziekte |                                                  |
|               |                                 | Longfibrose                          |                                                  |
|               |                                 | Fibroserende alveolitis              |                                                  |
|               |                                 | Interstitiële pneumonie              |                                                  |
|               |                                 | Interstitiële pneumonieën            |                                                  |
|               |                                 | Interstitiële pneumonitis            |                                                  |
|               |                                 | Fibrotische long                     |                                                  |
|               |                                 | IIP                                 |                                                  |
|               |                                 | Idiopathische interstitiële pneumonie|                                                  |
|               |                                 | Fibrotische interstitiële pneumonie  |                                                  |
|               |                                 | ILD                                 |                                                  |
| Ziekte               | Onderliggende auto-immuunziekte | Categorie ILD                  | Onderliggende medische aandoening |
|---------------------|---------------------------------|--------------------------------|----------------------------------|
| Ilieptische longziekte |                                |                                | Idiopathische longziekte         |
| Pulmonaire fibrotische |                                |                                | Pulmonaire fibrotische           |
| Restrictieve longziekte |                                |                                | Restrictieve longziekte          |
| UIP                 |                                |                                | UIP                              |
| Usual interstitial pneumonia |                                |                                | Usual interstitial pneumonia     |
| Diffuse parenchymale longziekte |                                |                                | Diffuse parenchymale longziekte  |
| Interstitiële alveolitis |                                |                                | Interstitiële alveolitis         |
| Acute interstitiële pneumonitis |                                |                                | Acute interstitiële pneumonitis  |
| AIP                 |                                |                                | AIP                              |
| Cryptogeen organiseren longontsteking |                |                                | Cryptogeen organiseren longontsteking |
| Desquamative interstitiële pneumonitis |                |                                | Desquamative interstitiële pneumonitis |
| Langerhans cel histiocytose |                    |                                | Langerhans cel histiocytose      |
| Langerhans histiocytose |                                |                                | Langerhans histiocytose          |
| Surfactant mutaties van de longen |                  |                                | Surfactant mutaties van de longen |
| Luchtwegen bronchiolitis |                                |                                | Luchtwegen bronchiolitis         |
| Idiopathische longziekte |                                |                                | Reumatoïde longziekte            |
| Pulmonaire fibrotische |                                |                                | RA-ILD                           |
| Restrictieve longziekte |                                |                                | RA met longbetrokkenheid          |
| Ziekte | Onderliggende auto-immuunziekte | Categorie ILD | Onderliggende medische aandoening |
|--------|---------------------------------|---------------|----------------------------------|
|        |                                 | ILD-SSc-ILD   | Systemische sclerose met longbetrokkenheid |
|        |                                 |               | Een ander ILD-fibrosing-sleutelwoord + een SSc sleutelwoord any SSc keyword op elk moment in de afgelopen 10 jaar |
|        |                                 | ILD- Gemengde bindweefselziekte (MCTD) | Gemengde bindweefselziekte |
|        |                                 |               | MCTD-ILD |
|        |                                 | ILD-Andere diffuse CTD | SLE |
|        |                                 |               | Juveniele dermatopolymyositis met longbetrokkenheid |
|        |                                 |               | Andere dermatopolymyositis met longbetrokkenheid |
|        |                                 |               | Dermatopolymyositis niet gespecificeerd met longbetrokkenheid |
|        |                                 |               | Polymyositis met respiratoire betrokkenheid |
|        |                                 |               | Sicca-syndroom met longbetrokkenheid |
|        |                                 |               | Sjogren |

Denmark
| Sygdom       | Underliggende autoimmune sygdom | ILS Kategori                      | Underliggende sygdomstilstand |
|--------------|---------------------------------|-----------------------------------|-------------------------------|
| ILS          | Ikke-Autoimmune                  | ILS-INSIP                         | DJ841B Idiopa. lungefibrose m non-specific interstitial pneumonia |
|              |                                  | ILS-IPF                           | DJ841C Idiopatisk lungefibrose UNS |
|              |                                  | ILS-Uklassificerbar interstitial idiopatisk lungebetændelse | DJ848 Anden interstitial lungesygdom |
|              |                                  | ILS-Overfølsomhed Pneumonitis     | DJ67.x Pneumonitis f.a. hypersensitivitet overfor organisk støv |
|              |                                  | ILS-Eksponering-relaterede ILS    | DJ60 Støvlunge forårsaget af kulstøv |
|              |                                  |                                   | DJ61 Støvlunge forårsaget af asbest og andre mineralfibre |
|              |                                  |                                   | DJ628 Anden form for silikose |
|              |                                  |                                   | DJ63x Støvlunge forårsaget af andet uorganisk støv |
|              |                                  |                                   | DJ649 Pneumokoniose UNS |
|              |                                  |                                   | DJ660 Byssinose |
|              |                                  | ILS-Sarkoidose                    | DD860 Sarkoidose i lunger |
|              |                                  |                                   | DD862 Sarkoidose i både lunger og lymfeknuder |
|              |                                  | ILS-Andet fibrosering             | DJ841 Anden interstitial lungesygdom med fibrose |
|              |                                  |                                   | DJ849 Interstitiel lungesygdom UNS |
|              |                                  | ILS-Andet (ikke-fibrotisk)        | DJ841D Akut interstitiel pneumoni |
| Sygdom                      | Underliggende autoimmun sygdom | ILS Kategori                                                                 | Underliggende sygdomstilstand                                                                 |
|-----------------------------|--------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Autoimmune/                 |                                | DJ843 Bronchiolitis obliterans organiseringe pneumoni (BOOP) or DJ841F       | DJ840A Proteinosis alveolaris pulmonum                                                                |
| bindevævssygdomme - ILS     |                                | DJ841G Deskvamativ interstitiel pneumoni                                    | DD760 Histiocyte i de Langerhanske celler                                                              |
| ILS- Rheumatoid arthritis-  | ILS- Rheumatoid arthritis-     | DM051 Reumatoid arthritis med lungemanifestationer                          |                                                                                               |
| associeret ILS              | associieret ILS                | DM348 Anden form for systemisk sklerodermi + DJ84X for lung involvement     |                                                                                               |
| ILS-SSc-ILS                 |                                | DM34x at any time within the last 10 years + any fibrotic code (DJ841/DJ848/DJ849) |                                                                                               |
| ILS- Blandet bindevævssygdom | ILS- Blandet bindevævssygdom (+ DJ84X til lungeinddragelse)                 | DM351 Andet blandingssyndrom ved generaliseret bindevævssygdom                |                                                                                               |
| ILS- Andre diffuse          |                                | DM321 Systemisk lupus erythematosus med organinvolving                      |                                                                                               |
| bindevævssygdomme           |                                | DM330 Dermatomyositis juvenilis                                              |                                                                                               |
|                             |                                | DM331 Anden dermatomyositis                                                   |                                                                                               |
|                             |                                | DM339 Dermatopolymyositis UNS                                                 |                                                                                               |
|                             |                                | DM332 Polymyositis                                                            |                                                                                               |
|                             |                                | DM350 Sjögrens syndrom                                                         |                                                                                               |
| Ilmestyönsaannin | Taustalla oleva autoimmuunisairaus | ILD-luokka | Lääketieteellinen tila: diagnoosi tai tekstilouhinta |
|-----------------|----------------------------------|------------|--------------------------------------------------|
| **ILD: Interstitiaalinen keuhkosaaraus** | Ei-autoimmuunisairaus | ILD-INSIP | NSIP + J84.x |
|                 |                                  | ILD-IPF   | J84.1 IPF/UIP, idiopaatinen keuhkofibroosi |
|                 |                                  | ILD-Unclassifiable IIP | NOT UIP/NSIP/COP/DIP/LIP/HP (NOT IPF) |
|                 |                                  | ILD-Hypersensitivity Pneumonitis | HP, hypersensitiviteetti pneumonia, allerginen alveoliitti, homepölykeuhko |
|                 |                                  | ILD-Altistumiseen liittyvä interstitiaalinen keuhkosaaraus | J61, J67.0 (altiste tiedossa), J62.8 |
|                 |                                  | ILD-sarkoidoosi | J86.0, D86.2 |
|                 |                                  | ILD-Muu fibroosi | NSIP/COP/DIP + J84.9 or J84.8 |
|                 |                                  | ILD-Muu (ei-fibroottinen) | NSIP/COP/DIP, ei IPF, ei UIP |
|                 |                                  |          | COP, kryptogeeninen organisoituva pneumoia |
|                 |                                  |          | DIP |
| Tauti                      | Taustalla oleva autoimmuunisairaus | ILD-luokka                                                                 | Lääketieteellisen tila: diagnoosi tai tekstilouhinta                      |
|---------------------------|------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------|
|                           | Autoimmuunisairaus                 | Deskvamatiivinen bronkioliitti                                           |                                                                         |
|                           |                                    | RB-ILD                                                                      |                                                                         |
|                           | ILD- nivelreumaan liittyvän         | M05.9, M06.0 + J99.0/J84.x/UIP/NSIP/fibroosi                             |                                                                         |
|                           | interstitiaalinen keuhkosairaus    |                                                                           |                                                                         |
|                           | ILD-SSc-ILD                        | M34.x + J99.0/J84.x/UIP/NSIP/fibroosi                                  |                                                                         |
|                           | ILD- Sekamuotoiset sidekudossaairaudet | M35.8, M35.9 + J99.0/J84.x/UIP/NSIP/fibroosi                          |                                                                         |
|                           | ILD-Muut diffusi sidekudossaairaudet | M33.x/M34.x/M35.0+J99.0 or J84.x/UIP/NSIP/fibroosi                  |                                                                         |

**Greece**

| Nosos | Ypokeimeni aftoanosi nosos | Kategoria diamesis pneumonopatheias | Ypokeimeni iatriki katastasi |
|-------|---------------------------|-------------------------------------|-----------------------------|
| ILD   | Mi-aftoanosa              | ILD-INSIP                           | Idiopathis mi eidiki diamesi pneumonia |
|       |                           |                                    | NSIP                         |
|       |                           |                                    | NSIP inotiki                 |
|       |                           |                                    | Inotiki mi-eidiki diamesi pneumonia |
|       |                           |                                    | Idiopathis pneumoniki inosi  |
| Nosos                  | Ypokeimeni aftoanosi nosos | Katigoria diamesis pneunonopatheias                                      | Ypokeimeni iatriki katastasi                                      |
|-----------------------|-----------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------|
|                       |                             | IPF                                                                        |                                                                  |
| ILD-Ataxinomiti idiopathis diamesi pnevmonia |                             | Idiopathis diamesi pnevmonia, mi prodiagrafoméni állos |                                                                  |
|                       |                             | Unclassifiable IIP                                                         |                                                                  |
| ILD-Pnevmónitida ypervéaisthísias |                             | Pnevmónitida ypervéaisthísias                                               |                                                                  |
|                       |                             | Pnevmonía yperevaisthisias                                                  |                                                                  |
|                       |                             | Exogenous allergikís kypseliditidas                                          |                                                                  |
| ILD-Díamesi pneunonopatheia schetizomeni me ekthesi |                             | Ergátes ánthraka                                                            |                                                                  |
|                       |                             | Amiántosi                                                                  |                                                                  |
|                       |                             | Pnevmoniokonía                                                             |                                                                  |
|                       |                             | Vysínóosi                                                                  |                                                                  |
| ILD-Sarkoeídosi       |                             | Sarkoeídosi tou pnévmona                                                    |                                                                  |
|                       |                             | Sarkoeídosi                                                                |                                                                  |
| ILD-Alles inotikes    |                             | Diámesi pnevmonopátheia                                                     |                                                                  |
|                       |                             | Diámeses pnevmonopátheies                                                   |                                                                  |
|                       |                             | Pnevmonikí inosi                                                           |                                                                  |
|                       |                             | Inotiki diámesi pnevmonopátheia                                             |                                                                  |
|                       |                             | Inódis kypseliditida                                                        |                                                                  |
| Nosos                                      | Ypoeimeni afoanosi nosos | Kategoría diamesis pneumonopatheias                                      | Ypoeimeni iatriki katastasi                              |
|-------------------------------------------|--------------------------|-------------------------------------------------------------------------|----------------------------------------------------------|
|                                           |                          | Diámesi pnevmonía                                                      |                                                          |
|                                           |                          | Diámesi pnevmonitída                                                   |                                                          |
|                                           |                          | Inódis pnévmona                                                         |                                                          |
|                                           |                          | IIP                                                                     |                                                          |
|                                           |                          | Idiopathitis diámesi pnevmonía                                         |                                                          |
|                                           |                          | Inotiki diámesi pnevmonía                                               |                                                          |
|                                           |                          | ILD                                                                     |                                                          |
|                                           |                          | Idiopathis pnevmonikí nóso                                              |                                                          |
|                                           |                          | Pnevmonikí inotikí                                                      |                                                          |
|                                           |                          | Perioristikí pnevmonikí nóso                                            |                                                          |
|                                           |                          | UIP                                                                     |                                                          |
|                                           |                          | Synithis diámesi pnevmonía                                              |                                                          |
| ILD Alles (mi inotikes)                   |                          | Diáchytí parenchymatikí pnevmonikí nóso                                 |                                                          |
|                                           |                          | Diámesi kypseliditída                                                   |                                                          |
|                                           |                          | Oxeía diámesi pnevmona                                                  |                                                          |
|                                           |                          | AIP                                                                     |                                                          |
|                                           |                          | Kryptogenis organoumeni pnevmonía                                       |                                                          |
| Nosos                  | Ypiskeimeni afloatanosi nosos | Katgoria diamesesi pneumonopatheias                                                                 | Ypiskeimeni iatriki katastasi                                                                 |
|-----------------------|-------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Aftoanosa/CTD-ILD     | ILD-Diamesi pneumonopatheia schetizomeni me revmateoidi artritida | Revmateoidis pneumonopatheia                                                                    | RA-ILD                                                                                       |
|                       | ILD-SSc-ILD                   | Systmatiki sklirynsi me emplokio ton pnevmnonon                                                  | Any ILD-other fibrosing keyword + any SSc keyword at any time within the last 10 years      |
|                       | ILD-Mikti nosos tou syndetikou istou | Mixed CTD-ILD diamesi pneumonopatheia apo mikti noso tou syndetikou istou                     | MCTD-ILD                                                                                    |
|                       | ILD-Alli diachyti nosos tou syndetikou istou | SLE                                                                                               | Neaniki dermatopolymiozitida me emplokio ton pnevmnonon                                  |
|                       |                               | Álli dermatopolymositida kai pnevmoniki emplokí                                                |                                                                                              |
| Nosos | Ypokeimeni afnonosi nosos | Kategoria diamesis pneumonopathias | Ypokeimeni iatriki katastasi |
|-------|-------------------------|---------------------------------|-------------------------------|
|       |                         |                                 | Dermatopolymiozylitida me kathorismeni me emploi ton pnevmonon |
|       |                         |                                 | Polymyositida me anaepnestiki aneparkeia |
|       |                         |                                 | Syndroma Sicca me emploi ton pnevmonon |
|       |                         |                                 | Syndroma sjogren |

Norway

| Sykdom    | Underliggende autoimmun sykdom | ILD Kategori | Underliggende medisinsk tilstand |
|-----------|--------------------------------|--------------|----------------------------------|
| ILD       | Ikke-Autoimmune                | ILD-INSIP    | Idiopatisk non-spesifik interstitiell pneumoni |
|           |                                |              | NSIP                             |
|           |                                |              | Fibrotisk NSIP                    |
|           |                                |              | Fibrotisk ikke-spesifik interstitial lungebetennelse |
|           |                                | ILD-IPF      | Idiopatisk lungefibrose           |
|           |                                |              | IPF                              |
|           |                                | ILD-Unclassifiable IIP | Idiopatisk interstitial lungebetennelse, ikke spesifisert ellers |
|           |                                |              | Unclassifiable IIP              |
| Sykdom | Underliggende autoimmun sykdom | ILD Kategori | Underliggende medisinsk tilstand |
|--------|--------------------------------|--------------|---------------------------------|
|        |                                | ILD- Overfølsomhet pneumonitt | Overfølsomhet pneumonitt         |
|        |                                |               | Overfølsomhet lungebetennelse    |
|        |                                |               | Ekstrinsisk allergisk alveolitis |
|        |                                | ILD- Eksponeringsrelatert interstitial lungesykdom | Kullarbeidere / kullarbeidere pneumokoniose |
|        |                                |               | Asbestose                       |
|        |                                |               | Pneumokoniose                    |
|        |                                |               | Byssinosis                       |
|        |                                | ILD- Sarcoïdose | Sarcoidose av lungen / Sarkoidose i lungene |
|        |                                |               | Sarcoidose + any ILD-other fibrosing keyword |
|        |                                | ILD- Andre fibrosering | Interstitiell lungesykdom / Interstitielle lungesykdommer |
|        |                                |               | Lungfibrose                      |
|        |                                |               | Fibrotisk interstitiell lungesykdom |
|        |                                |               | Pulmonal fibrose                 |
|        |                                |               | Fibrosing alveolitis / fibrosing alveolitt |
|        |                                |               | Interstital lungebetennelse      |
|        |                                |               | Interstitial pneumonitt          |
|        |                                |               | Fibrotisk lunge                  |
| **Sykdom** | **Underliggende autoimmun sykdom** | **ILD Kategori** | **Underliggende medisinsk tilstand** |
|------------|-----------------------------------|-----------------|-------------------------------------|
|            |                                   |                 | IIP                                 |
|            |                                   |                 | Idiopatisk interstitial lungebetennelse |
|            |                                   |                 | Fibrotisk interstitial lungebetennelse |
|            |                                   |                 | ILD                                 |
|            |                                   |                 | Idiopatisk lungesykdrom             |
|            |                                   |                 | Lungefibrotisk / pulmonal fibrotisk  |
|            |                                   |                 | Restriktiv lungesykdrom             |
|            |                                   |                 | UIP                                 |
|            |                                   |                 | Vanlig interstitial lungebetennelse |
|            |                                   |                 | Diffus parenkymal lungesykdrom      |
|            |                                   |                 | Interstitial alveolitis             |
|            | **ILD- Annet (ikke fibrotisk)**   |                 | Akutt interstitial pneumonitt       |
|            |                                   |                 | AIP                                 |
|            |                                   |                 | Kryptogen organisering lungebetennelse |
|            |                                   |                 | Desquamative interstitiell lungebetennelse |
|            |                                   |                 | Langerhans ‘cell histiocytose        |
|            |                                   |                 | Langerhans histiocytose             |
| Sykdom                                | Underliggende autoimmun sykdom | ILD Kategori                   | Underliggende medisinsk tilstand                                                                 |
|---------------------------------------|--------------------------------|--------------------------------|-------------------------------------------------------------------------------------------------|
| Autoimmune/ Bindevevssykdommer -ILD  |                                | I LD- RA assosiert lungesykdom | Surfaktant mutasjoner av lungen<br>Respiratorisk bronkiolit<br>Reumatoid lungesykdom<br>RA-ILD<br>Reumatoid artritt med lungenesamfunn |
|                                       | I LD-SSc-ILD                    |                                | Systemisk sklerose med lungenesamfunn<br>Any I LD-other fibrosing keyword + any SSc keyword at any time within the last 10 years |
| I LD- Blandede bindevevssykdommer     |                                | Mixed CTD-ILD                  |                                                                                                 |
| I LD-Andre diffuse bindevevssykdommer |                                |                                | Systemisk lupus erythematosus SLE<br>Juvenil dermatopolymyositis med lungenesamfunn<br>Øvrig dermatopolymyositis med lungebetennelse<br>Dermatopolymyositis unsp med lung involving<br>Polymyositis med respiratorisk involving<br>Sicca syndrom med lunge involving<br>Sjøgrens / sjogrens syndrom |
|                                       |                                | MCTD-ILD                       |                                                                                                 |
| Doença       | Doença auto-imune subjacente | DPI Categoria          | Condição médica subjacente                                      |
|--------------|------------------------------|-----------------------|-----------------------------------------------------------------|
| DPI          | Não autoimune                | DPI-PINEi             | *Pneumonia intersticial não específica idiopática*               |
|              |                              |                       | *PINE*                                                          |
|              |                              |                       | *NSIP*                                                          |
|              |                              |                       | *PINE fibrótica.*                                               |
|              |                              |                       | *NSIP*                                                          |
|              |                              |                       | *Pneumonia intersticial não específica fibrótica*               |
|              |                              | DPI-FPI               | *Fibrose pulmonar idiopática*                                   |
|              |                              |                       | *FPI*                                                           |
|              |                              | DPI - Inclassificável PII | *Pneumonia intersticial idiopática, não especificada*           |
|              |                              |                       | *Inclassificável PII*                                           |
|              |                              | DPI - Pneumonite de hipersensibilidade | *Pneumonite de hipersensibilidade*                             |
|              |                              |                       | *Pneumonia de hipersensibilidade*                               |
|              |                              |                       | *Alveolite alérgica extrínseca*                                 |
|              |                              |                       | *Trabalhadores de Carvão*                                       |
|              |                              |                       | *Asbestose*                                                    |
| Doença | Doença auto-imune subjacente | DPI Categoria | Condição médica subjacente |
|--------|-----------------------------|--------------|---------------------------|
| DPI- Doença pulmonar intersticial relacionada à exposição | DPI- Sarcoidose | Pneumoconiose |
| | | Bissinose |
| | DPI-Sarcoidose | Sarcoidose do pulmão |
| | | Sarcoidose |
| DPI-Other fibrosing | DPI- Other fibrosing | Doença pulmonar intersticial |
| | | Doenças pulmonares intersticiais |
| | | Fibrose pulmonar |
| | | Doença pulmonar intersticial fibrótica |
| | | Alveolite fibrosante |
| | | Pneumonia intersticial |
| | | Pneumonias intersticiais |
| | | Pneumonite intersticial |
| | | Pulmão fibrótico |
| | | PII |
| | | Pneumonia intersticial idiopática |
| | | Pneumonia intersticial fibrótica |
| Doença | Doença auto-imune subjacente | DPI Categoria | Condição médica subjacente |
|--------|-----------------------------|--------------|----------------------------|
| DPI    |                             |              | DPI                        |
|        |                             |              | Doença pulmonar idiopática |
|        |                             |              | Doença pulmonar restritiva |
|        |                             | PIU          | Pneumonia intersticial usual |
|        |                             | UIP          | Doença pulmonar parenquimatosa difusa |
|        |                             |              | Doença difusa do parênquima pulmonar |
|        |                             |              | Alveolite intersticial |
| DPI-Other (non fibrotic) | | | Pneumonite intersticial aguda |
|        |                             | PIA          | Pneumonia organizativa criptogénica |
|        |                             | AIP          | Pneumonia intersticial descamativa |
|        |                             |              | Histiocitose de células de Langerhans |
|        |                             |              | Histiocitose de Langerhans |
|        |                             |              | Mutações do surfactante do pulmão |
| Doença | Doença auto-imune subjacente | DPI Categoria | Condição médica subjacente |
|--------|-----------------------------|---------------|-----------------------------|
| Autoimune/DPI- doença do tecido conjuntivo |  |  | Bronquiolite respiratória |
|  | DPI - Artrite reumatóide com envolvimento pulmonar |  | Doença pulmonar reumatóide |
|  |  |  | AR-DPI |
|  |  |  | Artrite reumatóide com envolvimento pulmonar |
| DPI-SSc-ILD |  |  | Esclerose sistêmica com envolvimento pulmonar |
|  |  |  | Esclerodermia com envolvimento pulmonar |
|  |  |  | Outras DPI-fibróticas + esclerose sistêmica nos últimos 10 anos |
|  | DPI - Doença Mista do Tecido Conjuntivo | DMTC-DIP |  |
|  | DPI-Outra doença do tecido conjuntivo difusa |  | Lúpus eritematoso sistêmico SLE |
|  |  |  | Dermatomiositis juvenil com envolvimento pulmonar |
|  |  |  | Outras dermatomiosite com envolvimento pulmonary |
|  |  |  | Dermatopomiosite não especificada com envolvimento pulmonar |
|  |  |  | Polimiosite com envolvimento respiratório |
|  |  |  | Síndrome Sicca com envolvimento pulmonar |
|  |  |  | Síndrome de Sjögren |
Section B. Methodology for calculating prevalence, incidence and relative percentages in Phase 1

Prevalence

In each participating centre, the annual crude prevalence was calculated as shown below. For the whole study period, it was the average of annual prevalences available in the period.

\[
Prevalence = \frac{\text{Number of prevalent cases}}{\text{Sum of persons at risk}}
\]

Prevalent cases (numerator) were those patients in the database ≥18 years presenting with at least one code and/or keyword for the conditions of interest between 01-January and 31-December of a specific year (including both inpatients and outpatients and excluding duplicates). Patients with codes and/or keywords for >1 condition within a given year (e.g. both systemic sclerosis-associated interstitial lung disease [SSc-ILD] and idiopathic pulmonary fibrosis [IPF]), were counted in each condition, but only once in overarching categories such as fibrosing interstitial lung diseases [F-ILDs]).

For each year, persons at risk were those living in the centre’s area of influence (i.e. reference population) and who were alive and ≥18 years old at mid-year (i.e. 30-June). If only data from 01-January was available, the mean value between adjacent Januaries was used as a proxy for mid-year population.

Aside from this reference population, the participating centres receiving ILD cases from satellite centres (detailed in Table 1 in the main text) also had an extended (reference) population, formed by the population at risk in the centre’s own area of influence plus the population at risk in the satellites’ area of influence. When available, the main incidence calculations used this extended population as denominator, providing minimum estimates. However, as sensitivity analysis, maximum estimates were also obtained by using as denominator the reference population.

Both the reference and extended populations were provided by each centre. The total adult population for each country at each calendar year of the study period was obtained from the European Statistics Office (Eurostat) website.[1]

The prevalences obtained in the participating centres of each country were extrapolated to the whole country accounting for the relative size of the centres’ population at risk with respect to the total adult population of the country.
Incidence

In each participating centre, the annual crude incidence was calculated as shown below. For the whole study period, it was the sum of annual incidences available in the period.

\[
\text{Incidence} = \frac{\text{Number of incident cases}}{\text{Sum of person – years at risk}}
\]

Incident cases (numerator) were those prevalent cases without any prior code and/or keyword for the same condition in the previous 10 years. As with prevalent cases, patients with codes and/or keywords for >1 condition within a given year (e.g. both SSc-ILD and IPF) were counted in each condition, but only once in overarching categories (e.g. F-ILDs).

The person-years at risk (denominator) were obtained considering that the follow-up for each individual present at mid-year (30-June) accounted for the whole year (i.e. 1 person-year for each person at risk in each calendar year).

As with prevalence, minimum and maximum estimates were obtained by using as denominator, respectively, the person-years at risk of the extended and reference populations; and the incidences obtained in the participating centres of each country were extrapolated to the whole country accounting for the relative size of the centres’ population at risk with respect to the total adult population of the country.

Alternative methods and adjustments

Finland:

- The systematic search was performed in a database covering the entire population of the centre’s region. Therefore, there was only one population at risk and a single incidence/prevalence estimate was obtained for each ILD.

Denmark:

- The 2017 data were incomplete due to a delay in the database update, and unavailable for 2018 due to database maintenance. As the number of cases had been quite constant in the previous years, and assuming the 2017 delay affected all ILDs equally, a correction factor of 1.28 (average decrease from 2016 to 2017 across subtypes) was applied to 2017 data. For 2018, the site calculated the expected numbers based on the former years back to 2010.
• The systematic search was performed in a database covering the entire country population (Danish National Patient Registry, DNPR), therefore, there was only one population at risk and a single incidence/prevalence estimate was obtained for each ILD. The exceptions were IPF, other F-ILDs and the overarching ILD categories containing them. Based on a yet unpublished review of clinical records, and the review in Phase 2 of the present study, the Danish centre anticipated that a proportion of IPF cases would be recorded in DNPR with the same code as other F-ILDs (J849), probably because in many cases this general code was temporarily assigned at admission/referral but was not changed later, after the definitive diagnosis. According to the literature approximately 28% of all ILDs (except sarcoidosis) are IPF in Denmark. Therefore, the number of IPF cases was adjusted upwards by subtracting the incident/prevalent cases of sarcoidosis to total incident/prevalent cases of ILD and multiplying by a factor of 0.28. Similarly, the number of other F-ILD cases was adjusted downwards, by subtracting the additional cases obtained for IPF (after adjusting) to the misclassified cases of other F-ILD. Misclassified and adjusted IPF cases were used as numerator to obtain minimum and maximum estimates, respectively; while misclassified and adjusted cases of other F-ILD were the numerator to obtain maximum and minimum estimates. As a result of these adjustments, overarching categories including IPF and other F-ILDs (non-IPF F-ILDs, F-ILDs and ILDs) also had minimum and maximum estimates in Denmark.

• As the searched database was nationwide, there was no need to extrapolate the incidence/prevalence to the whole country population.

Norway:

• The reference population primarily reported by Oslo University Hospital accounted for the Oslo municipality only. However, the hospital is a reference centre receiving 40% of ILD cases from the Oslo municipality (=650,000 inhabitants), 40% from the rest of the South-East Health region (=3,000,000 inhabitants; =2,350,000 excluding Oslo municipality) and 20% from the rest of Norway (=5,300,000 inhabitants; =2,300,000 excluding the South-East region). Therefore, the population ratio for Oslo, the South-East region and whole Norway was 0.65/2.35/2.3 (i.e. 1/3.5/3.5), while the case ratio was 4/4/2 (i.e. 1/1/0.5). Assuming the centre caught 100% of cases in the Oslo municipality (i.e. that 4/0.65 was a valid relationship), the case ratio should had been

---

2 Knarborg, et al. Idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases in Denmark: clinical characteristics, treatment and economic consequences (PhD project, yet unpublished).
To achieve a case ratio of 1/1/0.5, the population ratio (denominator) was reduced to 0.65/0.65/0.32 thus obtaining a correction factor of 0.28 (0.65/2.35) for the South-East population and of 0.14 (0.32/2.3) for the Norwegian population. The reference population for each year of the study period was then calculated as follows: Oslo municipality + South-East region (excluding Oslo)*0.28 + Norway (excluding South-East region)*0.14. The whole South-East region population was used as extended population to obtain minimum estimates. Populations were obtained from the National Statistical Institute of Norway website.[3]

- ICD-10 codes used in the systematic search had only one decimal place, so cases of idiopathic non-specific interstitial pneumonia (iNSIP, coded J84.113), unclassifiable idiopathic interstitial pneumonias (uIIPs, coded J84.111) and other F-ILDs (coded J84.10) were merged. To correct this misclassification, incident and prevalent cases of these three ILDs were estimated based on their relative percentage in the other Scandinavian countries.

- The incidence of non-F-ILDs, missing for the period between 2015-2018, was calculated for each year based on its prevalence and on the average incidence/prevalence ratio of the other ILDs in the country.

Belgium:

- The Liege University Hospital Centre was of reference for rheumatological ILDs, receiving patients not only from the centre’s region (Wallonia), but also from the rest of the country and Luxembourg. To avoid overestimation, the incidence and prevalence of rheumatological ILDs were calculated using wider populations at risk than for other ILDs. The extended population encompassed the total adult population of Belgium and Luxembourg, while the reference population was limited to the adult population of the Wallonia region plus Luxembourg. The Wallonia region population was obtained from the Belgian Statistics Office[4] and the Luxemburg population from the country’s Statistics Portal.[5]

- Ghent University Hospital, a reference centre for SSc-ILD, only provided data for this condition. Also, this centre could not provide its reference and extended populations. However, they reported that most patients managed at the department came from the

---

3 The same occurred in Denmark and Finland. In Denmark, there were local codes in place which could be used in the systematic search to overcome this problem. In Finland, keywords could be used along with ICD-10 codes. In Norway, however, local codes and keywords could not be used.
regions of East and West Flanders. Therefore, the reference population considered was the sum of the total adult population for these regions (obtained from the Belgian Statistics Office[4]). This reference population was only used to obtain maximum incidence/prevalence estimates. Minimum estimates could not be obtained due to the lack of an extended population.

Greece:

- Only one of the four participating centres (University Hospital of Larissa) could capture most cases of rheumatological ILD. The relative distribution of non-IPF F-ILD subtypes in Larissa was used to obtain a correction factor, which was applied to adjust upwards the number of non-IPF F-ILD cases in the three Greek centres with missing information to avoid underestimation. The correction factor was the inverse ratio of pulmonary and rheumatological cases of non-IPF F-ILD ([inSIP + uIPs + exposure-related ILDs + sarcoïdosis + other F-ILDs + hypersensitivity pneumonitis (HP)] : [SSc-ILD + rheumatoid arthritis-associated ILD (RA-ILD) + mixed connective tissue disease (CTD)-ILD + other CTD-ILD]), and was multiplied by the total number of non-IPF F-ILD cases in each centre to obtain the number of rheumatological cases to be added (e.g. a ratio 2.5:1 would give a correction factor of 0.4. If the total number of non-IPF F-ILD cases was 71, then the final number after upwards adjustment would be 71+[71*0.4]=99).

Section C. Sample size calculations

The sample size for each study phase was calculated based on its primary objective. For Phase 1, the minimum population to obtain prevalence and incidence estimates with an acceptable precision was 100,000 persons, assuming most patients would have at least 1.5 years of follow-up. It was considered that, by including all subjects listed in each database from 01-January-2014 to 31-December-2018, this minimum sample would be exceeded. For Phase 2, assuming maximum uncertainty (p=q=50%) and a confidence of 95%, reviewing 100 prevalent cases per participating centre was calculated to offer a maximum margin of error (minimum precision) of 10% when describing the proportions of the primary variable.

---

4 The pulmonary department in Beatriz Angelo Hospital (Portugal) was neither able to capture cases managed at other departments of the centre. However, this missing information was considered negligible, as cases managed at other departments were estimated to be less than 10%.
Section D. Exceptions to the general methodology for PPV calculation in Phase 2

Belgium:

- The only participating centre allowing positive predictive value (PPV) calculation (i.e. participating in both Phase 1 and 2) was the Ghent University Hospital. This centre, however, had two particularities: it was a reference centre for SSc-ILD and only provided data for this condition; and they did not conduct the systematic search, but retrieved cases directly from a departmental database which included all SSc-ILD patients presenting for assessment during each year. Thus, they theoretical PPV was 1.0. As using this PPV would have led to overestimation, a conservative approach was preferred instead, and the PPV used was the average for all countries (except Belgium). This PPV, however, was not used uniformly across Belgium. As the Liege University Hospital Centre was a reference centre for rheumatological ILDs, overestimation of RA-ILD, mixed CTD-ILD and other CTD-ILD incidence/prevalence was expected, and an alternative PPV was used. The centre selected a random sample of 100 patients from those listed in their database in 2018. This sample was searched manually for the main categories (ILDs, F-ILDs and non-IPF F-ILD), but also automatically by using a refined version of the study algorithm. This version retrieved only patients with at least three (instead of one) code and/or keyword for the condition of interest between 01-January and 31-December. A PPV of 59% was obtained, and the corresponding correction factor of 0.59 was applied to adjust incidence/prevalence of the rheumatological ILDs above.

Denmark:

- Due to the classification issues with IPF and other F-ILD detailed in Section A, in Phase 2 the consecutive non-IPF F-ILD cases used as source population were pre-reviewed in order to exclude misclassified ones. In total, 140 consecutive cases were reviewed to obtain a sample of 100 non-IPF F-ILD patients. Of the 40 excluded patients, two were considered not evaluable (one died before examination and one lacked data for the entire 2-year period of retrospective follow-up) and 38 were excluded (29 did not finally had an ILD, and 9 had IPF). This gave a PPV of 100/138 (73%, i.e. correction factor of 0.73).

Section E. Sensitivity analyses

Three sensitivity analyses were performed to address the uncertainties around estimates. First, in Phase 1, both minimum and maximum incidence/prevalence estimates were obtained to
account for potential under/overestimation arising from the population taken as reference for calculations (see Section B of this Supplementary Material). Second, in Phase 2, four additional methods were applied to obtain incidence/prevalence of progressive-fibrosing ILDs (PF-ILDs), to assess the impact of potentially centre-related biasing factors such as type (i.e. secondary or tertiary), receipt of referrals, or heterogeneity in referral/treatment patterns. These analyses used: (1b) The weighted country mean percentage of PF behaviour (as in the primary analysis) but applying a correction factor to the coverage areas of the sites participating in Phase 2 (i.e. which directly reported a higher/lower-than-mean percentage of PF behaviour); (2) An overall pooled percentage of PF behaviour across countries obtained through a random-effects model meta-analysis, thus not accounting for distribution of non-IPF F-ILDs within country (heterogeneity among countries was evaluated through the $I^2$-statistic); (2b) The overall pooled percentage of PF behaviour (as in Method 2), but applying a correction factor to the coverage area of sites participating in Phase 2 (as in Method 1b); (3) The arithmetic mean for percentages of PF behaviour from each country. Finally, to account for possible overestimations arising from the use of code and/or keywords in the systematic search, the country PPV was applied to crude incidence/prevalence estimates of Phase 1 and 2 to obtain adjusted estimates.
If a patient fulfilled the algorithm for more than one condition within a given year, the case was counted in each separate condition, but only once in overarching categories. 

Abbreviations: CTD-ILD, connective tissue disease-associated interstitial lung disease; F-ILD, fibrosing interstitial lung disease; HP, hypersensitivity pneumonitis; ILD, interstitial lung disease; iNSIP, idiopathic non-specific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; RA-ILD; rheumatoid arthritis-associated interstitial lung disease; SSc-ILD, systemic sclerosis-associated interstitial lung disease; uIIP, idiopathic interstitial pneumonia; UIP, usual interstitial pneumonia.
Figure 2. Annual prevalence (per 10^5 persons) of SSc-ILD in the participating countries during the study period (2014-2018)

Areas show the widest variability observed in the primary plus sensitivity analyses. In Belgium, Greece, Norway and Portugal, this means the range between the minimum adjusted and the maximum crude estimates. In Denmark and Finland, there was only one participating centre which searched a national or regional database (respectively), so there were no reference and extended populations, but a single population (i.e. no maximum-minimum estimates, but a single estimate). In both countries, the area shows the range between the single crude and adjusted estimates. In Portugal, only one of the participating centres reported an extended population, and only for 2018. Therefore, minimum estimates could not be obtained for 2014-2017. For these years, the area shows the range from 0 to maximum crude estimates.

Abbreviations: SSc-ILD, systemic sclerosis-associated interstitial lung disease; NA, not available.
**SUPPLEMENTARY TABLES**

**sTable 1. PPVs by centre and country**

| Country   | Centre 1 | Centre 2 | Centre 3 | Overall |
|-----------|----------|----------|----------|---------|
| Belgium   | 0.75     |          |          | 0.75    |
| Denmark   | 0.73     |          |          | 0.73    |
| Finland   | 0.49     |          |          | 0.49    |
| Greece    | 0.64     | 0.93     | 0.80     | 0.79    |
| Norway    | 0.75     |          |          | 0.75    |
| Portugal  | 0.68     | 0.77     |          | 0.73    |

Belgium: Centre 1 - Ghent University Hospital.
Denmark: Centre 1 (Lillebælt Hospital).
Finland: Centre 1 (Turku University Hospital)
Greece: Centre 1 (University Hospital of Larissa), Centre 2 (General Hospital of Thessaloniki), Centre 3 (Athens Medical Centre).
Norway: Centre 1 (Oslo University Hospital, Rikshospitalet).
Portugal: Centre 1 (Sao Joao University Hospital Centre), Centre 2 (Beatriz Angelo Hospital).
Abbreviations: PPV, positive predictive value.
| Country | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|----------|--------------|------|------|------|------|------|
| **ILDs**<br>Belgium | Min 17.9 (16.9,18.9) | 17.5 (15.4,19.9)<br>17.2 (15.1,19.5)<br>21.0 (18.7,23.7)<br>20.5 (18.1,23.1) | 55.3 (49.3,62.1)<br>43.8 (41.9,45.8)<br>43.1 (41.2,45.0)<br>38.5 (36.8,40.4) | 63.5 (56.8,71.1)<br>71.4 (63.9,79.7)<br>86.9 (78.4,96.3)<br>83.6 (75.2,93.0) | 60.4 (58.2,62.8)<br>59.4 (57.2,61.7)<br>73.1 (51.0,85.3)<br>75.3 (53.2,75.5) | 42.4 (36.4,49.4)<br>46.1 (39.8,53.3)<br>50.6 (44.0,58.2)<br>53.7 (46.9,61.4) | 42.8 (38.1,44.9)<br>38.5 (33.6,43.3)<br>42.2 (34.3,46.1)<br>43.5 (40.6,46.5) | 53.5 (49.4,60.3)<br>42.4 (36.4,49.4)<br>46.1 (39.8,53.3)<br>50.6 (44.0,58.2) |
| **F-ILDs**<br>Belgium | Min 16.7 (15.8,17.7) | 16.0 (14.4,18.7)<br>19.9 (17.6,22.5)<br>18.7 (16.5,21.2) | 52.3 (46.5,58.8)<br>59.5 (53.0,66.7)<br>66.3 (59.2,74.3) | 52.3 (46.5,58.8)<br>59.5 (53.0,66.7)<br>66.3 (59.2,74.3) | 52.3 (46.5,58.8)<br>59.5 (53.0,66.7)<br>66.3 (59.2,74.3) | 52.3 (46.5,58.8)<br>59.5 (53.0,66.7)<br>66.3 (59.2,74.3) | 52.3 (46.5,58.8)<br>59.5 (53.0,66.7)<br>66.3 (59.2,74.3) | 52.3 (46.5,58.8) |
| **Country** | **Estimate** | **Study period** | **2014** | **2015** | **2016** | **2017** | **2018** | **2019** |
| Belgium | Min 17.9 (16.9,18.9) | 17.5 (15.4,19.9)<br>17.2 (15.1,19.5)<br>21.0 (18.7,23.7)<br>20.5 (18.1,23.1) | 55.3 (49.3,62.1)<br>43.8 (41.9,45.8)<br>43.1 (41.2,45.0)<br>38.5 (36.8,40.4) | 63.5 (56.8,71.1)<br>71.4 (63.9,79.7)<br>86.9 (78.4,96.3)<br>83.6 (75.2,93.0) | 60.4 (58.2,62.8)<br>59.4 (57.2,61.7)<br>73.1 (51.0,85.3)<br>75.3 (53.2,75.5) | 42.4 (36.4,49.4)<br>46.1 (39.8,53.3)<br>50.6 (44.0,58.2)<br>53.7 (46.9,61.4) | 42.8 (38.1,44.9)<br>38.5 (33.6,43.3)<br>42.2 (34.3,46.1)<br>43.5 (40.6,46.5) | 53.5 (49.4,60.3) |
| Country | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|----------|--------------|------|------|------|------|------|
| Greece  | Max      | 22.4 (21.5,23.4) | 18.9 (16.9,21.1) | 20.4 (18.6,22.5) | 21.6 (19.7,23.7) | 27.2 (25.1,29.6) | 23.1 (21.1,25.2) |
|         | Min      | 11.2 (10.6,11.8) | NA   | 11.0 (9.8,12.4) | 14.5 (13.2,16.0) | 10.1 (9.0,11.4) | 9.1 (8.1,10.2) |
|         | Max      | 28.5 (27.2,29.9) | NA   | 28.2 (25.6,31.1) | 37.7 (34.7,41.0) | 26.8 (24.3,29.6) | 22.2 (20.1,24.6) |
| Norway  | Min      | 6.3 (5.8,6.7)   | 4.6 (3.9,5.6)   | 6.0 (5.1,7.1)   | 5.4 (4.5,6.4)   | 7.2 (6.2,8.3) | 7.7 (6.8,8.7) |
|         | Max      | 8.6 (8.1,9.2)   | 6.4 (5.5,7.5)   | 8.3 (7.2,9.5)   | 7.4 (6.4,8.6)   | 9.9 (8.7,11.2) | 10.6 (9.5,11.8) |
| Portugal| Min      | 18.3 (16.6,19.9) | 20.6 (18.8,22.4) | 17.2 (15.5,18.8) | 17.5 (15.9,19.2) | 18.0 (16.4,19.7) | 17.9 (16.2,19.6) |
|         | Max      | 38.4 (35.6,41.2) | 40.0 (37.2,42.9) | 35.5 (32.8,38.2) | 38.0 (35.2,40.8) | 40.2 (37.4,43.1) | 38.3 (35.6,41.0) |
| Overall | Min      | 18.3 (16.6,19.9) | 20.6 (18.8,22.4) | 17.2 (15.5,18.8) | 17.5 (15.9,19.2) | 18.0 (16.4,19.7) | 17.9 (16.2,19.6) |
|         | Max      | 38.4 (35.6,41.2) | 40.0 (37.2,42.9) | 35.5 (32.8,38.2) | 38.0 (35.2,40.8) | 40.2 (37.4,43.1) | 38.3 (35.6,41.0) |

**IPF**

| Country | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|----------|--------------|------|------|------|------|------|
| Belgium | Min      | 0.9 (0.7,1.3) | 0.7 (0.3,1.5) | 1.1 (0.6,2.1) | 0.6 (0.3,1.4) | 1.2 (0.7,2.2) | 1.1 (0.6,2.1) |
|         | Max      | 3.8 (2,9,4,9) | 2.7 (1,4,5,5) | 4.1 (2,4,7,0) | 2.5 (1,2,5,3) | 5.0 (3,0,8,4) | 4.6 (2,7,9,9) |
| Denmark | Min      | 0.4 (0,4,0,5) | 0.4 (0,4,0,5) | 0.5 (0,5,0,6) | 0.4 (0,4,0,5) | 0.4 (0,3,0,4) | 0.4 (0,4,0,5) |
|         | Max      | 10.6 (10,2,11,1) | 10.3 (9,4,11,3) | 11.4 (10,4,12,4) | 11.4 (10,5,12,4) | 9.8 (8,9,10,7) | 10.3 (9,4,11,2) |
| Finland | Min      | 3.5 (2,7,4,4) | 4.2 (2,6,6,8) | 3.5 (2,1,6,0) | 3.0 (1,7,5,3) | 3.5 (2,1,5,9) | 3.2 (1,9,5,6) |
|         | Max      | 7.1 (6,0,8,4) | 8.5 (6,1,12,0) | 7.2 (5,0,10,4) | 6.1 (4,1,9,2) | 7.1 (4,9,10,3) | 6.6 (4,5,9,7) |
| Greece  | Min      | 3.5 (3,3,3,8) | 1.5 (1,2,2,0) | 3.5 (3,0,4,2) | 3.8 (3,2,4,5) | 4.3 (3,6,5,0) | 4.5 (3,9,5,3) |
|         | Max      | 8.0 (7,4,8,5) | 4.3 (3,4,5,4) | 7.6 (6,5,8,9) | 8.2 (7,0,9,5) | 9.2 (8,0,10,6) | 9.7 (8,5,11,2) |
| Norway  | Min      | 2.2 (1,9,2,5) | NA   | 2.1 (1,6,2,7) | 2.4 (1,9,3,0) | 2.2 (1,7,8,2) | 2.0 (1,6,2,6) |
|         | Max      | 5.5 (5,0,6,2) | NA   | 5.3 (4,2,6,6) | 6.2 (5,0,7,6) | 5.8 (4,7,7,2) | 4.9 (4,0,6,2) |
| Portugal| Min      | 0.9 (0,7,1,1) | 0.7 (0,4,1,1) | 0.7 (0,4,1,1) | 0.6 (0,4,1,0) | 1.2 (0,9,1,8) | 1.1 (0,8,1,5) |
|         | Max      | 1.2 (1,0,1,4) | 1.0 (0,7,1,5) | 0.9 (0,6,1,4) | 0.9 (0,6,1,3) | 1.7 (1,3,2,3) | 1.5 (1,1,2,0) |
| Overall | Min      | 2.0 (1,4,2,5) | 1.7 (1,2,2,3) | 2.0 (1,4,2,5) | 1.8 (1,3,2,4) | 2.2 (1,6,2,7) | 2.1 (1,5,2,7) |
|         | Max      | 6.0 (4,9,7,1) | 5.4 (4,3,6,4) | 6.1 (4,9,7,2) | 5.9 (4,8,7,0) | 6.4 (5,3,7,6) | 6.3 (5,2,7,4) |
| Belgium | Min      | 15.8 (14,9,16,7) | 12.6 (11,0,14,4) | 15.3 (13,3,17,5) | 15.4 (13,5,17,5) | 18.7 (16,6,21,2) | 17.6 (15,4,20,0) |
|         | Max      | 62.6 (59,5,65,9) | 49.5 (43,9,55,8) | 55.4 (49,3,62,3) | 63.8 (56,9,71,6) | 77.2 (69,4,86,0) | 71.7 (64,1,80,1) |
| Country   | Estimate | Study period | 2014       | 2015       | 2016       | 2017       | 2018       |
|-----------|----------|--------------|------------|------------|------------|------------|------------|
| **Non-IPF**<br>F-ILDs |          |              |            |            |            |            |            |
| **Denmark** | Min      | 32.5 (31.8,33.3) | 32.5 (30.8,34.2) | 34.6 (32.9,36.3) | 33.7 (32.0,35.4) | 30.4 (28.8,32.0) | 31.6 (30.0,33.3) |
|           | Max      | 54.9 (53.9,55.9) | 54.6 (52.4,56.8) | 58.3 (56.1,60.6) | 57.3 (55.1,59.6) | 51.1 (49.1,53.3) | 53.3 (51.2,55.4) |
| **Finland** | Min      | 19.0 (17.1,21.0) | 28.9 (24.0,34.8) | 14.7 (11.4,19.1) | 15.2 (11.8,19.6) | 17.8 (14.1,22.5) | 18.2 (14.5,23.0) |
|           | Max      | 38.7 (36.0,41.5) | 58.9 (51.8,67.1) | 30.1 (25.1,36.1) | 31.0 (25.9,37.0) | 36.4 (30.9,42.8) | 37.2 (31.7,43.8) |
| **Greece** | Min      | 6.3 (5.9,6.7) | 3.8 (3.2,4.5) | 5.9 (5.1,6.7) | 6.8 (6.0,7.7) | 8.0 (7.2,9.0) | 6.9 (6.1,7.9) |
|           | Max      | 15.5 (14.8,16.3) | 15.2 (13.4,17.2) | 13.5 (12.0,15.2) | 14.4 (12.9,16.1) | 19.6 (17.8,21.6) | 14.8 (13.3,16.6) |
| **Norway** | Min      | 9.0 (8.5,9.6) | NA          | NA          | NA          | NA          | NA          |
|           | Max      | 23.0 (21.8,24.2) | NA          | NA          | NA          | NA          | NA          |
| **Portugal** | Min      | 5.4 (5.0,5.8) | 3.9 (3.2,4.8) | 5.3 (4.5,6.3) | 4.7 (4.0,5.7) | 5.9 (5.0,7.0) | 6.6 (5.7,7.6) |
|           | Max      | 7.4 (7.0,7.9) | 5.4 (4.6,6.4) | 7.4 (6.4,8.5) | 6.5 (5.6,7.6) | 8.2 (7.1,9.4) | 9.1 (8.1,10.2) |
| **Overall** | Min      | 15.1 (13.6,16.7) | 17.6 (15.9,19.2) | 14.0 (12.5,15.5) | 14.5 (13.0,16.0) | 14.8 (13.3,16.3) | 14.7 (13.2,16.3) |
|           | Max      | 34.3 (31.7,36.9) | 36.7 (34.0,39.5) | 31.3 (28.8,33.8) | 34.1 (31.5,36.7) | 35.6 (32.9,38.3) | 33.9 (31.4,36.4) |
| **SSc-ILD** |          |              |            |            |            |            |            |
| **Belgium** | Min      | 0.9 (0.7,1.0) | 0.4 (0.2,0.8) | 1.1 (0.8,1.6) | 1.1 (0.8,1.6) | 0.7 (0.4,1.1) | 1.0 (0.6,1.4) |
|           | Max      | 1.1 (1.0,1.4) | 0.5 (0.3,0.9) | 1.5 (1.1,2.0) | 1.5 (1.1,2.1) | 1.0 (0.6,1.4) | 1.3 (0.9,1.8) |
| **Denmark** | Min      | 0.5 (0.4,0.6) | 0.5 (0.3,0.7) | 0.5 (0.3,0.7) | 0.4 (0.3,0.7) | 0.5 (0.3,0.7) | 0.5 (0.3,0.7) |
|           | Max      | 0.6 (0.5,0.7) | 0.7 (0.5,1.0) | 0.6 (0.4,0.9) | 0.6 (0.4,0.8) | 0.6 (0.4,0.9) | 0.6 (0.4,0.9) |
| **Finland** | Min      | 0.3 (0.1,0.7) | 0.4 (0.1,1.9) | 0.1 (0.0,2.1) | 0.4 (0.1,1.9) | 0.2 (0.0,1.8) | 0.5 (0.1,2.0) |
|           | Max      | 0.7 (0.4,1.1) | 0.8 (0.3,2.4) | 0.3 (0.0,1.8) | 0.8 (0.2,2.4) | 0.5 (0.1,2.0) | 1.0 (0.4,2.7) |
| **Greece** | Min      | 0.4 (0.3,0.5) | 0.4 (0.2,0.6) | 0.4 (0.2,0.6) | 0.4 (0.2,0.6) | 0.5 (0.3,0.8) | 0.4 (0.3,0.7) |
|           | Max      | 1.1 (0.9,1.4) | 1.4 (0.9,2.1) | 1.0 (0.6,1.5) | 0.7 (0.4,1.2) | 1.7 (1.2,2.3) | 1.0 (0.7,1.5) |
| **Norway** | Min      | 0.9 (0.7,1.1) | NA          | 0.7 (0.4,1.1) | 1.5 (1.1,2.0) | 0.7 (0.5,1.1) | 0.6 (0.4,1.0) |
|           | Max      | 2.2 (1.9,2.6) | NA          | 1.8 (1.2,2.6) | 3.8 (2.9,5.0) | 1.9 (1.3,2.8) | 1.5 (1.0,2.2) |
|           | Min      | 0.3 (0.3,0.5) | 0.3 (0.1,0.6) | 0.5 (0.3,0.9) | 0.3 (0.1,0.6) | 0.3 (0.1,0.6) | 0.3 (0.2,0.6) |
| Country | Estimate | Study period | 2014       | 2015       | 2016       | 2017       | 2018       |
|---------|----------|--------------|------------|------------|------------|------------|------------|
| Portugal| Max      | 0.5 (0.4,0.6) | 0.4 (0.2,0.7) | 0.7 (0.5,1.2) | 0.4 (0.2,0.8) | 0.4 (0.2,0.8) | 0.5 (0.3,0.8) |
|         | Min      | 0.5 (0.2,0.8) | 0.4 (0.1,0.6) | 0.5 (0.2,0.8) | 0.6 (0.3,0.9) | 0.5 (0.2,0.7) | 0.5 (0.2,0.8) |
| Overall | Max      | 1.0 (0.6,1.4) | 0.7 (0.4,1.1) | 1.0 (0.6,1.4) | 1.3 (0.8,1.8) | 1.0 (0.6,1.4) | 1.0 (0.6,1.4) |

The table shows the widest variability observed. In Belgium, Greece and Norway, this means the minimum adjusted and the maximum crude estimates (the participating centre in Norway could not retrieve incident cases for 2014, and thus incidence could not be estimated for that year). In Denmark and Finland, there was only one participating centre which searched a national or regional database (respectively), so there were no reference and extended populations, but a single population (i.e. no maximum-minimum estimates, but a single estimate). In these countries, the single crude and adjusted estimates are shown. In Portugal, only one of the participating centres reported an extended population, and only for 2018. Plus, incident cases for 2018 could not be retrieved in this centre, so minimum adjusted estimates could not be obtained for Portugal. Instead, the table shows the nearest estimates (maximum adjusted) as minimum values.

Abbreviations: CI, confidence interval; ILDs, interstitial lung diseases; F-ILDs, fibrosing interstitial lung diseases; IPF, idiopathic pulmonary fibrosis; NA, not available; SSc-ILD, systemic sclerosis-associated interstitial lung disease.
Table 3. Prevalence per 10^5 persons (95%CI) of ILD, F-ILD, IPF, non-IPF F-ILD, and SSc-ILD in each country and overall, annually and for the whole study period

| Country | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|----------|--------------|------|------|------|------|------|
| **ILDs** |          |              |      |      |      |      |      |
| Belgium |          |              |      |      |      |      |      |
| Min     | 49.8 (46.7,53.0) | 37.5 (34.9,40.1) | 45.5 (42.5,48.5) | 52.0 (48.8,55.3) | 55.4 (52.0,58.9) | 61.4 (57.8,65.1) |
| Max     | 195.1 (184.3,205.8) | 145.4 (136.7,154.2) | 163.3 (154.1,172.6) | 213.1 (201.5,224.6) | 225.4 (213.4,237.5) | 247.4 (234.6,260.1) |
| Denmark |          |              |      |      |      |      |      |
| Min     | 132.2 (128.9,135.6) | 130.8 (127.4,134.2) | 141.1 (137.6,144.6) | 128.5 (125.2,131.8) | 121.7 (118.5,124.9) | 139.2 (135.7,142.6) |
| Max     | 182.4 (178.5,186.3) | 180.4 (176.5,184.4) | 194.7 (190.6,198.7) | 177.2 (173.1,181.1) | 167.9 (164.1,171.6) | 191.9 (187.9,195.9) |
| Finland |          |              |      |      |      |      |      |
| Min     | 90.9 (81.4,100.3) | 90.8 (81.3,100.3) | 85.8 (76.8,95.0) | 87.8 (78.5,97.1) | 90.7 (81.3,100.1) | 99.0 (89.2,108.8) |
| Max     | 185.4 (172.0,198.9) | 185.3 (171.8,198.9) | 175.1 (162.0,188.3) | 179.2 (166.0,192.5) | 185.2 (171.7,198.6) | 202.1 (188.1,216.1) |
| Greece  |          |              |      |      |      |      |      |
| Min     | 23.8 (21.0,26.6) | 16.3 (14.0,18.6) | 17.5 (15.1,19.8) | 23.0 (20.3,25.8) | 28.5 (25.4,31.5) | 33.6 (30.3,36.9) |
| Max     | 93.3 (85.0,101.5) | 67.7 (60.7,74.7) | 67.4 (60.4,74.4) | 90.3 (82.2,98.4) | 113.0 (103.9,122.1) | 128.3 (118.6,138.0) |
| Norway  |          |              |      |      |      |      |      |
| Min     | 55.8 (53.0,58.5) | 48.2 (45.5,50.8) | 49.5 (46.8,52.1) | 59.9 (57.0,62.7) | 63.4 (60.6,66.3) | 56.8 (54.1,59.5) |
| Max     | 142.1 (136.0,148.2) | 121.1 (115.3,126.9) | 126.5 (120.6,132.4) | 155.6 (149.1,162.0) | 167.4 (160.8,174.0) | 138.8 (133.1,144.5) |
| Portugal|          |              |      |      |      |      |      |
| Min     | 31.3 (28.1,34.4) | NA | NA | NA | NA | 35.4 (32.1,38.8) |
| Max     | 52.4 (47.9,56.9) | 35.9 (32.2,39.5) | 45.9 (41.8,49.9) | 51.8 (47.5,56.2) | 58.0 (53.4,62.6) | 76.7 (70.6,82.9) |
| Overall |          |              |      |      |      |      |      |
| Min     | 65.8 (62.3,69.4) | 60.1 (56.7,63.6) | 63.3 (59.8,66.8) | 65.8 (62.6,69.3) | 67.9 (64.3,71.5) | 72.1 (68.4,75.8) |
| Max     | 142.6 (136.4,148.8) | 122.6 (116.9,128.4) | 128.8 (122.9,134.7) | 145.4 (138.3,150.8) | 152.8 (146.4,159.2) | 164.2 (157.5,170.9) |
| **F-ILDs** |          |              |      |      |      |      |      |
| Belgium |          |              |      |      |      |      |      |
| Min     | 48.3 (45.2,51.4) | 36.6 (34.1,39.2) | 44.3 (41.4,47.2) | 50.3 (47.2,53.5) | 53.9 (50.5,57.2) | 58.9 (55.3,62.4) |
| Max     | 189.0 (178.5,199.5) | 142.0 (133.4,150.6) | 159.0 (149.9,168.0) | 205.9 (194.6,217.1) | 219.0 (207.2,230.8) | 236.8 (224.5,249.1) |
| Denmark |          |              |      |      |      |      |      |
| Min     | 129.7 (126.3,133.0) | 128.1 (124.8,131.4) | 138.6 (135.2,142.1) | 125.9 (122.7,129.2) | 119.2 (116.0,122.3) | 136.6 (133.2,139.9) |
| Max     | 178.8 (175.0,182.7) | 176.7 (172.8,180.6) | 191.2 (187.2,195.3) | 173.7 (169.9,177.5) | 164.4 (160.7,168.1) | 188.3 (184.4,192.3) |
| Finland |          |              |      |      |      |      |      |
| Min     | 83.0 (73.9,92.0) | 84.3 (75.2,93.5) | 79.9 (71.0,88.8) | 79.3 (70.5,88.1) | 82.3 (73.9,91.2) | 89.0 (79.7,98.3) |
| Max     | 169.3 (156.4,182.2) | 172.1 (159.1,185.2) | 163.1 (150.4,175.7) | 161.8 (149.2,174.4) | 167.9 (155.1,180.7) | 181.6 (168.3,194.9) |

Min = Minimum; Max = Maximum; CI = Confidence Interval
| Country   | Estimate | Study period | 2014       | 2015       | 2016       | 2017       | 2018       |
|-----------|----------|--------------|------------|------------|------------|------------|------------|
| Greece    | Max      | 89.5 (81.4, 97.6) | 65.5 (58.6, 72.3) | 65.2 (58.3, 72.1) | 87.2 (79.2, 95.2) | 108.3 (99.4, 117.2) | 121.6 (112.1, 131.0) |
| Norway    | Min      | 50.9 (48.3, 53.5) | 44.0 (41.4, 46.5) | 44.8 (42.2, 47.3) | 53.1 (50.4, 55.8) | 58.6 (55.8, 61.4) | 52.9 (50.2, 55.5) |
|           | Max      | 129.7 (123.9, 135.5) | 110.6 (105.1, 116.2) | 114.4 (108.8, 120.0) | 138.0 (131.9, 144.1) | 154.8 (148.5, 161.2) | 129.2 (123.7, 134.7) |
| Portugal  | Min      | 20.3 (17.8, 22.8) | NA         | NA         | NA         | 26.7 (23.8, 29.6) | 26.7 (23.8, 29.6) |
| Norway    | Max      | 34.0 (30.4, 37.6) | 21.0 (18.2, 23.7) | 28.4 (25.1, 31.6) | 32.2 (28.8, 35.6) | 36.9 (33.2, 40.5) | 57.9 (52.5, 63.2) |
| Portugal  | Max      | 60.6 (57.2, 64.0) | 55.7 (52.4, 59.0) | 58.6 (55.2, 62.0) | 59.8 (56.4, 63.2) | 62.0 (58.6, 65.5) | 66.8 (63.2, 70.4) |
| Overall   | Min      | 132.5 (126.5, 138.5) | 114.6 (109.1, 120.2) | 120.2 (114.5, 125.9) | 133.1 (127.2, 139.1) | 141.9 (135.7, 148.1) | 152.6 (146.1, 159.0) |
| Belgium   | Min      | 4.4 (3.0, 5.8) | 0.9 (0.3, 1.6) | 2.9 (1.8, 4.0) | 4.9 (3.5, 6.4) | 5.8 (4.2, 7.4) | 7.5 (5.7, 9.3) |
|           | Max      | 17.8 (12.9, 22.6) | 3.8 (1.5, 6.0) | 10.6 (7.0, 14.2) | 20.9 (15.5, 26.2) | 24.2 (18.5, 30.0) | 31.0 (24.5, 37.4) |
| Denmark   | Min      | 2.7 (2.2, 3.1) | 2.6 (2.2, 3.1) | 2.8 (2.3, 3.3) | 2.7 (2.2, 3.2) | 2.3 (1.9, 2.7) | 2.8 (2.4, 3.3) |
| Finland   | Max      | 27.7 (26.2, 29.3) | 25.9 (24.4, 27.4) | 29.3 (27.8, 30.9) | 27.4 (25.9, 28.9) | 25.7 (24.2, 27.1) | 30.4 (28.8, 32.0) |
| Greece    | Min      | 11.2 (7.8, 14.5) | 8.5 (5.6, 11.4) | 10.5 (7.2, 13.7) | 11.3 (8.0, 14.6) | 12.5 (9.0, 16.0) | 13.0 (9.5, 16.6) |
|           | Max      | 22.8 (18.0, 27.5) | 17.3 (13.2, 21.5) | 21.3 (16.8, 25.9) | 23.0 (18.3, 27.8) | 25.4 (20.4, 30.4) | 26.6 (21.5, 31.7) |
| Norway    | Min      | 6.2 (4.8, 7.7) | 2.9 (1.9, 3.9) | 4.1 (2.9, 5.2) | 5.9 (4.5, 7.3) | 8.0 (6.4, 9.6) | 10.3 (8.4, 12.1) |
|           | Max      | 17.8 (14.2, 21.4) | 8.2 (5.8, 10.7) | 11.7 (8.8, 14.6) | 16.9 (13.4, 20.5) | 23.0 (18.9, 27.1) | 29.3 (24.7, 33.9) |
| Portugal  | Min      | 8.1 (7.1, 9.2) | 8.1 (7.0, 9.2) | 6.5 (5.5, 7.4) | 8.1 (7.0, 9.2) | 8.7 (7.6, 9.8) | 9.0 (7.9, 10.1) |
| Norway    | Max      | 20.7 (18.3, 23.0) | 20.5 (18.1, 22.8) | 16.5 (14.4, 18.7) | 21.0 (18.6, 23.4) | 22.9 (20.5, 25.4) | 22.0 (19.7, 24.3) |
| Portugal  | Min      | 2.8 (1.9, 3.7) | NA         | NA         | NA         | 3.1 (2.1, 4.1) | 3.1 (2.1, 4.1) |
| Norway    | Max      | 4.7 (3.4, 6.0) | 2.8 (1.8, 3.8) | 4.1 (2.9, 5.3) | 4.9 (3.6, 6.3) | 5.5 (4.1, 6.9) | 6.8 (4.9, 8.6) |
| Portugal  | Min      | 6.2 (5.1, 7.3) | 4.4 (3.4, 5.4) | 5.3 (4.2, 6.3) | 6.3 (5.2, 7.5) | 7.1 (5.9, 8.4) | 7.8 (6.6, 9.1) |
| Norway    | Max      | 18.6 (16.3, 20.9) | 13.1 (11.1, 15.0) | 15.6 (13.5, 17.7) | 19.0 (16.7, 21.3) | 21.1 (18.7, 23.6) | 24.3 (21.7, 27.0) |
| Belgium   | Min      | 44.2 (41.3, 47.0) | 35.7 (33.2, 38.2) | 41.4 (38.7, 44.2) | 45.4 (42.5, 48.3) | 48.1 (45.0, 51.2) | 51.4 (48.2, 54.6) |
| Belgium   | Max      | 172.4 (162.6, 182.1) | 138.2 (129.8, 146.6) | 148.4 (139.8, 157.0) | 185.0 (174.6, 195.3) | 194.8 (184.0, 205.6) | 205.8 (194.8, 216.9) |
| Country | Estimate | Study period | 2014     | 2015     | 2016     | 2017     | 2018     |
|---------|----------|--------------|----------|----------|----------|----------|----------|
| **Non-IPF F-ILDs** |          |              |          |          |          |          |          |
| Denmark | Min      |              | 109.6 (106.6,112.7) | 109.3 (106.2,112.4) | 117.7 (114.5,120.9) | 106.3 (103.3,109.3) | 100.3 (97.4,103.3) | 114.7 (111.6,117.8) |
|         | Max      |              | 175.3 (171.5,179.2) | 173.0 (169.1,176.9) | 187.8 (183.7,191.8) | 170.2 (166.4,174.0) | 160.9 (157.2,164.6) | 184.8 (180.8,188.7) |
| Finland | Min      |              | 71.8 (63.4,80.2) | 75.9 (67.2,84.5) | 69.4 (61.2,77.7) | 68.0 (59.8,76.2) | 69.8 (61.5,78.0) | 75.9 (67.4,84.5) |
|         | Max      |              | 146.5 (134.6,158.5) | 154.8 (142.4,167.2) | 187.8 (183.7,191.8) | 170.2 (166.4,174.0) | 160.9 (157.2,164.6) | 184.8 (180.8,188.7) |
| Greece  | Min      |              | 17.2 (14.9,19.6) | 13.7 (11.6,15.8) | 13.4 (11.3,15.5) | 16.9 (14.6,19.3) | 19.8 (17.3,22.4) | 22.3 (19.6,25.0) |
|         | Max      |              | 69.0 (61.9,76.1) | 55.5 (49.2,61.8) | 51.9 (45.7,58.0) | 67.8 (60.8,74.9) | 82.1 (74.3,89.8) | 88.1 (80.0,96.1) |
| Norway  | Min      |              | 42.8 (40.4,45.2) | 35.9 (33.6,38.2) | 38.3 (35.9,40.6) | 45.0 (42.5,47.5) | 49.9 (47.4,52.5) | 43.9 (41.5,46.2) |
|         | Max      |              | 109.0 (103.7,114.4) | 90.2 (85.1,95.2) | 97.9 (92.7,103.0) | 117.0 (111.4,122.6) | 131.9 (126.0,137.8) | 107.2 (102.2,112.2) |
| Portugal | Min       |              | 17.5 (15.1,19.8) | NA        | NA        | NA        | 23.6 (20.8,26.3) |          |
|         | Max      |              | 29.3 (25.9,32.6) | 18.2 (15.6,20.8) | 24.3 (21.3,27.3) | 27.3 (24.1,30.4) | 31.4 (28.0,34.7) | 51.1 (46.1,56.1) |
| **Overall** |          |              | 51.8 (48.7,55.0) | 48.9 (45.9,52.0) | 50.6 (47.5,53.8) | 51.0 (47.8,54.1) | 52.5 (49.3,55.6) | 56.2 (52.9,59.4) |
|         | Min      |              | 117.4 (111.8,123.1) | 105.0 (99.7,110.3) | 108.6 (103.3,114.0) | 117.7 (112.1,123.3) | 123.9 (118.2,129.7) | 132.0 (126.0,137.9) |
| **SSc-ILD** |          |              |          |          |          |          |          |          |
| Belgium | Min      |              | 4.1 (3.0,5.3) | 3.0 (2.0,4.0) | 3.7 (2.6,4.8) | 4.5 (3.3,5.7) | 4.4 (3.3,5.6) | 4.9 (3.7,6.2) |
|         | Max      |              | 5.5 (4.2,6.8) | 4.0 (2.9,5.1) | 4.9 (3.7,6.2) | 6.0 (4.6,7.4) | 5.9 (4.5,7.3) | 6.5 (5.1,8.0) |
| Denmark | Min      |              | 2.2 (1.8,2.7) | 2.5 (2.1,3.0) | 2.6 (2.1,3.0) | 2.3 (1.8,2.7) | 1.6 (1.3,2.0) | 2.3 (1.8,2.7) |
|         | Max      |              | 3.1 (2.6,3.6) | 3.5 (2.9,4.0) | 3.5 (3.0,4.1) | 3.1 (2.6,3.6) | 2.2 (1.8,2.7) | 3.1 (2.6,3.6) |
| Finland | Min      |              | 2.0 (0.6,3.4) | 1.6 (0.4,2.9) | 1.9 (0.5,3.3) | 2.0 (0.6,3.4) | 1.9 (0.5,3.2) | 2.6 (1.0,4.2) |
|         | Max      |              | 4.1 (2.1,6.1) | 3.4 (1.5,5.2) | 3.9 (1.9,5.8) | 4.1 (2.1,6.1) | 3.8 (1.9,5.7) | 5.3 (3.0,7.6) |
| Greece  | Min      |              | 1.3 (0.7,2.0) | 1.2 (0.6,1.8) | 1.1 (0.5,1.7) | 1.3 (0.6,1.9) | 1.5 (0.8,2.3) | 1.6 (0.9,2.4) |
|         | Max      |              | 4.1 (2.4,5.9) | 2.0 (0.8,3.2) | 2.7 (1.3,4.2) | 3.9 (2.2,5.6) | 5.8 (3.7,7.8) | 6.2 (4.1,8.4) |
| Norway  | Min      |              | 5.3 (4.4,6.1) | 4.9 (4.0,5.7) | 4.3 (3.5,5.0) | 6.1 (5.2,7.0) | 6.9 (5.9,7.8) | 4.2 (3.4,4.9) |
|         | Max      |              | 13.4 (11.5,15.3) | 12.3 (10.4,14.1) | 10.9 (9.1,12.6) | 15.8 (13.7,17.9) | 18.2 (16.0,20.4) | 10.1 (8.6,11.7) |
|         | Min      |              | 1.3 (0.7,2.0) | NA        | NA        | NA        | NA        | 1.4 (0.8,2.1) |
| Country   | Estimate | Study period | 2014     | 2015     | 2016     | 2017     | 2018     |
|-----------|----------|--------------|----------|----------|----------|----------|----------|
| Portugal  | Max      |              | 2.3 (1.3,3.2) | 1.4 (0.7,2.1) | 2.1 (1.2,3.0) | 2.3 (1.4,3.2) | 2.6 (1.6,3.6) | 3.1 (1.9,4.3) |
| Overall   | Min      |              | 2.6 (1.9,3.4) | 2.3 (1.6,3.0) | 2.4 (1.7,3.1) | 2.8 (2.1,3.6) | 2.9 (2.1,3.6) | 2.8 (2.0,3.5) |
|           | Max      |              | 5.4 (4.3,6.6) | 4.4 (3.4,5.5) | 4.7 (3.6,5.8) | 5.9 (4.6,7.1) | 6.4 (5.2,7.7) | 5.7 (4.5,6.9) |

The table shows the widest variability observed. In Belgium, Greece and Norway and Portugal, this means the minimum adjusted and the maximum crude estimates (in Portugal, only one of the participating centres reported an extended population, and only for 2018, so minimum estimates could only be obtained for that year). In Denmark and Finland, there was only one participating centre which searched a national or regional database (respectively), so there were no reference and extended populations, but a single population (i.e. no maximum-minimum estimates, but a single estimate). In both countries, the single crude and adjusted estimates are shown.

Abbreviations: CI, confidence interval; ILDs, interstitial lung diseases; F-ILDs, fibrosing interstitial lung diseases; IPF, idiopathic pulmonary fibrosis; NA, not available; SSc-ILD, systemic sclerosis-associated interstitial lung disease.
**Table 4. Incidence per 10^5 person-years (95%CI) of non-IPF F-ILD subtypes in each country and overall, annually and for the whole study period**

|         | Country | Estimate | Study period | 2014   | 2015   | 2016   | 2017   | 2018   |
|---------|---------|----------|--------------|--------|--------|--------|--------|--------|
| iNSIP   |         |          |              |        |        |        |        |        |
|         | Belgium | Min      | 2.1 (1.7,2.5)| 1.2 (0.7,2.2)| 2.0 (1.3,3.2)| 2.4 (1.6,3.7)| 2.6 (1.8,4.0)| 2.1 (1.4,3.3)|
|         |         | Max      | 8.4 (7.0,10.0)| 4.8 (2.8,8.1)| 7.5 (5.0,11.2)| 10.1 (7.0,14.6)| 11.0 (7.8,15.7)| 8.8 (5.9,13.0)|
|         | Denmark | Min      | 0.4 (0.3,0.5)| 0.4 (0.3,0.7)| 0.5 (0.4,0.8)| 0.4 (0.3,0.7)| 0.3 (0.2,0.6)| 0.4 (0.2,0.6)|
|         |         | Max      | 0.6 (0.5,0.7)| 0.6 (0.4,0.9)| 0.7 (0.5,1.0)| 0.6 (0.4,0.8)| 0.5 (0.3,0.7)| 0.5 (0.4,0.8)|
|         | Finland | Min      | 1.7 (1.2,2.4)| 2.4 (1.3,4.6)| 1.0 (0.4,2.7)| 1.0 (0.4,2.7)| 2.4 (1.2,4.5)| 1.7 (0.8,3.7)|
|         |         | Max      | 3.5 (2.7,4.4)| 4.9 (3.1,7.7)| 2.1 (1.0,4.1)| 2.0 (1.0,4.1)| 4.8 (3.1,7.6)| 3.5 (2.1,6.0)|
|         | Greece  | Min      | 0.4 (0.3,0.5)| 0.2 (0.1,0.5)| 0.5 (0.3,0.8)| 0.4 (0.3,0.7)| 0.5 (0.3,0.8)| 0.2 (0.1,0.4)|
|         |         | Max      | 0.8 (0.7,1.0)| 0.7 (0.4,1.2)| 1.0 (0.7,1.5)| 0.9 (0.6,1.4)| 1.0 (0.7,1.5)| 0.5 (0.3,0.9)|
|         | Norway  | Min      | 0.9 (0.8,1.1)| NA       | 0.8 (0.5,1.2)| 1.4 (1.0,1.9)| 0.9 (0.6,1.4)| 0.7 (0.4,1.0)|
|         |         | Max      | 2.4 (2.0,2.8)| NA       | 2.0 (1.4,2.9)| 3.6 (2.8,4.7)| 2.5 (1.8,3.4)| 1.6 (1.1,2.3)|
|         | Portugal| Min      | 0.1 (0.1,0.2)| 0.1 (0.1,0.4)| 0.1 (0.0,0.3)| 0.2 (0.1,0.5)| 0.1 (0.0,0.4)| 0.2 (0.1,0.4)|
|         |         | Max      | 0.2 (0.1,0.3)| 0.2 (0.1,0.5)| 0.1 (0.0,0.3)| 0.2 (0.1,0.5)| 0.2 (0.1,0.4)| 0.2 (0.1,0.5)|
|         | Overall | Min      | 1.0 (0.6,1.4)| 1.0 (0.6,1.4)| 0.8 (0.5,1.2)| 0.9 (0.6,1.3)| 1.2 (0.8,1.6)| 0.9 (0.5,1.3)|
|         |         | Max      | 2.6 (1.9,3.4)| 2.2 (1.6,2.9)| 2.2 (1.5,2.9)| 2.9 (2.1,3.7)| 3.3 (2.5,4.2)| 2.5 (1.8,3.2)|
| uIPs    |         |          |              |        |        |        |        |        |
|         | Belgium | Min      | 0.1 (0.1,0.2)| 0.1 (0.1,0.4)| 0.1 (0.0,0.3)| 0.2 (0.1,0.5)| 0.1 (0.0,0.4)| 0.2 (0.1,0.4)|
|         |         | Max      | 13.6 (11.8,15.6)| 10.6 (7.5,15.1)| 13.7 (10.2,18.4)| 15.8 (11.8,21.3)| 13.5 (9.9,18.6)| 14.4 (10.6,19.6)|
|         | Denmark | Min      | 3.0 (2.8,3.2)| 3.3 (2.8,3.9)| 3.1 (2.7,3.7)| 3.0 (2.5,3.5)| 2.7 (2.2,3.2)| 3.0 (2.5,3.5)|
|         |         | Max      | 4.1 (3.9,4.4)| 4.5 (3.9,5.2)| 4.3 (3.8,5.0)| 4.1 (3.5,4.7)| 3.7 (3.1,4.3)| 4.1 (3.5,4.7)|
|         | Finland | Min      | 1.0 (0.6,1.5)| 0.8 (0.2,2.4)| 0.6 (0.2,2.2)| 0.9 (0.3,2.5)| 0.7 (0.2,2.3)| 1.7 (0.8,3.7)|
|         |         | Max      | 1.9 (1.4,2.7)| 1.6 (0.7,3.5)| 1.3 (0.5,3.1)| 1.8 (0.9,3.8)| 1.5 (0.7,3.4)| 3.5 (2.1,6.0)|
|         | Greece  | Min      | 1.0 (0.6,1.5)| 0.8 (0.2,2.4)| 0.6 (0.2,2.2)| 0.9 (0.3,2.5)| 0.7 (0.2,2.3)| 1.7 (0.8,3.7)|
|         |         | Max      | 1.7 (1.4,1.9)| 1.1 (0.7,1.7)| 1.1 (0.8,1.7)| 2.0 (1.4,2.7)| 2.3 (1.7,3.0)| 1.7 (1.2,2.3)|
| Country | Estimate | Study period | 2014     | 2015     | 2016     | 2017     | 2018     |
|---------|----------|--------------|----------|----------|----------|----------|----------|
|         |          |              |          |          |          |          |          |
| Norway  | Min      | 0.9 (0.7,1.1)| NA       | 0.7 (0.4,1.1)| 1.6 (1.2,2.1)| 0.5 (0.3,0.8)| 0.8 (0.6,1.2)|
|         | Max      | 2.3 (1.9,2.7)| NA       | 1.8 (1.2,2.6)| 4.0 (3.1,5.2)| 1.2 (0.8,2.0)| 2.0 (1.4,2.8)|
| Portugal| Min      | 0.8 (0.7,1.0)| 0.5 (0.3,0.9)| 0.7 (0.4,1.1)| 0.7 (0.5,1.2)| 1.1 (0.7,1.6)| 1.1 (0.8,1.5)|
|         | Max      | 1.2 (1.0,1.4)| 0.7 (0.5,1.2)| 0.9 (0.6,1.4)| 1.0 (0.7,1.5)| 1.5 (1.1,2.1)| 1.5 (1.1,2.0)|
| Overall | Min      | 1.6 (1.1,2.1)| 1.5 (1.0,1.9)| 1.5 (1.0,2.0)| 1.7 (1.2,2.2)| 1.5 (1.0,1.9)| 1.8 (1.2,2.3)|
|         | Max      | 4.2 (3.2,5.1)| 3.7 (2.8,4.6)| 3.9 (3.0,4.8)| 4.8 (3.8,5.8)| 4.0 (3.1,4.9)| 4.5 (3.6,5.5)|
| RA-ILD  | Belgium  | Min      | 0.6 (0.5,0.6)| 0.6 (0.5,0.8)| 0.5 (0.4,0.6)| 0.6 (0.5,0.8)| 0.6 (0.5,0.8)| 0.5 (0.4,0.6)|
|         | Max      | 1.7 (1.5,1.9)| 1.8 (1.4,2.3)| 1.5 (1.2,1.9)| 1.9 (1.5,2.4)| 1.9 (1.5,2.4)| 1.5 (1.2,1.9)|
| Denmark | Min      | 0.5 (0.4,0.6)| 0.6 (0.4,0.9)| 0.5 (0.3,0.7)| 0.5 (0.3,0.7)| 0.5 (0.3,0.7)| 0.4 (0.3,0.7)|
|         | Max      | 0.7 (0.6,0.8)| 0.9 (0.6,1.2)| 0.6 (0.4,0.9)| 0.6 (0.4,0.9)| 0.6 (0.4,0.9)| 0.6 (0.4,0.9)|
| Finland | Min      | 0.9 (0.6,1.5)| 1.0 (0.4,2.7)| 1.3 (0.5,3.1)| 0.5 (0.1,2.0)| 0.7 (0.2,2.3)| 1.1 (0.4,2.8)|
|         | Max      | 1.9 (1.4,2.6)| 2.1 (1.0,4.1)| 2.6 (1.4,4.8)| 1.0 (0.4,2.7)| 1.5 (0.7,3.4)| 2.3 (1.2,4.4)|
| Greece  | Min      | 1.0 (0.8,1.1)| 0.5 (0.3,0.8)| 1.0 (0.8,1.4)| 1.0 (0.7,1.3)| 1.1 (0.8,1.5)| 1.2 (0.9,1.6)|
|         | Max      | 3.1 (2.8,3.5)| 3.7 (2.9,4.8)| 2.8 (2.1,3.6)| 2.3 (1.7,3.0)| 4.0 (3.2,4.9)| 3.1 (2.4,4.0)|
| Norway  | Min      | 0.5 (0.4,0.7)| 0.6 (0.4,0.7)| 0.5 (0.3,0.7)| 0.5 (0.3,0.7)| 0.5 (0.3,0.7)| 0.4 (0.3,0.7)|
|         | Max      | 1.4 (1.1,1.7)| NA       | 0.4 (0.2,0.9)| 1.7 (1.2,2.6)| 1.5 (1.0,2.3)| 1.7 (1.2,2.5)|
| Portugal| Min      | 0.4 (0.3,0.5)| 0.3 (0.2,0.7)| 0.3 (0.1,0.6)| 0.4 (0.2,0.8)| 0.4 (0.2,0.8)| 0.5 (0.3,0.9)|
|         | Max      | 0.6 (0.4,0.7)| 0.5 (0.3,0.8)| 0.4 (0.2,0.7)| 0.6 (0.3,1.0)| 0.6 (0.4,1.0)| 0.7 (0.5,1.1)|
| Overall | Min      | 0.7 (0.4,0.9)| 0.6 (0.4,0.9)| 0.6 (0.4,0.9)| 0.6 (0.3,0.8)| 0.6 (0.4,0.9)| 0.7 (0.5,1.0)|
|         | Max      | 1.6 (1.1,2.1)| 1.8 (1.3,2.3)| 1.4 (0.9,1.8)| 1.4 (0.9,1.8)| 1.7 (1.2,2.2)| 1.7 (1.2,2.1)|
| Mixed CTD-ILD | Belgium | Min      | 0.1 (0.1,0.2)| 0.1 (0.1,0.2)| 0.1 (0.1,0.2)| 0.1 (0.1,0.2)| 0.1 (0.1,0.2)|
|         | Max      | 0.4 (0.3,0.5)| 0.3 (0.2,0.6)| 0.4 (0.3,0.7)| 0.4 (0.2,0.6)| 0.4 (0.2,0.6)| 0.4 (0.3,0.7)|
| Country     | Estimate | Study period | 2014        | 2015        | 2016        | 2017        | 2018        |
|-------------|----------|--------------|-------------|-------------|-------------|-------------|-------------|
| Denmark     | Max      | 0.6 (0.5,0.7)| 0.5 (0.3,0.8)| 0.6 (0.4,0.9)| 0.7 (0.5,1.0)| 0.5 (0.3,0.8)| 0.6 (0.4,0.9)|
|             | Min      | 1.3 (0.9,1.9)| 2.8 (1.5,5.1)| 0.5 (0.1,2.0)| 1.3 (0.5,3.0)| 1.1 (0.4,2.9)| 0.9 (0.3,2.5)|
|             | Max      | 2.7 (2.0,3.5)| 5.7 (3.7,8.6)| 1.0 (0.4,2.7)| 2.6 (1.4,4.8)| 2.3 (1.2,4.4)| 1.8 (0.8,3.7)|
| Finland     | Min      | 0.2 (0.1,0.2)| 0.1 (0.0,0.3)| 0.2 (0.1,0.4)| 0.1 (0.0,0.3)| 0.3 (0.2,0.6)| 0.2 (0.1,0.4)|
|             | Max      | 0.6 (0.4,0.7)| 0.5 (0.3,1.0)| 0.5 (0.3,0.9)| 0.2 (0.1,0.5)| 1.1 (0.8,1.7)| 0.5 (0.3,0.9)|
| Greece      | Min      | 0.4 (0.3,0.6)| NA          | 0.3 (0.1,0.6)| 0.8 (0.5,1.2)| 0.3 (0.1,0.5)| 0.4 (0.2,0.7)|
|             | Max      | 1.1 (0.9,1.4)| NA          | 0.7 (0.4,1.3)| 2.1 (1.5,3.0)| 0.7 (0.4,1.3)| 0.9 (0.6,1.5)|
| Norway      | Min      | 0.1 (0.0,0.1)| 0.1 (0.0,0.3)| 0.1 (0.0,0.3)| 0.0 (0.0,0.0)| 0.1 (0.0,0.3)| 0.1 (0.0,0.3)|
|             | Max      | 0.1 (0.1,0.2)| 0.1 (0.0,0.3)| 0.1 (0.0,0.4)| 0.0 (0.0,0.0)| 0.1 (0.0,0.4)| 0.1 (0.0,0.3)|
| Portugal    | Min      | 0.5 (0.3,0.7)| 0.9 (0.6,1.2)| 0.3 (0.1,0.4)| 0.5 (0.3,0.7)| 0.4 (0.2,0.6)| 0.4 (0.2,0.6)|
|             | Max      | 0.9 (0.5,1.3)| 1.4 (1.0,1.9)| 0.6 (0.3,0.9)| 1.0 (0.6,1.4)| 0.9 (0.5,1.2)| 0.7 (0.4,1.0)|
| Overall     | Min      | 0.3 (0.2,0.3)| 0.4 (0.3,0.5)| 0.3 (0.2,0.4)| 0.2 (0.2,0.4)| 0.3 (0.2,0.4)| 0.2 (0.2,0.4)|
|             | Max      | 0.9 (0.8,1.0)| 1.2 (0.9,1.6)| 0.8 (0.6,1.2)| 0.8 (0.5,1.1)| 0.9 (0.6,1.2)| 0.8 (0.5,1.1)|
| Belgium     | Min      | 0.6 (0.5,0.8)| 0.7 (0.5,0.9)| 0.6 (0.5,0.9)| 0.6 (0.4,0.9)| 0.6 (0.4,0.9)| 0.6 (0.4,0.9)|
|             | Max      | 0.9 (0.8,1.0)| 0.9 (0.7,1.2)| 0.9 (0.7,1.2)| 0.9 (0.6,1.2)| 0.9 (0.6,1.2)| 0.9 (0.6,1.2)|
| Finland     | Min      | 2.5 (1.9,3.3)| 2.8 (1.5,5.1)| 2.1 (1.1,4.2)| 2.0 (1.5,7.3)| 2.5 (1.3,4.7)| 2.0 (1.0,4.0)|
|             | Max      | 5.1 (4.2,6.2)| 5.7 (3.7,8.6)| 4.4 (2.7,7.0)| 6.1 (4.1,9.2)| 5.1 (3.7,9.2)| 4.1 (2.5,6.6)|
| Greece      | Min      | 0.4 (0.4,0.6)| 0.5 (0.3,0.8)| 0.3 (0.2,0.5)| 0.4 (0.3,0.7)| 0.5 (0.3,0.8)| 0.5 (0.3,0.8)|
|             | Max      | 1.3 (1.1,1.6)| 2.9 (2.2,3.9)| 0.7 (0.4,1.2)| 1.0 (0.6,1.5)| 1.2 (0.8,1.8)| 1.2 (0.8,1.8)|
| Norway      | Min      | 1.1 (0.9,1.3)| NA          | 1.5 (1.1,2.1)| 0.9 (0.6,1.4)| 0.9 (0.6,1.8)| 1.0 (0.7,1.4)|
|             | Max      | 2.7 (2.3,3.2)| NA          | 3.9 (3.0,5.1)| 2.4 (1.7,3.4)| 2.3 (1.7,3.3)| 2.3 (1.7,3.2)|
| Portugal    | Min      | 0.6 (0.5,0.8)| 0.2 (0.1,0.5)| 0.8 (0.5,1.3)| 0.6 (0.3,1.0)| 0.6 (0.4,1.0)| 0.8 (0.5,1.2)|
|             | Max      | 0.8 (0.7,1.0)| 0.3 (0.1,0.6)| 1.1 (0.8,1.7)| 0.8 (0.5,1.2)| 0.9 (0.6,1.3)| 1.1 (0.8,1.5)|

**Other CTD-ILD**
| Country     | Estimate | Study period | 2014    | 2015    | 2016    | 2017    | 2018    |
|-------------|----------|--------------|---------|---------|---------|---------|---------|
| Overall     | Min      | 1.0 (0.7,1.4)| 1.1 (0.8,1.4)| 1.0 (0.7,1.4)| 1.1 (0.8,1.4)| 1.0 (0.7,1.3)| 0.9 (0.6,1.2)|
|             | Max      | 2.0 (1.4,2.5)| 2.2 (1.6,2.8)| 2.0 (1.4,2.5)| 2.0 (1.4,2.5)| 1.9 (1.3,2.4)| 1.7 (1.2,2.2)|
| Belgium     | Min      | 1.3 (1.0,1.7)| 2.0 (1.2,3.1)| 1.4 (0.8,2.4)| 0.8 (0.4,1.6)| 1.5 (0.9,2.6)| 0.9 (0.5,1.9)|
|             | Max      | 5.3 (4.2,6.6)| 7.9 (5.2,11.8)| 5.0 (3.1,8.1)| 3.2 (1.7,6.2)| 6.4 (4.0,10.2)| 3.9 (2.1,7.0)|
| Denmark     | Min      | 2.2 (2.0,2.4)| 2.2 (1.8,2.7)| 1.7 (1.3,2.1)| 2.4 (2.0,2.9)| 2.4 (2.0,2.9)| 2.3 (1.9,2.8)|
|             | Max      | 3.0 (2.8,3.2)| 3.0 (2.6,3.6)| 2.3 (1.9,2.8)| 3.3 (2.8,3.9)| 3.3 (2.8,3.8)| 3.1 (2.7,3.7)|
| Finland     | Min      | 3.2 (2.5,4.1)| 6.0 (4.0,9.0)| 3.4 (2.0,5.8)| 2.4 (1.3,4.5)| 2.0 (1.0,4.0)| 2.1 (1.1,4.2)|
|             | Max      | 6.4 (5.4,7.7)| 12.1 (9.1,16.2)| 6.9 (4.8,10.1)| 4.9 (3.1,7.6)| 4.1 (2.5,6.6)| 4.3 (2.7,6.9)|
| Greece      | Min      | 0.3 (0.3,0.4)| 0.2 (0.1,0.4)| 0.3 (0.2,0.6)| 0.4 (0.3,0.7)| 0.3 (0.2,0.6)| 0.4 (0.3,0.7)|
|             | Max      | 0.8 (0.6,1.0)| 0.6 (0.3,1.2)| 0.7 (0.4,1.2)| 0.9 (0.6,1.4)| 0.7 (0.4,1.1)| 1.0 (0.6,1.5)|
| Norway      | Min      | 0.2 (0.1,0.3)| NA | 0.3 (0.2,0.6)| 0.2 (0.1,0.4)| 0.2 (0.1,0.5)| 0.1 (0.0,0.3)|
|             | Max      | 0.5 (0.4,0.7)| NA | 0.9 (0.5,1.5)| 0.4 (0.2,0.9)| 0.6 (0.3,1.2)| 0.2 (0.1,0.7)|
| Portugal    | Min      | 0.2 (0.2,0.3)| 0.2 (0.1,0.5)| 0.0 (0.0,0.3)| 0.1 (0.1,0.4)| 0.5 (0.3,0.9)| 0.3 (0.2,0.6)|
|             | Max      | 0.3 (0.2,0.5)| 0.2 (0.1,0.5)| 0.0 (0.0,0.3)| 0.2 (0.1,0.5)| 0.7 (0.4,1.1)| 0.5 (0.3,0.8)|
| Overall     | Min      | 1.5 (1.0,1.9)| 2.5 (1.8,3.1)| 1.3 (0.9,1.8)| 1.1 (0.7,1.6)| 1.2 (0.8,1.6)| 1.1 (0.7,1.5)|
|             | Max      | 2.9 (2.1,3.6)| 4.8 (3.8,5.8)| 2.6 (1.9,3.4)| 2.2 (1.5,2.8)| 2.6 (1.9,3.4)| 2.2 (1.5,2.8)|
| Sarcoidosis | Belgium  | 4.3 (3.7,4.9)| 4.4 (3.2,6.1)| 4.7 (3.5,6.4)| 3.9 (2.8,5.5)| 4.8 (3.5,6.4)| 3.6 (2.5,5.1)|
|             | Max      | 17.2 (15.2,19.5)| 17.8 (13.6,23.3)| 17.1 (13.2,22.3)| 16.5 (12.4,22.1)| 20.0 (15.4,25.9)| 14.8 (10.9,20.0)|
| Denmark     | Min      | 13.7 (13.3,14.2)| 14.1 (13.1,15.3)| 14.4 (13.3,15.5)| 13.5 (12.4,14.6)| 13.2 (12.2,14.3)| 13.5 (12.5,14.6)|
|             | Max      | 18.9 (18.4,19.5)| 19.5 (18.3,20.9)| 19.8 (18.5,21.1)| 18.6 (17.3,19.9)| 18.2 (17.0,19.5)| 18.7 (17.5,20.0)|
| Finland     | Min      | 6.2 (5.2,7.5)| 9.8 (7.1,13.4)| 3.4 (2.0,5.8)| 4.4 (2.7,7.0)| 7.1 (4.9,10.3)| 6.6 (4.5,9.7)|
|             | Max      | 12.7 (11.3,14.4)| 19.9 (15.9,24.9)| 6.9 (4.8,10.1)| 9.0 (6.4,12.5)| 14.5 (11.2,18.8)| 13.4 (10.3,17.6)|
|             | Min      | 1.4 (1.2,1.6)| 0.9 (0.7,1.3)| 1.3 (1.0,1.7)| 1.5 (1.2,2.0)| 1.8 (1.4,2.3)| 1.2 (0.9,1.7)|
| Country | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|----------|--------------|------|------|------|------|------|
| Greece  | Max      | 3.1 (2.8,3.5)| 2.6 (1.9,3.6)| 2.8 (2.2,3.6)| 3.3 (2.6,4.2)| 3.9 (3.2,4.9)| 2.7 (2.1,3.5) |
|         | Min      | 2.0 (1.8,2.3)| NA   | 2.3 (1.7,2.9)| 2.1 (1.6,2.7)| 2.4 (1.9,3.0)| 1.3 (0.9,1.8) |
|         | Max      | 5.1 (4.6,5.7)| NA   | 5.8 (4.6,7.2)| 5.5 (4.4,6.9)| 6.3 (5.1,7.7)| 3.2 (2.4,4.2) |
| Portugal| Min      | 1.5 (1.3,1.8)| 0.9 (0.6,1.4)| 2.0 (1.5,2.6)| 1.1 (0.8,1.6)| 1.4 (1.0,1.9)| 2.2 (1.7,2.7) |
|         | Max      | 2.1 (1.9,2.4)| 1.2 (0.9,1.8)| 2.7 (2.2,3.5)| 1.6 (1.1,2.1)| 1.9 (1.4,2.5)| 3.0 (2.4,3.7) |
| Overall | Min      | 5.1 (4.2,6.0)| 6.4 (5.4,7.4)| 4.5 (3.7,5.4)| 4.4 (3.5,5.2)| 5.2 (4.3,6.1)| 4.8 (3.9,5.7) |
|         | Max      | 10.1 (8.7,11.5)| 12.2 (10.6,13.8)| 9.2 (7.8,10.6)| 9.1 (7.7,10.4)| 10.8 (9.3,12.3)| 9.3 (8.0,10.6) |
| Norway  | Min      | 2.8 (2.3,3.3)| 1.4 (0.8,2.4)| 1.4 (0.8,2.4)| 2.2 (1.4,3.4)| 3.9 (2.8,5.5)| 4.9 (3.7,6.6) |
|         | Max      | 11.1 (9.5,13.0)| 5.5 (3.4,8.9)| 5.0 (3.1,8.1)| 9.4 (6.4,13.7)| 16.4 (12.3,21.9)| 20.4 (15.8,26.4) |
| Denmark | Min      | 10.0 (9.6,10.4)| 9.1 (8.3,10.1)| 11.7 (10.7,12.7)| 11.2 (10.3,12.2)| 8.6 (7.7,9.4)| 9.2 (8.4,10.2) |
|         | Max      | 23.8 (23.1,24.4)| 22.4 (21.0,23.8)| 26.8 (25.3,28.3)| 26.3 (24.8,27.8)| 21.0 (19.8,22.4)| 22.4 (21.1,23.8) |
| Finland | Min      | 0.4 (0.2,0.8)| 0.4 (0.1,1.9)| 0.6 (0.2,2.2)| 0.3 (0.0,1.8)| 0.2 (0.0,1.8)| 0.4 (0.1,1.9) |
|         | Max      | 0.8 (0.5,1.3)| 0.8 (0.3,2.4)| 1.3 (0.5,3.1)| 0.5 (0.1,2.0)| 0.5 (0.1,2.0)| 0.8 (0.2,2.4) |
| Greece  | Min      | 0.5 (0.4,0.6)| 0.4 (0.2,0.6)| 0.5 (0.3,0.8)| 0.5 (0.3,0.8)| 0.6 (0.4,0.9)| 0.7 (0.5,1.0) |
|         | Max      | 1.2 (1.0,1.4)| 1.0 (0.6,1.6)| 1.0 (0.7,1.5)| 1.0 (0.7,1.6)| 1.3 (0.9,1.9)| 1.5 (1.0,2.1) |
| Norway  | Min      | 1.8 (1.5,2.0)| NA   | 1.9 (1.5,2.5)| 2.8 (2.2,3.4)| 1.2 (0.8,1.6)| 1.3 (0.9,1.8) |
|         | Max      | 4.5 (4.0,5.1)| NA   | 4.9 (3.9,6.2)| 7.2 (5.9,8.7)| 3.1 (2.3,4.1)| 3.1 (2.4,4.1) |
| Portugal| Min      | 0.5 (0.4,0.6)| 0.6 (0.3,1.0)| 0.6 (0.3,1.0)| 0.4 (0.2,0.8)| 0.4 (0.2,0.8)| 0.4 (0.2,0.7) |
|         | Max      | 0.7 (0.5,0.8)| 0.8 (0.5,1.2)| 0.8 (0.5,1.2)| 0.6 (0.4,1.0)| 0.6 (0.4,1.0)| 0.6 (0.3,0.9) |
| Overall | Min      | 2.5 (1.8,3.1)| 2.2 (1.6,2.8)| 2.6 (2.0,3.2)| 2.7 (2.0,3.3)| 2.3 (1.7,2.9)| 2.6 (1.9,3.3) |
|         | Max      | 7.1 (5.9,8.3)| 6.1 (5.0,7.2)| 6.6 (5.4,7.8)| 7.5 (6.3,8.7)| 7.2 (5.9,8.4)| 8.1 (6.9,9.4) |

**Other F-ILDs**

| Country | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|----------|--------------|------|------|------|------|------|
| Belgium | Min      | 0.2 (0.1,0.4)| 0.0 (0.0,0.0)| 0.3 (0.1,0.9)| 0.3 (0.1,0.9)| 0.3 (0.1,0.9)| 0.3 (0.1,0.9) |
|         | Max      | 0.8 (0.5,1.5)| 0.0 (0.0,0.0)| 0.9 (0.3,2.9)| 1.1 (0.3,3.3)| 1.1 (0.3,3.3)| 1.1 (0.3,3.3) |

**HP**

| Country | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|----------|--------------|------|------|------|------|------|
| Belgium | Min      | 0.2 (0.1,0.4)| 0.0 (0.0,0.0)| 0.3 (0.1,0.9)| 0.3 (0.1,0.9)| 0.3 (0.1,0.9)| 0.3 (0.1,0.9) |
|         | Max      | 0.8 (0.5,1.5)| 0.0 (0.0,0.0)| 0.9 (0.3,2.9)| 1.1 (0.3,3.3)| 1.1 (0.3,3.3)| 1.1 (0.3,3.3) |
| Country     | Estimate | Study period | 2014          | 2015          | 2016          | 2017           | 2018          |
|-------------|----------|--------------|---------------|---------------|---------------|----------------|---------------|
| Denmark     | Min      | 1.2 (1.1,1.4)| 1.1 (0.9,1.5) | 1.2 (0.9,1.6) | 1.2 (0.9,1.6) | 1.3 (1.0,1.7)  | 1.3 (1.0,1.7) |
|             | Max      | 1.7 (1.5,1.9)| 1.6 (1.2,2.0) | 1.7 (1.3,2.1) | 1.7 (1.3,2.1) | 1.8 (1.4,2.2)  | 1.8 (1.4,2.2) |
| Finland     | Min      | 0.9 (0.6,1.5)| 1.1 (0.4,2.9) | 0.9 (0.3,2.5) | 0.9 (0.3,2.5) | 0.9 (0.3,2.5)  | 0.9 (0.3,2.5) |
|             | Max      | 1.9 (1.4,2.6)| 2.3 (1.2,4.5) | 1.8 (0.9,3.8) | 1.8 (0.9,3.8) | 1.8 (0.8,3.7)  | 1.8 (0.8,3.7) |
| Greece      | Min      | 1.2 (1.0,1.3)| 0.4 (0.3,0.7) | 1.1 (0.8,1.5) | 1.4 (1.0,1.8) | 1.4 (1.1,1.9)  | 1.5 (1.2,2.0) |
|             | Max      | 2.6 (2.3,3.0)| 1.2 (0.8,1.9) | 2.3 (1.8,3.1) | 2.9 (2.3,3.7) | 3.1 (2.4,4.0)  | 3.2 (2.6,4.1) |
| Norway      | Min      | 0.3 (0.2,0.4)| NA            | 0.3 (0.2,0.6) | 0.3 (0.1,0.5) | 0.3 (0.2,0.6)  | 0.3 (0.2,0.6) |
|             | Max      | 0.8 (0.6,1.1)| NA            | 0.9 (0.5,1.5) | 0.7 (0.4,1.3) | 0.9 (0.5,1.5)  | 0.7 (0.4,1.3) |
| Portugal    | Min      | 1.6 (1.4,1.8)| 1.4 (1.0,2.0) | 1.7 (1.3,2.3) | 1.5 (1.1,2.1) | 1.7 (1.2,2.3)  | 1.5 (1.1,2.0) |
|             | Max      | 2.2 (1.9,2.4)| 2.0 (1.5,2.6) | 2.4 (1.8,3.1) | 2.1 (1.6,2.8) | 2.3 (1.8,3.0)  | 2.1 (1.6,2.6) |
| Overall     | Min      | 0.9 (0.5,1.3)| 0.9 (0.5,1.2) | 0.9 (0.5,1.3) | 0.9 (0.5,1.3) | 1.0 (0.6,1.3)  | 0.9 (0.5,1.3) |
|             | Max      | 1.7 (1.1,2.3)| 1.4 (0.9,2.0) | 1.7 (1.1,2.2) | 1.7 (1.1,2.3) | 1.8 (1.2,2.4)  | 1.8 (1.2,2.4) |

The table shows the widest variability observed. In Belgium, Greece and Norway, this means the minimum adjusted and the maximum crude estimates (the participating centre in Norway could not retrieve incident cases for 2014, and thus incidence could not be estimated for that year). In Denmark and Finland, there was only one participating centre which searched a national or regional database (respectively), so there were no reference and extended populations, but a single population (i.e. no maximum-minimum estimates, but a single estimate). In these countries, the single crude and adjusted estimates are shown. In Portugal, only one of the participating centres reported an extended population, and only for 2018. Plus, incident cases for 2018 could not be retrieved in this centre, so minimum adjusted estimates could not be obtained for Portugal. Instead, the table shows the nearest estimates (maximum adjusted) as minimum values.

Abbreviations: CI, confidence interval; CTD-ILD, connective tissue disease-associated interstitial lung disease; F-ILDs, fibrosing interstitial lung diseases; HP, hypersensitivity pneumonitis; iNSIP, idiopathic non-specific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; RA-ILD, rheumatoid arthritis-associated interstitial lung disease; SSc-ILD, systemic sclerosis-associated interstitial lung disease; uIIPs, unclassifiable idiopathic interstitial pneumonias.
Table 5. Prevalence per 10^5 persons (95%CI) of non-IPF F-ILD subtypes in each country and overall, annually and for the whole study period

| Subtype | Country | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|---------|----------|--------------|------|------|------|------|------|
| iNSIP   | Belgium | Min      | 3.1 (2.0,4.3)| 1.5  | 1.7  | 2.8  | 3.7  | 3.9  | 3.7  |
|         |         | Max      | 12.6 (8.6,16.7)| 6.2  | 10.3 | 15.5 | 16.4 | 15.5 | 15.5 |
|         | Denmark | Min      | 1.7 (1.3,2.1)| 1.6  | 1.9  | 1.9  | 1.5  | 1.5  | 1.6  |
|         |         | Max      | 2.3 (1.9,2.8)| 2.2  | 2.6  | 2.6  | 2.0  | 2.2  | 2.2  |
|         | Finland | Min      | 5.4 (3.1,7.7)| 4.4  | 4.9  | 4.4  | 6.1  | 7.1  | 7.1  |
|         |         | Max      | 11.0 (7.7,14.3)| 9.0  | 10.0 | 9.0  | 12.5 | 14.4 | 14.4 |
|         | Greece  | Min      | 1.5 (0.8,2.1)| 1.4  | 1.4  | 1.4  | 1.3  | 1.8  | 1.1  |
|         |         | Max      | 4.1 (2.4,5.9)| 4.0  | 4.0  | 3.9  | 3.6  | 5.2  | 3.2  |
|         | Norway  | Min      | 5.5 (4.6,6.4)| 4.1  | 4.8  | 5.8  | 6.6  | 5.9  | 5.9  |
|         |         | Max      | 14.0 (12.1,15.9)| 10.4 | 12.3 | 15.1 | 17.5 | 14.4 | 14.4 |
| Portugal| Min      | 0.5 (0.1,1.0)| NA   | NA   | NA   | 0.5  | 1.0  | 0.3  |
|         | Max      | 0.9 (0.3,1.5)| 0.9  | 0.9  | 0.9  | 0.9  | 1.0  | 0.3  |
| Overall | Min      | 3.1 (2.3,3.9)| 2.4  | 2.9  | 3.0  | 3.5  | 3.6  | 2.8  |
|         | Max      | 7.5 (6.1,9.0)| 5.4  | 6.7  | 7.8  | 8.8  | 8.8  | 7.2  |
| uILPs   | Belgium | Min      | 6.0 (4.4,7.6)| 5.3  | 6.4  | 6.1  | 6.6  | 5.8  | 4.2  |
|         |         | Max      | 24.3 (18.7,30.0)| 21.2 | 23.4 | 25.9 | 27.4 | 23.9 | 18.2 |
|         | Denmark | Min      | 9.4 (8.5,10.3)| 10.8 | 11.2 | 8.7  | 7.7  | 8.8  | 7.9  |
|         |         | Max      | 13.0 (11.9,14.0)| 14.8 | 15.5 | 10.6 | 12.1 | 11.1 | 13.1 |
|         | Finland | Min      | 2.3 (0.8,3.8)| 1.3  | 1.6  | 2.1  | 2.6  | 3.8  | 1.9  |
|         |         | Max      | 4.7 (2.6,6.9)| 2.6  | 3.3  | 4.4  | 5.3  | 7.9  | 5.1  |
|         | Greece  | Min      | 1.4 (0.7,2.0)| 0.5  | 0.8  | 1.3  | 1.9  | 2.3  | 1.5  |
|         |         | Max      | 3.9 (2.2,5.6)| 1.5  | 2.2  | 3.8  | 5.5  | 6.6  | 4.5  |
| Subtype          | Country       | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|------------------|---------------|----------|--------------|------|------|------|------|------|
|                  |               | Min      |              |      |      |      |      |      |
| RA-ILD           | Norway        | 3.8 (3.1,4.5) | 2.5 (1.9,3.1) | 3.0 (2.3,3.6) | 4.3 (3.5,5.1) | 4.4 (3.6,5.1) | 4.6 (3.8,5.3) |
|                  | Max           | 9.6 (8.0,11.2) | 6.2 (4.9,7.6) | 7.6 (6.2,9.0) | 11.1 (9.4,12.9) | 11.5 (9.8,13.3) | 11.1 (9.5,12.7) |
|                  | Min           | 2.1 (1.3,2.9) | NA           | NA   | NA   | NA   | 2.6 (1.7,3.6) |
|                  | Max           | 3.5 (2.4,4.7) | 1.8 (1.0,2.6) | 2.8 (1.8,3.8) | 3.6 (2.5,4.7) | 4.3 (3.0,5.5) | 5.7 (4.0,7.4) |
|                  | Overall       | 4.0 (3.1,4.9) | 3.4 (2.5,4.2) | 3.9 (3.0,4.9) | 4.0 (3.1,4.9) | 4.2 (3.2,5.1) | 4.5 (3.6,5.5) |
|                  | Min           | 3.1 (1.3,4.8) | 2.0 (0.6,3.4) | 2.9 (1.2,4.6) | 3.3 (1.5,5.1) | 3.4 (1.6,5.2) | 3.8 (1.9,5.8) |
|                  | Max           | 6.3 (3.8,8.8) | 4.1 (2.1,6.2) | 5.9 (3.5,8.3) | 6.7 (4.1,9.2) | 6.9 (4.3,9.5) | 7.9 (5.1,10.6) |
|                  | Min           | 2.5 (1.6,3.4) | 1.9 (1.1,2.7) | 2.1 (1.3,2.9) | 2.7 (1.7,3.6) | 2.9 (1.9,3.9) | 3.0 (2.0,4.0) |
|                  | Max           | 16.0 (12.6,19.4) | 13.0 (9.9,16.0) | 13.2 (10.1,16.4) | 16.7 (13.2,20.2) | 19.0 (15.2,22.7) | 18.1 (14.4,21.7) |
|                  | Min           | 0.8 (0.5,1.1) | 0.1 (0.0,0.2) | 0.4 (0.1,0.6) | 1.1 (0.7,1.5) | 1.4 (0.9,1.8) | 1.0 (0.7,1.4) |
|                  | Max           | 2.1 (1.3,2.8) | 0.2 (0.0,0.5) | 0.9 (0.4,1.4) | 2.9 (2.0,3.7) | 3.6 (2.6,4.6) | 2.5 (1.7,3.3) |
|                  | Min           | 1.9 (1.1,2.6) | NA           | NA   | NA   | NA   | 1.9 (1.1,2.7) |
|                  | Max           | 3.1 (2.0,4.2) | 2.3 (1.4,3.3) | 2.7 (1.7,3.7) | 3.2 (2.1,4.2) | 3.5 (2.4,4.6) | 4.1 (2.7,5.6) |
|                  | Min           | 2.4 (1.9,2.9) | 1.8 (1.4,2.3) | 2.2 (1.7,2.7) | 2.6 (2.0,3.1) | 2.7 (2.1,3.3) | 2.7 (2.1,3.3) |
|                  | Max           | 7.3 (6.1,8.4) | 5.7 (4.7,6.8) | 6.4 (5.3,7.5) | 7.7 (6.5,8.9) | 8.2 (6.9,9.4) | 8.3 (7.0,9.5) |
|                  | Min           | 0.2 (0.1,0.3) | 0.2 (0.1,0.3) | 0.2 (0.1,0.3) | 0.2 (0.1,0.3) | 0.2 (0.1,0.3) | 0.2 (0.1,0.3) |
|                  | Max           | 0.6 (0.4,0.9) | 0.6 (0.4,0.9) | 0.6 (0.3,0.8) | 0.6 (0.4,0.9) | 0.6 (0.4,0.9) | 0.6 (0.4,0.9) |
|                  | Min           | 2.4 (2.0,2.9) | 2.6 (2.1,3.0) | 2.6 (2.1,3.1) | 2.3 (1.9,2.8) | 2.3 (1.8,2.7) | 2.3 (1.9,2.8) |
|                  | Max           | 2.6 (2.1,3.0) | 2.6 (2.1,3.1) | 2.3 (1.9,2.8) | 2.3 (1.8,2.7) | 2.3 (1.9,2.8) | 2.3 (1.9,2.8) |
| Subtype | Country   | Estimate | Study period | 2014            | 2015            | 2016            | 2017            | 2018            |
|---------|-----------|----------|--------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|         |           |          |              |                 |                 |                 |                 |                 |
| Denmark | Max       | 3.3 (2.8,3.9) | 3.5 (3.0,4.1) | 3.6 (3.0,4.1)  | 3.2 (2.7,3.7)  | 3.1 (2.6,3.6)  | 3.2 (2.7,3.7)  |
|         | Min       | 2.7 (1.1,4.3) | 2.9 (1.2,4.6) | 1.6 (0.4,2.9)  | 2.5 (0.9,4.1)  | 3.1 (1.4,4.9)  | 3.4 (1.5,5.2)  |
|         | Max       | 5.5 (3.2,7.9) | 5.9 (3.5,8.4) | 3.3 (1.5,5.2)  | 5.1 (2.9,7.4)  | 6.4 (3.9,8.9)  | 6.8 (4.3,9.4)  |
| Finland | Min       | 0.4 (0.1,0.8) | 0.3 (0.0,0.7) | 0.3 (0.0,0.5)  | 0.4 (0.0,0.7)  | 0.6 (0.1,1.0)  | 0.6 (0.1,1.0)  |
|         | Max       | 2.5 (1.2,3.9) | 2.1 (0.8,3.3) | 1.4 (0.4,2.4)  | 2.2 (0.9,3.5)  | 3.6 (1.9,5.2)  | 3.4 (1.8,5.0)  |
| Greece  | Min       | 2.8 (2.2,3.4) | 1.2 (0.7,1.6) | 1.6 (1.1,2.1)  | 3.6 (2.9,4.3)  | 3.7 (3.0,4.4)  | 3.8 (3.1,4.5)  |
|         | Max       | 7.2 (5.8,8.6) | 2.9 (2.0,3.8) | 4.0 (3.0,5.1)  | 9.3 (7.7,10.9) | 9.8 (8.2,11.4) | 9.3 (7.9,10.8) |
| Portugal| Min       | 0.2 (0.0,0.5) | NA            | NA              | NA              | 0.2 (0.0,0.5)  |                |
|         | Max       | 0.3 (0.0,0.7) | 0.2 (0.1,0.5) | 0.3 (0.0,0.6)  | 0.3 (0.0,0.7)  | 0.5 (0.1,0.9)  | 0.5 (0.0,1.0)  |
| Overall | Min       | 1.5 (1.1,2.0) | 1.3 (0.9,1.7) | 1.1 (0.7,1.5)  | 1.6 (1.2,2.0)  | 1.8 (1.3,2.2)  | 1.8 (1.4,2.3)  |
|         | Max       | 3.2 (2.4,4.0) | 2.5 (1.8,3.3) | 2.2 (1.6,2.9)  | 3.5 (2.6,4.3)  | 4.0 (3.1,4.9)  | 4.0 (3.1,4.9)  |
| Belgium | Min       | 1.1 (0.9,1.3) | 1.1 (0.9,1.4) | 1.1 (0.9,1.3)  | 1.1 (0.9,1.3)  | 1.2 (0.9,1.4)  | 1.1 (0.9,1.4)  |
|         | Max       | 3.5 (2.9,4.1) | 3.5 (3.0,4.1) | 3.5 (2.9,4.0)  | 3.3 (2.7,3.8)  | 3.6 (3.0,4.1)  | 3.6 (3.0,4.1)  |
| Denmark | Min       | 2.4 (2.0,2.9) | 2.5 (2.0,2.9) | 2.4 (2.0,2.9)  | 2.4 (2.0,2.9)  | 2.4 (1.9,2.8)  | 2.4 (1.9,2.8)  |
|         | Max       | 3.3 (2.8,3.9) | 3.4 (2.8,3.9) | 3.4 (2.8,3.9)  | 3.3 (2.8,3.8)  | 3.3 (2.7,3.8)  |                |
| Finland | Min       | 6.1 (3.7,8.6) | 6.1 (3.6,8.5) | 5.7 (3.3,8.0)  | 7.0 (4.4,9.7)  | 5.9 (3.5,8.2)  | 6.1 (3.6,8.5)  |
|         | Max       | 12.5 (9.0,16.0) | 12.4 (8.9,15.9) | 11.6 (8.2,15.0) | 14.3 (10.6,18.1) | 12.0 (8.5,15.4) | 12.4 (8.9,15.9) |
| Greece  | Min       | 1.3 (0.6,1.9) | 1.4 (0.7,2.1) | 1.0 (0.5,1.6)  | 1.3 (0.7,2.0)  | 1.3 (0.7,1.9)  | 1.2 (0.6,1.8)  |
|         | Max       | 6.7 (4.5,8.9) | 8.2 (5.8,10.6) | 5.3 (3.4,7.3)  | 7.2 (4.9,9.5)  | 6.9 (4.7,9.2)  | 5.9 (3.8,7.9)  |
| Norway  | Min       | 6.8 (5.8,7.7) | 4.8 (4.0,5.7) | 7.7 (6.6,8.7)  | 7.0 (6.0,7.9)  | 7.7 (6.7,8.7)  | 6.5 (5.6,7.4)  |
|         | Max       | 17.2 (15.1,19.4) | 12.1 (10.3,13.9) | 19.7 (17.4,22.0) | 18.1 (15.9,20.3) | 20.3 (18.0,22.6) | 15.9 (14.0,17.9) |
| Portugal| Min       | 1.7 (0.9,2.4) | NA            | NA              | NA              | NA              | 2.4 (1.5,3.3)  |
|         | Max       | 2.8 (1.8,3.8) | 1.1 (0.5,1.8) | 2.1 (1.3,3.0)  | 2.6 (1.7,3.6)  | 3.4 (2.3,4.6)  | 5.2 (3.6,6.8)  |
| Subtype             | Country | Estimate | Study period | 2014       | 2015       | 2016       | 2017       | 2018       |
|---------------------|---------|----------|--------------|------------|------------|------------|------------|------------|
| Overall             | Min     | 3.4 (2.8,4.1) | 3.0 (2.4,3.6) | 3.4 (2.7,4.0) | 3.7 (3.0,4.3) | 3.6 (2.9,4.3) | 3.4 (2.8,4.1) |
|                     | Max     | 7.7 (6.5,8.9) | 6.8 (5.6,7.9) | 7.6 (6.4,8.8) | 8.1 (6.9,9.4) | 8.2 (7.0,9.5) | 7.7 (6.5,8.9) |
| Exposure-related ILDs | Belgium | Min | 4.9 (3.5,6.4) | 5.8 (4.2,7.4) | 5.2 (3.7,6.7) | 5.2 (3.7,6.7) | 4.2 (2.8,5.5) | 4.3 (2.9,5.6) |
|                     | Max     | 19.9 (14.7,25.0) | 23.3 (17.7,28.8) | 21.9 (14.2,23.8) | 21.9 (16.4,27.4) | 17.5 (12.6,22.3) | 17.6 (12.7,22.5) |
|                     | Denmark | Min | 3.9 (3.4,4.5) | 4.1 (3.5,4.7) | 3.3 (2.8,3.8) | 4.1 (3.5,4.6) | 3.8 (3.2,4.3) | 4.5 (3.9,5.1) |
|                     | Max     | 5.4 (4.8,6.1) | 5.7 (5.0,6.4) | 4.6 (3.9,5.2) | 5.6 (4.9,6.3) | 5.2 (4.5,5.8) | 6.2 (5.5,6.9) |
|                     | Finland | Min | 17.7 (13.5,21.8) | 20.1 (15.7,24.6) | 19.8 (15.4,24.2) | 17.3 (13.2,21.4) | 16.3 (12.3,20.3) | 14.9 (11.1,18.7) |
|                     | Max     | 36.1 (30.1,42.0) | 41.1 (34.7,47.5) | 40.4 (34.1,46.7) | 35.3 (29.4,41.2) | 33.3 (27.6,39.0) | 30.4 (25.0,35.8) |
|                     | Greece  | Min | 0.6 (0.2,1.1) | 0.3 (0.0,0.6) | 0.5 (0.1,0.8) | 0.7 (0.2,1.2) | 0.8 (0.3,1.3) | 1.0 (0.4,1.5) |
|                     | Max     | 1.8 (0.7,3.0) | 0.8 (0.1,1.6) | 1.3 (0.3,2.3) | 2.1 (0.8,3.3) | 2.3 (1.0,3.6) | 2.7 (1.3,4.1) |
|                     | Norway  | Min | 0.5 (0.2,0.7) | 0.6 (0.3,0.9) | 0.6 (0.3,0.9) | 0.3 (0.1,0.5) | 0.5 (0.2,0.7) | 0.4 (0.1,0.6) |
|                     | Max     | 1.2 (0.6,1.7) | 1.5 (0.8,2.1) | 1.6 (0.9,2.2) | 0.8 (0.4,1.3) | 1.2 (0.7,1.8) | 0.9 (0.4,1.3) |
|                     | Portugal | Min | 0.6 (0.1,1.0) | NA | NA | NA | NA | 1.6 (0.9,2.4) |
|                     | Max     | 1.0 (0.4,1.6) | 0.5 (0.1,1.0) | 0.4 (0.0,0.8) | 0.5 (0.1,0.9) | 0.5 (0.1,1.0) | 3.6 (2.2,4.9) |
|                     | Overall | Min | 5.6 (4.6,6.7) | 6.3 (5.1,7.5) | 6.0 (4.9,7.2) | 5.6 (4.5,6.7) | 5.2 (4.1,6.2) | 5.2 (4.1,6.2) |
|                     | Max     | 10.9 (9.2,12.7) | 12.1 (10.3,14.0) | 11.2 (9.4,13.0) | 11.0 (9.3,12.8) | 10.0 (8.3,11.7) | 10.2 (8.5,11.9) |
| Sarcoidosis         | Belgium | Min | 16.6 (13.9,19.3) | 13.9 (11.4,16.3) | 16.4 (13.8,19.1) | 17.0 (14.3,19.8) | 17.7 (14.9,20.5) | 18.0 (15.2,20.8) |
|                     | Max     | 67.0 (57.6,76.4) | 55.8 (47.2,64.3) | 60.2 (51.7,68.6) | 71.9 (62.0,81.9) | 74.1 (64.0,84.2) | 74.2 (64.2,84.3) |
|                     | Denmark | Min | 60.4 (58.1,62.6) | 63.8 (61.4,66.1) | 65.1 (62.8,67.5) | 57.5 (55.3,59.7) | 55.3 (53.1,57.4) | 60.3 (58.1,62.6) |
|                     | Max     | 83.3 (80.6,85.9) | 88.0 (85.2,90.8) | 89.8 (87.1,92.6) | 79.3 (76.7,81.9) | 76.3 (73.7,78.8) | 83.2 (80.6,85.9) |
|                     | Finland | Min | 24.9 (19.9,29.8) | 27.2 (22.0,32.4) | 22.4 (17.7,27.1) | 22.3 (17.6,27.0) | 24.8 (19.9,29.7) | 27.6 (22.4,32.7) |
|                     | Max     | 50.8 (43.7,57.8) | 55.6 (48.1,63.0) | 45.8 (39.1,52.5) | 45.6 (38.9,52.3) | 50.6 (43.6,57.6) | 56.2 (48.8,63.6) |
|                     |        | Min | 5.0 (3.7,6.3) | 4.8 (3.5,6.0) | 4.2 (3.0,5.4) | 4.9 (3.7,6.2) | 5.5 (4.1,6.8) | 5.7 (4.4,7.1) |
| Subtype     | Country | Estimate | Study period | 2014         | 2015         | 2016         | 2017         | 2018         |
|-------------|---------|----------|--------------|--------------|--------------|--------------|--------------|--------------|
|              |         |          |              | 2014         | 2015         | 2016         | 2017         | 2018         |
|              |         |          |              | 2014         | 2015         | 2016         | 2017         | 2018         |
|              |         |          |              |              |              |              |              |              |
| Greece      | Max     | 14.3     | (11.1,17.6)  | 13.5         | (10.4,16.7)  | 12.0         | (9.1,15.0)   | 14.1         | (10.9,17.3)  | 15.6         | (12.3,19.0)  | 16.4         | (12.9,19.9)  |
| Norway      | Min     | 7.7      | (6.7,8.7)    | 10.3         | (9.1,11.5)   | 7.4          | (6.4,8.5)    | 6.4          | (5.5,7.4)    | 8.0          | (7.0,9.0)    | 6.5          | (5.6,7.4)    |
|             | Max     | 19.6     | (17.3,21.9)  | 25.9         | (23.2,28.6)  | 19.0         | (16.8,21.3)  | 16.7         | (14.6,18.8)  | 21.2         | (18.8,23.5)  | 15.9         | (14.0,17.8)  |
| Portugal    | Min     | 10.8     | (8.9,12.6)   | NA           | NA           | NA           | NA           | NA           | 10.7         | (8.9,12.6)   |
|             | Max     | 18.0     | (15.4,20.7)  | 14.5         | (12.2,16.8)  | 16.8         | (14.4,19.3)  | 17.9         | (15.3,20.4)  | 19.1         | (16.5,21.8)  | 23.3         | (19.9,26.7)  |
| Overall     | Min     | 21.2     | (19.1,23.4)  | 22.0         | (19.8,24.2)  | 21.3         | (19.1,23.4)  | 20.2         | (18.1,22.3)  | 21.0         | (18.9,23.1)  | 21.8         | (19.7,23.9)  |
|             | Max     | 42.3     | (38.8,45.7)  | 42.2         | (38.7,45.7)  | 40.6         | (37.2,44.0)  | 40.9         | (37.5,44.3)  | 42.8         | (39.4,46.3)  | 44.9         | (41.3,48.4)  |
|              |         |          |              |              |              |              |              |              |              |
| Other F-ILDs| Belgium | Min     | 4.1          | (2.7,5.4)    | 2.4          | (1.4,3.4)    | 2.2          | (1.2,3.2)    | 3.4          | (2.2,4.6)    | 5.2          | (3.7,6.7)    | 7.1          | (5.3,8.8)    |
|             | Max     | 16.3     | (11.7,21.0)  | 9.6          | (6.0,13.1)   | 8.1          | (5.0,11.2)   | 14.4         | (9.9,18.8)   | 21.7         | (16.3,27.2)  | 29.2         | (22.9,35.5)  |
|             | Denmark | Min     | 22.4         | (21.0,23.8)  | 16.8         | (15.6,18.0)  | 23.9         | (22.5,25.4)  | 22.5         | (21.2,23.9)  | 20.8         | (19.5,22.1)  | 27.8         | (26.3,29.4)  |
|             | Max     | 55.0     | (52.8,57.2)  | 45.4         | (43.4,47.4)  | 58.4         | (56.2,60.7)  | 54.8         | (52.6,56.9)  | 51.2         | (49.1,53.2)  | 64.9         | (62.6,67.3)  |
|             | Finland | Min     | 1.1          | (0.1,2.1)    | 0.8          | (0.1,1.6)    | 1.3          | (0.1,2.4)    | 1.1          | (0.1,2.2)    | 1.0          | (0.0,2.0)    | 1.4          | (0.2,2.5)    |
|             | Max     | 2.3      | (0.8,3.7)    | 1.6          | (0.3,2.8)    | 2.6          | (1.0,4.2)    | 2.3          | (0.8,3.8)    | 2.0          | (0.6,3.4)    | 2.8          | (1.1,4.4)    |
|             | Greece  | Min     | 0.8          | (0.3,1.3)    | 0.6          | (0.1,1.0)    | 0.6          | (0.2,1.0)    | 0.7          | (0.2,1.2)    | 0.9          | (0.4,1.5)    | 1.1          | (0.5,1.7)    |
|             | Max     | 2.2      | (0.9,3.4)    | 1.6          | (0.5,2.6)    | 1.7          | (0.6,2.8)    | 2.0          | (0.8,3.2)    | 2.6          | (1.2,4.0)    | 3.1          | (1.6,4.5)    |
|             | Norway  | Min     | 7.8          | (6.8,8.8)    | 4.8          | (4.0,5.7)    | 6.7          | (5.7,7.7)    | 8.9          | (7.8,10.1)   | 9.1          | (8.0,10.2)   | 9.1          | (8.0,10.2)   |
|             | Max     | 19.9     | (17.6,22.2)  | 12.1         | (10.3,13.9)  | 17.1         | (15.0,19.3)  | 23.2         | (20.8,25.7)  | 24.0         | (21.5,26.5)  | 22.2         | (20.0,24.5)  |
|             | Portugal| Min     | 1.6          | (0.9,2.4)    | NA           | NA           | NA           | NA           | NA           | 1.7          | (1.0,2.5)    |
|             | Max     | 2.7      | (1.7,3.8)    | 1.8          | (1.0,2.6)    | 2.4          | (1.5,3.4)    | 2.8          | (1.8,3.9)    | 3.2          | (2.1,4.2)    | 3.8          | (2.4,5.1)    |
|             | Overall | Min     | 5.9          | (4.7,7.0)    | 4.1          | (3.2,5.1)    | 5.7          | (4.6,6.8)    | 6.0          | (4.9,7.1)    | 6.1          | (4.9,7.2)    | 7.5          | (6.2,8.7)    |
|             | Max     | 16.4     | (14.3,18.6)  | 12.0         | (10.2,13.9)  | 15.1         | (13.0,17.1)  | 16.6         | (14.4,18.7)  | 17.4         | (15.2,19.7)  | 21.0         | (18.6,23.4)  |
| HP          | Belgium | Min     | 1.1          | (0.4,1.8)    | 0.3          | (0.1,0.6)    | 0.8          | (0.2,1.3)    | 1.0          | (0.4,1.7)    | 1.3          | (0.5,2.0)    | 2.1          | (1.2,3.1)    |
|             | Max     | 4.4      | (2.0,6.8)    | 1.0          | (0.1,2.2)    | 2.8          | (1.0,4.6)    | 4.3          | (1.9,6.8)    | 5.3          | (2.6,8.0)    | 8.8          | (5.3,12.2)   |
| Subtype   | Country | Estimate | Study period | 2014     | 2015     | 2016     | 2017     | 2018     |
|-----------|---------|----------|--------------|----------|----------|----------|----------|----------|
|           |         | Min      |              | 3.4 (2.9,3.9) | 3.4 (2.9,4.0) | 3.2 (2.7,3.7) | 3.6 (3.1,4.2) | 3.3 (2.8,3.9) |
|           |         | Max      |              | 4.7 (4.1,5.3) | 4.7 (4.1,5.4) | 4.4 (3.8,5.0) | 5.0 (4.3,5.6) | 4.6 (4.0,5.2) |
| Denmark   | Min     | 3.3 (1.5,5.0) | 3.0 (1.3,4.8) | 2.6 (1.0,4.3) | 3.4 (1.6,5.2) | 3.6 (1.7,5.5) | 3.6 (1.7,5.5) |
| Finland   | Max     | 6.7 (4.1,9.2) | 6.2 (3.7,8.7) | 5.4 (3.1,7.7) | 6.9 (4.3,9.5) | 7.4 (4.7,10.1) | 7.3 (4.7,10.0) |
| Greece    | Min     | 2.5 (1.6,3.4) | 1.4 (0.7,2.0) | 1.6 (0.9,2.3) | 2.3 (1.5,3.2) | 3.3 (2.2,4.3) | 4.0 (2.9,5.2) |
|           | Max     | 7.2 (4.9,9.5) | 3.9 (2.2,5.6) | 4.6 (2.7,6.4) | 6.7 (4.5,9.0) | 9.4 (6.8,12.0) | 11.5 (8.6,14.4) |
| Norway    | Min     | 1.9 (1.4,2.4) | 2.6 (2.0,3.2) | 1.8 (1.3,2.3) | 1.4 (1.0,1.9) | 1.7 (1.3,2.2) | 1.9 (1.4,2.4) |
| Portugal  | Max     | 4.8 (3.7,5.9) | 6.5 (5.2,7.9) | 4.6 (3.5,5.7) | 3.8 (2.8,4.8) | 4.6 (3.5,5.7) | 4.6 (3.5,5.6) |
|           | Min     | 6.1 (4.8,7.5) | NA           | NA        | NA        | NA        | 6.6 (5.2,8.1) |
|           | Max     | 10.3 (8.3,12.3) | 7.0 (5.4,8.6) | 9.2 (7.3,11.0) | 10.5 (8.5,12.4) | 11.6 (9.5,13.6) | 14.3 (11.7,17.0) |
| Overall   | Min     | 3.1 (2.3,4.0) | 2.6 (1.9,3.4) | 2.8 (2.0,3.5) | 3.1 (2.3,4.0) | 3.6 (2.7,4.5) | 3.5 (2.7,4.4) |
|           | Max     | 6.4 (5.1,7.7) | 4.9 (3.7,6.1) | 5.2 (4.0,6.4) | 6.1 (4.8,7.4) | 7.2 (5.8,8.6) | 8.5 (7.0,10.1) |

The table shows the widest variability observed. In Belgium, Greece and Norway and Portugal, this means the minimum adjusted and the maximum crude estimates (in Portugal, only one of the participating centres reported an extended population, and only for 2018, so minimum estimates could only be obtained for that year). In Denmark and Finland, there was only one participating centre which searched a national or regional database (respectively), so there were no reference and extended populations, but a single population (i.e. no maximum-minimum estimates, but a single estimate). In both countries, the single crude and adjusted estimates are shown.

Abbreviations: CI, confidence interval; CTD-ILD, connective tissue disease-associated interstitial lung disease; F-ILDs, fibrosing interstitial lung diseases; HP, hypersensitivity pneumonitis; iNSIP, idiopathic non-specific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; RA-ILD, rheumatoid arthritis-associated interstitial lung disease; SSc-ILD, systemic sclerosis-associated interstitial lung disease; uIIPs, unclassifiable idiopathic interstitial pneumonias.
## Table 6. Relative percentage (95%CI) of each non-IPF F-ILD subtype in each country, annually and for the whole study period

| Country | Subtype          | Study period | 2014            | 2015           | 2016           | 2017           | 2018           |
|---------|------------------|--------------|-----------------|----------------|----------------|----------------|----------------|
|         |                  |              | 2014            | 2015           | 2016           | 2017           | 2018           |
|         |                  |              | 2014            | 2015           | 2016           | 2017           | 2018           |
|         |                  |              | 2014            | 2015           | 2016           | 2017           | 2018           |
|         |                  |              | 2014            | 2015           | 2016           | 2017           | 2018           |
|         |                  |              | 2014            | 2015           | 2016           | 2017           | 2018           |
| Belgium | iNSIP            | 3.0 (2.0,3.9)| 1.7 (0.9,2.4)   | 2.8 (1.8,3.7)  | 3.6 (2.5,4.7)  | 3.6 (2.6,4.6)  | 3.2 (2.3,4.2)  |
|         | uIPs             | 5.7 (4.4,7.0)| 5.8 (4.4,7.2)   | 6.3 (4.9,7.7)  | 6.0 (4.7,7.4)  | 6.0 (4.7,7.3)  | 5.0 (3.9,6.2)  |
|         | RA-ILD           | 47.0 (44.2,49.8)| 48.2 (45.2,51.2)| 47.6 (44.8,50.4)| 51.0 (48.2,53.8)| 45.5 (42.7,48.2)| 46.0 (43.3,48.7)|
|         | Mixed CTD-ILD    | 2.0 (1.2,2.8)| 2.4 (1.5,3.3)   | 2.1 (1.3,2.9)  | 1.9 (1.1,2.7)  | 2.0 (1.2,2.7)  | 1.9 (1.2,2.7)  |
|         | Other CTD-ILD    | 11.5 (9.7,13.3)| 13.2 (11.2,15.2)| 11.8 (10.0,13.6)| 11.2 (9.4,13.0)| 11.4 (9.7,13.1)| 10.8 (9.1,12.4)|
|         | Exposure-related ILDs | 4.7 (3.5,5.9) | 6.3 (4.9,7.8) | 5.1 (3.9,6.4) | 5.1 (3.9,6.4) | 3.8 (2.8,4.9) | 3.7 (2.7,4.7) |
|         | Sarcoïdosis      | 15.8 (13.8,17.9)| 15.1 (13.0,17.3)| 16.3 (14.2,18.4)| 16.8 (14.7,18.9)| 16.2 (14.2,18.3)| 15.6 (13.6,17.5)|
|         | Other F-ILDs     | 3.9 (2.8,4.9)| 2.6 (1.6,3.6)   | 2.2 (1.4,3.0)  | 3.4 (2.3,4.4)  | 4.8 (3.6,5.9)  | 6.1 (4.8,7.4)  |
|         | SSC-ILD          | 5.4 (4.1,6.6)| 4.5 (3.2,5.7)   | 5.1 (3.8,6.3)  | 6.0 (4.7,7.4)  | 5.6 (4.3,6.8)  | 5.9 (4.6,7.1)  |
|         | HP               | 1.0 (0.5,1.6) | 0.3 (0.0,0.6)   | 0.8 (0.3,1.3)  | 1.0 (0.4,1.6)  | 1.2 (0.6,1.8)  | 1.8 (1.1,2.6)  |
| Denmark | iNSIP            | 1.6 (1.3,1.9)| 1.4 (1.2,1.7)   | 1.6 (1.3,1.9)  | 1.8 (1.4,2.1)  | 1.5 (1.2,1.8)  | 1.4 (1.1,1.7)  |
|         | uIPs             | 8.8 (8.1,9.5)| 9.9 (9.1,10.6)  | 9.5 (8.9,10.2) | 8.2 (7.5,8.8)  | 7.8 (7.1,8.5)  | 7.6 (7.0,8.3)  |
|         | RA-ILD           | 1.2 (1.0,1.5)| 1.2 (0.9,1.4)   | 1.0 (0.8,1.2)  | 1.3 (1.0,1.6)  | 1.5 (1.2,1.8)  | 1.2 (0.9,1.4)  |
|         | Mixed CTD-ILD    | 2.3 (1.9,2.6)| 2.3 (2.0,2.7)   | 2.2 (1.9,2.5)  | 2.2 (1.8,2.5)  | 2.3 (1.9,2.7)  | 2.0 (1.7,2.4)  |
|         | Other CTD-ILD    | 2.3 (1.9,2.6)| 2.2 (1.9,2.6)   | 2.1 (1.7,2.4)  | 2.3 (1.9,2.6)  | 2.4 (2.0,2.8)  | 2.1 (1.7,2.4)  |
|         | Exposure-related ILDs | 3.7 (3.2,4.1) | 3.8 (3.3,4.2) | 2.8 (2.4,3.2) | 3.8 (3.4,4.3) | 3.8 (3.3,4.3) | 3.9 (3.5,4.4) |
|         | Sarcoïdosis      | 56.3 (55.1,57.5)| 58.4 (57.2,59.5)| 55.4 (54.2,56.5)| 54.1 (52.9,55.3)| 55.9 (54.7,57.1)| 52.6 (51.5,53.8)|
| Country | Subtype          | Study period | 2014       | 2015       | 2016       | 2017       | 2018       |
|---------|-----------------|--------------|------------|------------|------------|------------|------------|
|         | Other F-ILDs    |              | 20.9 (19.9,21.9) | 15.4 (14.5,16.3) | 20.3 (19.4,21.3) | 21.2 (20.2,22.2) | 21.0 (20.0,22.0) | 24.3 (23.3,25.3) |
| Finland | SSc-ILD         |              | 2.1 (1.8,2.4)  | 2.3 (2.0,2.7)  | 2.2 (1.8,2.5)  | 2.1 (1.8,2.5)  | 1.6 (1.3,2.0)  | 2.0 (1.7,2.3)  |
|         | HP              |              | 3.2 (2.8,3.6)  | 3.1 (2.7,3.5)  | 2.9 (2.5,3.3)  | 3.0 (2.6,3.4)  | 3.7 (3.2,4.1)  | 2.9 (2.5,3.3)  |
|         | iNSIP           | Finland      | 7.9 (5.6,10.1) | 6.4 (4.3,8.4)  | 7.8 (5.4,10.1) | 6.7 (4.6,8.9)  | 8.9 (6.5,11.3) | 10.1 (7.6,12.5) |
|         | uIIPs           |              | 3.4 (1.9,4.9)  | 1.8 (0.7,2.9)  | 2.6 (1.2,4.0)  | 3.3 (1.7,4.8)  | 3.8 (2.2,5.4)  | 5.5 (3.6,7.3)  |
|         | RA-ILD          |              | 4.5 (2.8,6.2)  | 2.9 (1.5,4.3)  | 4.6 (2.8,6.4)  | 5.0 (3.1,6.9)  | 4.9 (3.1,6.7)  | 5.5 (3.6,7.3)  |
|         | Mixed CTD-ILD   |              | 4.0 (2.3,5.6)  | 4.2 (2.5,5.9)  | 2.6 (1.2,4.0)  | 3.8 (2.2,5.5)  | 4.5 (2.8,6.3)  | 4.8 (3.0,6.5)  |
|         | Other CTD-ILD   |              | 9.0 (6.6,11.4) | 8.7 (6.4,11.1) | 9.0 (6.5,11.5) | 10.7 (8.1,13.4) | 8.5 (6.2,10.9) | 8.6 (6.3,11.0) |
|         | Exposure-related ILDs |          | 25.8 (22.1,29.5) | 29.0 (25.2,32.8) | 31.3 (27.3,35.4) | 26.4 (22.7,30.2) | 23.8 (20.2,27.3) | 21.2 (17.8,24.5) |
| Greece  | Sarcoidosis     |              | 36.3 (32.3,40.3) | 39.2 (35.1,43.3) | 35.5 (31.3,39.7) | 34.1 (30.0,38.2) | 36.1 (32.1,40.1) | 39.2 (35.1,43.2) |
|         | Other F-ILDs    |              | 1.6 (0.6,2.7)  | 1.1 (0.2,2.0)  | 2.0 (0.8,3.2)  | 1.7 (0.6,2.8)  | 1.5 (0.5,2.5)  | 1.9 (0.8,3.1)  |
|         | SSc-ILD         |              | 2.9 (1.5,4.3)  | 2.4 (1.1,3.6)  | 3.0 (1.5,4.5)  | 3.1 (1.6,4.5)  | 2.7 (1.4,4.1)  | 3.7 (2.1,5.3)  |
|         | HP              |              | 4.8 (3.0,6.5)  | 4.4 (2.7,6.1)  | 4.2 (2.4,6.0)  | 5.2 (3.3,7.1)  | 5.3 (3.4,7.1)  | 5.1 (3.3,6.9)  |
| Greece  | iNSIP           | Greece       | 8.4 (5.0,11.7) | 11.3 (6.7,15.8) | 10.4 (6.2,14.6) | 8.0 (4.7,11.4) | 6.3 (3.6,9.1) | 8.1 (5.2,11.0) |
|         | uIIPs           |              | 7.9 (4.7,11.2) | 4.3 (1.4,7.2)  | 5.8 (2.6,9.0)  | 7.8 (4.5,11.1) | 9.6 (6.3,12.9) | 10.4 (7.1,13.6) |
|         | RA-ILD          |              | 14.6 (10.3,18.9) | 15.6 (10.4,20.8) | 15.7 (10.7,20.7) | 15.8 (11.3,20.2) | 14.6 (10.6,18.6) | 13.6 (9.9,17.2) |
|         | Mixed CTD-ILD   |              | 2.4 (0.6,4.3)  | 2.7 (0.4,5.0)  | 1.9 (0.0,3.7)  | 2.2 (0.4,3.9)  | 2.8 (1.0,4.7)  | 2.6 (0.9,4.3)  |
|         | Other CTD-ILD   |              | 7.3 (4.1,10.4) | 11.3 (6.7,15.8) | 7.6 (4.0,11.3) | 7.9 (4.6,11.2) | 6.5 (3.7,9.3) | 5.4 (3.0,7.9)  |
| Country  | Subtype     | Study period | 2014   | 2015   | 2016   | 2017   | 2018   |
|----------|-------------|--------------|--------|--------|--------|--------|--------|
|          | Exposure-related ILDs |            | 3.7 (1.4, 6.0) | 2.3 (0.2, 4.5) | 3.3 (0.9, 5.8) | 4.2 (1.7, 6.7) | 4.0 (1.8, 6.2) | 4.2 (2.1, 6.4) |
|          | Sarcoidosis  |              | 29.0 (23.5, 34.5) | 38.7 (31.7, 45.7) | 31.1 (24.7, 37.4) | 28.9 (23.3, 34.4) | 27.4 (22.3, 32.4) | 25.6 (20.9, 30.3) |
|          | Other F-ILDs |              | 4.4 (1.9, 6.9) | 4.5 (1.5, 7.5) | 4.4 (1.6, 7.3) | 4.0 (1.6, 6.4) | 4.6 (2.2, 7.0) | 4.8 (2.5, 7.0) |
|          | SSc-ILD     |              | 7.7 (4.5, 11.0) | 9.5 (5.3, 13.7) | 8.0 (4.3, 11.8) | 7.4 (4.2, 10.7) | 7.8 (4.7, 10.7) | 7.3 (4.5, 10.1) |
|          | HP          |              | 14.6 (10.3, 18.9) | 11.1 (6.6, 15.6) | 11.8 (7.4, 16.3) | 13.8 (9.6, 18.0) | 16.4 (12.2, 20.6) | 18.0 (13.9, 22.1) |
| Norway   | iNSIP       |              | 12.9 (11.2, 14.5) | 13.3 (11.3, 15.3) | 12.6 (10.8, 14.3) | 12.9 (11.3, 14.5) | 13.3 (11.8, 14.8) | 13.5 (11.9, 15.1) |
|          | ulIPs       |              | 8.8 (7.4, 10.2) | 8.0 (6.4, 9.6) | 7.8 (6.4, 9.2) | 9.5 (8.1, 10.9) | 8.8 (7.5, 10.0) | 10.4 (9.0, 11.8) |
|          | RA-ILD      |              | 1.9 (1.2, 2.6) | 0.3 (0.0, 0.6) | 0.9 (0.4, 1.5) | 2.4 (1.7, 3.2) | 2.8 (2.0, 3.5) | 2.3 (1.6, 3.1) |
|          | Mixed CTD-ILD |            | 6.6 (5.4, 7.8) | 3.7 (2.6, 4.9) | 4.1 (3.1, 5.2) | 8.0 (6.7, 9.3) | 7.4 (6.2, 8.6) | 8.7 (7.4, 10.1) |
|          | Other CTD-ILD |          | 15.8 (14.0, 17.6) | 15.5 (13.4, 17.7) | 20.1 (18.0, 22.3) | 15.5 (13.8, 17.2) | 15.4 (13.8, 17.0) | 14.9 (13.2, 16.6) |
|          | Exposure-related ILDs |        | 1.1 (0.6, 1.6) | 1.9 (1.1, 2.7) | 1.6 (0.9, 2.3) | 0.7 (0.3, 1.1) | 0.93 (0.5, 1.4) | 0.8 (0.4, 1.2) |
|          | Sarcoidosis  |              | 18.0 (16.1, 19.9) | 33.2 (30.4, 36.0) | 19.5 (17.4, 21.6) | 14.3 (12.6, 16.0) | 16.1 (14.4, 17.7) | 14.8 (13.2, 16.5) |
|          | Other F-ILDs |              | 18.3 (16.4, 20.2) | 15.5 (13.4, 17.7) | 17.5 (15.5, 19.5) | 20.0 (18.0, 21.8) | 18.2 (16.5, 19.9) | 20.8 (18.9, 22.7) |
|          | SSc-ILD     |              | 12.3 (10.7, 13.9) | 15.7 (13.5, 17.9) | 11.1 (9.5, 12.8) | 13.5 (11.9, 15.2) | 13.8 (12.2, 15.3) | 9.5 (8.1, 10.9) |
|          | HP          |              | 4.4 (3.4, 5.4) | 8.4 (6.7, 10.0) | 4.7 (3.6, 5.8) | 3.2 (2.4, 4.1) | 3.5 (2.7, 4.3) | 4.3 (3.3, 5.2) |
| Portugal | iNSIP       |              | 2.0 (0.7, 3.3) | 2.9 (1.1, 4.7) | 2.2 (0.8, 3.5) | 1.9 (0.7, 3.2) | 1.9 (0.7, 3.1) | 1.6 (0.5, 2.6) |
|          | ulIPs       |              | 7.8 (5.3, 10.3) | 5.6 (3.1, 8.0) | 7.1 (4.6, 9.5) | 8.1 (5.6, 10.5) | 8.6 (6.2, 11.04) | 8.9 (6.4, 11.4) |
|          | RA-ILD      |              | 6.9 (4.6, 9.3) | 7.4 (4.6, 10.2) | 6.8 (4.4, 9.2) | 7.1 (4.8, 9.4) | 7.0 (4.8, 9.2) | 6.4 (4.3, 8.6) |
| Country          | Subtype                  | Study period | 2014     | 2015     | 2016     | 2017     | 2018     |
|------------------|--------------------------|--------------|----------|----------|----------|----------|----------|
|                  | Mixed CTD-ILD            |              | 0.8 (0.0,1.6) | 0.6 (0.0,1.4) | 0.7 (0.0,1.5) | 0.7 (0.0,1.5) | 1.0 (0.1,1.8) | 0.8 (0.0,1.5) |
|                  | Other CTD-ILD            |              | 6.2 (4.0,8.4) | 3.6 (1.6,5.6) | 5.4 (3.2,7.5) | 5.9 (3.8,8.1) | 6.9 (4.8,9.1) | 8.1 (5.7,10.5) |
|                  | Exposure-related ILDs    |              | 2.1 (0.8,3.5) | 1.7 (0.3,3.0) | 1.1 (0.1,2.1) | 1.1 (0.1,2.0) | 1.0 (0.2,1.9) | 5.5 (3.5,7.5) |
|                  | Sarcoïdosis              |              | 40.1 (35.6,44.7) | 45.8 (40.4,51.1) | 42.4 (37.7,47.2) | 40.1 (35.7,44.6) | 38.6 (34.4,42.7) | 36.1 (31.8,40.3) |
|                  | Other F-ILDs             |              | 6.1 (3.9,8.3) | 5.7 (3.2,8.2) | 6.1 (3.8,8.4) | 6.4 (4.2,8.6) | 6.4 (4.3,8.5) | 5.8 (3.8,7.9) |
|                  | SSc-ILD                  |              | 5.0 (3.0,7.1) | 4.5 (2.3,6.8) | 5.3 (3.1,7.4) | 5.2 (3.2,7.2) | 5.2 (3.3,7.1) | 4.8 (2.9,6.7) |
|                  | HP                       |              | 22.9 (19.0,26.8) | 22.3 (17.8,26.8) | 23.1 (19.0,27.1) | 23.5 (19.6,27.3) | 23.4 (19.7,27.0) | 22.2 (18.5,25.8) |

Percentages calculated based on the total number of prevalent cases of non-IPF F-ILD in each country.

Abbreviations: CI, confidence interval; CTD-ILD, connective tissue disease-associated interstitial lung disease; F-ILDs, fibrosing interstitial lung diseases; HP, hypsersensitivity pneumonitis; INSIP, idiopathic non-specific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; RA-ILD, rheumatoid arthritis-associated interstitial lung disease; SSc-ILD, systemic sclerosis-associated interstitial lung disease; uILPs, unclassifiable idiopathic interstitial pneumonias.
| Country         | Estimate | Study period | 2014      | 2015      | 2016       | 2017       | 2018       |
|----------------|----------|--------------|-----------|-----------|------------|------------|------------|
| **Incidence**  |          |              |           |           |            |            |            |
| Belgium        | Min      | 1.2 (0.9,1.6)| 0.8 (0.4,1.6)| 1.1 (0.6,2.1)| 1.2 (0.7,2.2)| 1.1 (0.6,2.1)| 1.8 (1.1,2.9)|
|                | Max      | 4.8 (3.8,6.1)| 3.1 (1.6,5.9)| 4.1 (2.4,7.0)| 5.0 (3.0,8.5)| 4.6 (2.7,8.0)| 7.4 (4.8,11.3)|
| Denmark        | Min      | 1.0 (0.9,1.2)| 1.0 (0.7,1.3)| 1.0 (0.8,1.3)| 1.1 (0.8,1.4)| 1.0 (0.8,1.4)| 1.1 (0.8,1.4)|
|                | Max      | 1.4 (1.3,1.6)| 1.4 (1.1,1.7)| 1.4 (1.1,1.8)| 1.5 (1.2,1.9)| 1.4 (1.1,1.8)| 1.5 (1.1,1.9)|
| Finland        | Min      | 3.8 (3.0,4.8)| 3.7 (2.2,6.2)| 2.5 (1.3,4.7)| 4.4 (2.7,7.0)| 3.6 (2.1,6.1)| 4.8 (3.1,7.6)|
|                | Max      | 7.8 (6.6,9.1)| 7.5 (5.2,10.8)| 5.1 (3.3,8.0)| 9.0 (6.4,12.5)| 7.4 (5.1,10.6)| 9.9 (7.2,13.5)|
| Greece         | Min      | 0.8 (0.7,0.9)| 0.5 (0.3,0.8)| 0.6 (0.4,0.9)| 0.8 (0.6,1.2)| 1.0 (0.7,1.3)| 1.0 (0.7,1.4)|
|                | Max      | 1.8 (1.5,2.0)| 1.4 (1.0,2.2)| 1.3 (0.9,1.9)| 1.7 (1.2,2.4)| 2.1 (1.5,2.8)| 2.1 (1.6,2.9)|
| Norway         | Min      | 1.3 (1.1,1.5)| NA         | 1.3 (0.9,1.8)| 2.1 (1.6,2.7)| 1.0 (0.7,1.4)| 0.8 (0.5,1.2)|
|                | Max      | 3.2 (2.8,3.7)| NA         | 3.2 (2.4,4.3)| 5.4 (4.3,6.8)| 2.6 (1.9,3.6)| 2.0 (1.4,2.8)|
| Portugal       | Min      | 0.9 (0.7,1.1)| 0.9 (0.6,1.4)| 0.7 (0.5,1.2)| 1.2 (0.8,1.7)| 0.8 (0.5,1.2)| 0.7 (0.5,1.1)|
|                | Max      | 1.2 (1.0,1.4)| 1.3 (0.9,1.8)| 1.0 (0.7,1.5)| 1.7 (1.2,2.3)| 1.1 (0.8,1.6)| 1.0 (0.7,1.4)|
| **Overall**    | Min      | 1.7 (1.1,2.2)| 1.6 (1.1,2.1)| 1.3 (0.8,1.7)| 2.0 (1.4,2.5)| 1.6 (1.1,2.1)| 1.9 (1.3,2.5)|
|                | Max      | 3.4 (2.5,4.2)| 2.9 (2.1,3.7)| 2.7 (1.9,3.4)| 4.1 (3.1,5.0)| 3.2 (2.4,4.0)| 4.0 (3.1,4.8)|
| **Prevalence** |          |              |           |           |            |            |            |
| Belgium        | Min      | 1.6 (0.7,2.4)| 0.9 (0.2,1.5)| 1.2 (0.5,1.9)| 1.7 (0.8,2.6)| 1.5 (0.7,2.3)| 2.5 (1.5,3.6)|
|                | Max      | 6.3 (3.4,9.2)| 3.4 (1.3,5.5)| 4.4 (2.1,6.7)| 7.2 (4.0,10.3)| 6.4 (3.5,9.4)| 10.6 (6.8,14.3)|
| Denmark        | Min      | 2.6 (2.1,3.0)| 2.7 (2.2,3.2)| 2.5 (2.0,3.0)| 2.5 (2.1,3.0)| 2.5 (2.1,3.0)| 2.6 (2.1,3.1)|
|                | Max      | 3.6 (3.0,4.1)| 3.7 (3.2,4.3)| 3.4 (2.9,4.0)| 3.5 (2.9,4.0)| 3.5 (2.9,4.0)| 3.6 (3.0,4.1)|
| Finland        | Min      | 7.9 (5.2,10.7)| 6.5 (3.9,9.0)| 5.9 (3.5,8.3)| 8.5 (5.6,11.4)| 8.6 (5.7,11.5)| 10.2 (7.0,13.3)|
|                | Max      | 16.2 (12.2,20.2)| 13.2 (9.6,16.8)| 12.1 (8.6,15.5)| 17.4 (13.3,21.6)| 17.5 (13.4,21.7)| 20.8 (16.3,25.3)|
|                | Min      | 1.1 (0.5,1.7)| 0.7 (0.2,1.2)| 0.7 (0.2,1.2)| 0.9 (0.4,1.5)| 1.4 (0.7,2.0)| 1.9 (1.1,2.7)|
The table shows the widest variability observed. In Belgium, Greece and Norway, this means the minimum adjusted and the maximum crude estimates. The participating centre in Norway could not retrieve incident cases for 2014, and thus incidence could not be estimated for that year. In Portugal, only one of the participating centres reported an extended population, and only for 2018. Therefore, minimum prevalence estimates could only be obtained for that year. Plus, incident cases for 2018 could not be retrieved in this centre, so minimum adjusted incidence estimates could not be obtained for Portugal. Instead, the table shows the nearest estimates (maximum adjusted) as minimum values. In Denmark and Finland, there was only one participating centre which searched a national or regional database (respectively), so there were no reference and extended populations, but a single population (i.e. no maximum-minimum estimates, but a single estimate). In both countries, the single crude and adjusted estimates are shown.

Abbreviations: CI, confidence interval; ILD, interstitial lung disease; F-ILDs, fibrosing interstitial lung diseases; IPF, idiopathic pulmonary fibrosis; NA, not available; SSc-ILD, systemic sclerosis-associated interstitial lung disease.
| Subtype                      | PF only       | UIP-like only | PF plus UIP-like | Non-PF-non-UIP-like |
|-----------------------------|---------------|---------------|------------------|--------------------|
| iNSIP                       | 22.5 (10.8,34.1) | 8.2 (0.5,15.8) | 12.2 (3.1,21.4)  | 57.1 (43.3,71.0)   |
| uIIPs                       | 24.3 (14.5,34.1) | 18.9 (10.0,27.8) | 17.6 (8.9,26.2)  | 39.2 (28.1,50.3)   |
| RA-ILD                      | 11.1 (1.9,20.3)  | 33.3 (19.6,47.1) | 26.7 (13.7,39.6) | 28.9 (15.6,42.1)   |
| Mixed CTD-ILD              | 0.0 (0.0,0.0)   | 10.0 (0.0,28.6)  | 20.0 (0.0,44.8)  | 70.0 (41.6,98.4)   |
| Other CTD-ILD              | 14.6 (4.6,24.6)  | 16.7 (6.1,27.2)  | 25.0 (12.8,37.3) | 43.8 (29.7,57.8)   |
| Exposure-related ILDs       | 18.2 (5.0,31.3)  | 9.1 (0.0,18.9)   | 18.2 (5.0,31.3)  | 54.6 (37.6,71.5)   |
| Sarcoidosis                 | 8.5 (4.3,12.8)   | 4.9 (1.6,8.2)    | 1.8 (0.0,3.9)    | 84.8 (79.3,90.3)   |
| Other F-ILDs                | 25.0 (14.5,34.8) | 16.0 (7.3,24.6)  | 8.7 (2.0,15.3)   | 50.7 (38.9,62.52)  |
| SSc-ILD                     | 5.3 (0.0,11.1)   | 38.6 (26.5,51.2) | 31.6 (19.5,43.7) | 24.6 (13.4,35.7)   |
| HP                          | 27.4 (19.6,35.3) | 10.5 (5.1,15.9)  | 22.6 (15.2,30.0) | 39.5 (30.9,48.1)   |
| Total non-IPF F-ILDs        | 16.2 (13.1,19.2) | 14.4 (11.5,17.3) | 14.0 (11.1,16.9) | 55.5 (51.3,59.6)   |

Only centres reporting complete data (i.e. all non-IPF F-ILD subtypes, and both pulmonary and rheumatology cases) were considered. Percentages were calculated based on the total number of cases for each subtype, and in the last row, based on the total number of non-IPF F-ILD cases.

Abbreviations: CI, confidence interval; CTD-ILD, connective tissue disease-associated interstitial lung disease; F-ILDs, fibrosing interstitial lung diseases; HP, hypersensitivity pneumonitis; iNSIP, idiopathic non-specific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; PF, progressive-fibrosing; RA-ILD, rheumatoid arthritis-associated interstitial lung disease; SSc-ILD, systemic sclerosis-associated interstitial lung disease; uIIPs, unclassifiable idiopathic interstitial pneumonias; UIP, usual interstitial pneumonia.
Table 9. Exploratory p-values for pairwise comparisons of PF behaviour percentage between non-IPF F-ILD subtypes (all countries)

| Subtype                  | iNSIP | uIIPs | RA-ILD | Mixed CTD-ILD | Other CTD-ILD | Exposure-related ILDs | Sarcoidosis | Other F-ILDs | SSc-ILD | HP           |
|--------------------------|-------|-------|--------|---------------|---------------|-----------------------|-------------|--------------|---------|--------------|
| iNSIP                    | -     | 0.0072| 0.9019 | 0.0015        | 0.0683        | 0.2583                | 1.0000      | 0.3749       | 0.0366  | <0.0001      |
| uIIPs                    | -     | -     | 0.0087 | <0.0001       | 0.3857        | 0.0002                | 0.0072      | 0.0619       | 0.5818  | 0.0032       |
| RA-ILD                   | -     | -     | -      | 0.0001        | 0.0820        | 0.2054                | 0.9019      | 0.4357       | 0.0442  | <0.0001      |
| Mixed CTD-ILD            | -     | -     | -      | <0.0001        | 0.0263        | 0.0015                | 0.0001      | <0.0001       | <0.0001 |
| Other CTD-ILD            | -     | -     | -      | <0.0001        | 0.0037        | 0.0683                | 0.3287      | 0.7666       | 0.0002  |
| Exposure-related ILDs    | -     | -     | -      | -              | -              | 0.2583                | 0.0445      | 0.0016       | <0.0001 |
| Sarcoidosis              | -     | -     | -      | -              | -              | -                     | 0.3749      | 0.0366       | <0.0001 |
| Other F-ILDs             | -     | -     | -      | -              | -              | -                     | -           | 0.2069       | <0.0001 |
| SSc-ILD                  | -     | -     | -      | -              | -              | -                     | -           | 0.0008       |         |
| HP                       | -     | -     | -      | -              | -              | -                     | -           | -            |         |

P-values below the significance level of p<0.05 are shown in bold.
Abbreviations: CTD-ILD, connective tissue disease-associated interstitial lung disease; F-ILDs, fibrosing interstitial lung diseases; HP, hypersensitivity pneumonitis; iNSIP, idiopathic non-specific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; PF, progressive-fibrosing; RA-ILD, rheumatoid arthritis-associated interstitial lung disease; SSc-ILD, systemic sclerosis-associated interstitial lung disease; uIIPs, unclassifiable idiopathic interstitial pneumonias.
Table 10. Incidence per 10^9 person-years (95%CI) of PF-ILDs in each country and overall, annually and for the whole study period. Primary analysis (Method 1) and sensitivity analyses (Methods 1b-3)

| Country | Method | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|--------|----------|--------------|------|------|------|------|------|
|         |        | Min      |              |      |      |      |      |      |
| Belgium | 1      | 5.8 (5.5,6.1) | 4.6 (4.1,5.2) | 5.6 (5.0,6.4) | 5.7 (5.1,6.4) | 6.9 (6.2,7.7) | 6.5 (5.8,7.3) |
|         | Max    | 13.7 (13.0,14.6) | 12.0 (10.5,13.8) | 12.8 (11.2,14.6) | 13.7 (12.0,15.6) | 15.9 (14.0,18.0) | 14.5 (12.7,16.5) |
|         | 1b     | Min      |              |      |      |      |      |      |
|         |        | 5.8 (5.5,6.1) | 4.6 (4.1,5.2) | 5.6 (5.0,6.4) | 5.7 (5.1,6.4) | 6.9 (6.2,7.7) | 6.5 (5.8,7.3) |
|         | Max    | 13.7 (13.0,14.6) | 12.0 (10.5,13.8) | 12.8 (11.2,14.6) | 13.7 (12.0,15.6) | 15.9 (14.0,18.0) | 14.5 (12.7,16.5) |
|         | 2      | Min      |              |      |      |      |      |      |
|         |        | 5.6 (5.2,6.0) | 4.4 (3.7,5.3) | 5.4 (4.6,6.4) | 5.4 (4.6,6.4) | 6.6 (5.7,7.7) | 6.2 (5.3,7.3) |
|         | Max    | 22.1 (20.3,24.1) | 17.5 (14.3,21.4) | 19.6 (16.1,23.9) | 22.6 (18.6,27.4) | 27.3 (22.8,32.7) | 25.3 (21.0,30.6) |
|         | 2b     | Min      |              |      |      |      |      |      |
|         |        | 5.6 (5.3,6.1) | 4.4 (3.9,5.2) | 5.4 (4.8,6.4) | 5.4 (4.8,6.4) | 6.6 (5.9,7.7) | 6.2 (5.5,7.3) |
|         | Max    | 13.1 (12.4,14.0) | 11.5 (10.0,13.3) | 12.2 (10.6,14.0) | 13.1 (11.4,15.0) | 15.2 (13.4,17.2) | 13.8 (12.1,15.8) |
|         | 3      | Min      |              |      |      |      |      |      |
|         |        | 6.3 (5.7,6.9) | 5.0 (4.0,6.3) | 6.1 (4.9,7.6) | 6.1 (5.0,7.6) | 7.5 (6.2,9.1) | 7.0 (5.7,8.6) |
|         | Max    | 25.1 (23.8,26.4) | 19.8 (17.6,22.3) | 22.2 (19.7,24.9) | 25.5 (22.8,28.6) | 30.9 (27.8,34.4) | 28.7 (25.6,32.1) |
| Denmark | 1      | Min      |              |      |      |      |      |      |
|         |        | 8.5 (8.3,8.5) | 8.5 (7.9,8.9) | 9.1 (8.5,9.4) | 8.8 (8.2,9.2) | 8.0 (7.4,8.3) | 8.3 (7.7,8.6) |
|         | Max    | 14.4 (13.9,14.9) | 14.3 (13.2,15.5) | 15.3 (14.2,16.5) | 15.0 (14.0,16.2) | 13.4 (12.4,14.5) | 14.0 (12.9,15.1) |
|         | 1b     | Min      |              |      |      |      |      |      |
|         |        | 8.3 (8.0,8.5) | 8.2 (7.6,8.9) | 8.8 (8.2,9.4) | 8.5 (7.9,9.2) | 7.7 (7.1,8.3) | 8.0 (7.5,8.6) |
|         | Max    | 13.9 (13.5,14.4) | 13.8 (12.8,15.0) | 14.8 (13.7,16.0) | 14.5 (13.5,15.7) | 13.0 (12.0,14.1) | 13.5 (12.5,14.6) |
|         | 2      | Min      |              |      |      |      |      |      |
|         |        | 11.5 (11.2,11.8) | 11.5 (10.8,12.2) | 12.2 (11.5,13.0) | 11.9 (11.2,12.7) | 10.7 (10.1,11.4) | 11.2 (10.5,11.9) |
|         | Max    | 19.4 (18.8,20.0) | 19.3 (18.0,20.6) | 20.6 (19.3,22.0) | 20.3 (19.0,21.6) | 18.1 (16.9,19.4) | 18.8 (17.6,20.1) |
|         | 2b     | Min      |              |      |      |      |      |      |
|         |        | 10.4 (10.1,8.5) | 10.4 (9.7,8.9) | 11.1 (10.4,9.4) | 10.8 (10.1,9.2) | 9.7 (9.1,8.3) | 10.1 (9.5,8.6) |
|         | Max    | 17.6 (17.0,18.1) | 17.5 (16.3,18.7) | 18.7 (17.4,20.0) | 18.4 (17.1,19.6) | 16.4 (15.3,17.6) | 17.1 (15.9,18.3) |
|         | 3      | Min      |              |      |      |      |      |      |
|         |        | 9.2 (8.8,9.6) | 9.1 (8.3,10.0) | 9.7 (8.9,10.7) | 9.6 (8.7,10.5) | 8.5 (7.7,9.4) | 8.9 (8.1,9.8) |
|         | Max    | 12.6 (12.4,12.9) | 12.5 (12.1,13.1) | 13.4 (12.9,13.9) | 13.2 (12.7,13.7) | 11.8 (11.3,12.3) | 12.3 (11.8,12.7) |
|         |        | 5.0 (4.5,4.5) | 7.6 (6.3,7.5) | 3.9 (3.0,4.1) | 4.0 (3.1,4.2) | 4.7 (3.7,4.9) | 4.8 (3.8,5.0) |
| Country | Method | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|--------|----------|--------------|------|------|------|------|------|
| Finland | 1      | Max      | 10.1 (8.8,11.6) | 15.4 (12.0,19.9) | 7.9 (5.5,11.2) | 8.1 (5.7,11.5) | 9.5 (6.9,13.1) | 9.7 (7.1,13.4) |
|         | 1b     | Min      | 4.0 (3.6,4.5) | 6.1 (5.0,7.5) | 3.1 (2.4,4.1) | 3.2 (2.5,4.2) | 3.8 (3.0,4.9) | 3.9 (3.0,5.0) |
|         |        | Max      | 8.2 (7.0,9.6) | 12.5 (9.4,16.6) | 6.4 (4.3,9.5) | 6.6 (4.5,9.7) | 7.7 (5.4,11.0) | 7.9 (5.6,11.2) |
|         | 2      | Min      | 6.7 (6.2,7.3) | 10.2 (8.8,11.9) | 5.2 (4.2,6.5) | 5.4 (4.3,6.6) | 6.3 (5.2,7.6) | 6.4 (5.3,7.8) |
|         |        | Max      | 13.7 (12.1,15.4) | 20.8 (16.7,25.9) | 10.6 (7.8,14.4) | 10.9 (8.1,14.8) | 12.9 (9.8,16.9) | 13.2 (10.0,17.3) |
|         | 2b     | Min      | 4.0 (3.6,4.5) | 6.1 (5.0,7.5) | 3.1 (2.4,4.1) | 3.2 (2.5,4.2) | 3.8 (3.0,4.9) | 3.9 (3.0,5.0) |
|         |        | Max      | 8.2 (7.0,9.6) | 12.5 (9.4,16.6) | 6.4 (4.3,9.5) | 6.6 (4.5,9.7) | 7.7 (5.4,11.0) | 7.9 (5.6,11.2) |
|         | 3      | Min      | 4.0 (3.2,5.0) | 6.1 (4.1,9.2) | 3.1 (1.8,5.5) | 3.2 (1.9,5.6) | 3.8 (2.3,6.3) | 3.9 (2.3,6.4) |
|         |        | Max      | 8.2 (7.7,8.8) | 12.5 (11.0,14.3) | 6.4 (5.3,7.7) | 6.6 (5.5,7.9) | 7.7 (6.6,9.1) | 7.9 (6.7,9.3) |
| Greece  | 1      | Min      | 2.1 (1.9,1.9) | 1.3 (1.0,1.5) | 2.0 (1.6,2.0) | 2.3 (1.9,2.2) | 2.7 (2.3,2.6) | 2.3 (2.0,2.3) |
|         |        | Max      | 5.2 (4.8,5.7) | 5.1 (4.1,6.3) | 4.5 (3.7,5.5) | 4.8 (4.0,5.9) | 6.6 (5.6,7.8) | 5.0 (4.1,6.0) |
|         | 1b     | Min      | 1.8 (1.6,1.9) | 1.2 (0.9,1.5) | 1.6 (1.3,2.0) | 1.8 (1.5,2.2) | 2.2 (1.8,2.6) | 1.9 (1.6,2.3) |
|         |        | Max      | 4.3 (3.9,4.7) | 4.8 (3.9,6.0) | 3.7 (3.0,4.6) | 3.9 (3.1,4.8) | 5.3 (4.4,6.4) | 4.0 (3.2,4.9) |
|         | 2      | Min      | 2.2 (2.1,2.4) | 1.3 (1.1,1.7) | 2.1 (1.7,2.5) | 2.4 (2.0,2.8) | 2.8 (2.4,3.3) | 2.5 (2.1,2.9) |
|         |        | Max      | 5.5 (5.0,6.0) | 5.4 (4.3,6.6) | 4.8 (3.9,5.8) | 5.1 (4.2,6.2) | 6.9 (5.9,8.2) | 5.2 (4.3,6.3) |
|         | 2b     | Min      | 1.8 (1.7,1.9) | 1.2 (1.0,1.5) | 1.7 (1.4,2.0) | 1.9 (1.6,2.2) | 2.2 (1.9,2.6) | 2.0 (1.6,2.3) |
|         |        | Max      | 4.5 (4.1,4.9) | 5.1 (4.1,6.3) | 3.9 (3.1,4.8) | 4.0 (3.2,4.9) | 5.5 (4.5,6.6) | 4.1 (3.3,5.1) |
|         | 3      | Min      | 1.5 (1.4,1.7) | 0.9 (0.7,1.3) | 1.4 (1.1,1.9) | 1.7 (1.3,2.1) | 2.0 (1.6,2.5) | 1.7 (1.3,2.2) |
|         |        | Max      | 3.8 (3.6,4.0) | 3.7 (3.3,4.2) | 3.3 (2.9,3.7) | 3.5 (3.1,3.9) | 4.8 (4.3,5.3) | 3.6 (3.2,4.0) |
| Norway  | 1      | Min      | 2.7 (2.5,2.9) | NA | 2.7 (2.2,3.2) | 3.6 (3.1,4.2) | 2.4 (2.0,2.8) | 2.1 (1.8,2.6) |
|         |        | Max      | 6.8 (6.2,7.5) | NA | 6.8 (5.6,8.3) | 9.4 (7.9,11.1) | 6.2 (5.1,7.7) | 5.2 (4.2,6.4) |
|         | 1b     | Min      | 2.7 (2.5,2.9) | NA | 2.7 (2.3,3.2) | 3.6 (3.1,4.2) | 2.4 (2.0,2.8) | 2.1 (1.8,2.6) |
|         |        | Max      | 6.9 (6.3,7.6) | NA | 6.9 (5.6,8.4) | 9.5 (8.0,11.2) | 6.3 (5.1,7.7) | 5.2 (4.2,6.4) |
| Country | Method | Estimate | Study period | 2014    | 2015    | 2016    | 2017    | 2018    |
|---------|--------|----------|--------------|---------|---------|---------|---------|---------|
| 2       | Min    | 3.2 (2.9,3.4) | NA           | 3.2 (2,7,3.7) | 4.3 (3.7,4.9) | 2.8 (2,4,3.3) | 2.5 (2,1,3.0) |
|         | Max    | 8.1 (7.4,8.9) | NA           | 8.1 (6,7,9.7) | 11.1 (9,5,13.0) | 7.4 (6,1,8.9) | 6.1 (5,0,7.4) |
| 2b      | Min    | 2.7 (2.5,2.9) | NA           | 2.7 (2,3,3.2) | 3.6 (3,1,4.2) | 2.4 (2,0,2.8) | 2.1 (1,8,2.6) |
|         | Max    | 6.9 (6,3,7.6) | NA           | 6.9 (5,6,8.4) | 9.5 (8,0,11.2) | 6.3 (5,1,7.7) | 5.2 (4,2,6.4) |
| 3       | Min    | 2.7 (2.4,3.0) | NA           | 2.7 (2,1,3.4) | 3.6 (3,0,4.4) | 2.4 (1,9,3.0) | 2.1 (1,7,2.7) |
|         | Max    | 6.9 (6,5,7.3) | NA           | 6.9 (6,2,7.7) | 9.5 (8,6,10.4) | 6.3 (5,6,7.0) | 5.2 (4,6,5.8) |
| Portugal| 1      | Min    | 2.1 (1,9,2.9) | 1.5 (1,2,2.5) | 2.1 (1,7,3.2) | 1.8 (1,5,2.8) | 2.3 (1,9,3.4) | 2.6 (2,2,3.6) |
|         | Max    | 2.9 (2,6,3.2) | 2.1 (1,6,2.8) | 2.9 (2,3,3.6) | 2.5 (2,0,3.3) | 3.2 (2,5,3.9) | 3.5 (2,9,4.3) |
| 1b      | Min    | 2.6 (2,4,2.9) | 2.1 (1,7,2.5) | 2.7 (2,3,3.2) | 2.3 (1,9,2.8) | 2.9 (2,5,3.4) | 3.1 (2,7,3.6) |
|         | Max    | 3.6 (3,3,4.0) | 2.9 (2,3,3.6) | 3.7 (3,0,4.6) | 3.2 (2,6,4.0) | 4.0 (3,3,4.9) | 4.2 (3,6,5.0) |
| 2       | Min    | 1.9 (1,7,2.1) | 1.4 (1,1,1.8) | 1.9 (1,5,2.3) | 1.7 (1,3,2.1) | 2.1 (1,7,2.5) | 2.3 (2,0,2.8) |
|         | Max    | 2.6 (2,4,2.9) | 1.9 (1,4,2.6) | 2.6 (2,0,3.3) | 2.3 (1,8,3.0) | 2.9 (2,3,3.6) | 3.2 (2,6,3.9) |
| 2b      | Min    | 2.6 (2,4,2.9) | 2.0 (1,7,2.5) | 2.6 (2,2,3.2) | 2.3 (1,9,2.8) | 2.8 (2,4,3.4) | 2.9 (2,5,3.6) |
|         | Max    | 3.5 (3,2,3.9) | 2.8 (2,2,3.6) | 3.6 (3,0,4.5) | 3.1 (2,5,3.9) | 3.9 (3,2,4.7) | 4.0 (3,4,4.8) |
| 3       | Min    | 2.6 (2,3,2.9) | 1.9 (1,4,2.5) | 2.6 (2,0,3.3) | 2.3 (1,8,3.0) | 2.8 (2,2,3.6) | 3.2 (2,6,3.9) |
|         | Max    | 3.6 (3,3,3.8) | 2.6 (2,2,3.1) | 3.5 (3,1,4.1) | 3.1 (2,7,3.7) | 3.9 (3,4,4.5) | 4.4 (3,9,4.9) |
| Overall | 1      | Min    | 4.4 (3,7,5.0) | 5.0 (4,2,5.5) | 4.1 (3,5,4.7) | 4.3 (3,6,4.8) | 4.4 (3,7,5.0) | 4.4 (3,7,4.9) |
|         | Max    | 9.0 (7,8,10.3) | 9.8 (8,5,11.2) | 8.4 (7,3,9.6) | 8.9 (7,8,10.2) | 9.1 (7,9,10.5) | 8.6 (7,5,9.9) |
| 1b      | Min    | 4.2 (3,5,5.0) | 4.6 (3,9,5.5) | 4.0 (3,3,4.7) | 4.1 (3,4,4.8) | 4.2 (3,5,5.0) | 4.2 (3,5,4.9) |
|         | Max    | 8.5 (7,4,9.8) | 9.2 (8,0,10.6) | 8.0 (7,0,9.3) | 8.6 (7,4,9.8) | 8.7 (7,5,10.0) | 8.2 (7,1,9.5) |
| 2       | Min    | 5.3 (4,6,6.3) | 6.2 (5,3,7.3) | 4.9 (4,2,5.8) | 5.1 (4,4,6.0) | 5.2 (4,5,6.2) | 5.2 (4,4,6.1) |
|         | Max    | 12.1 (10,6,13.8) | 13.0 (11,4,14.8) | 11.1 (9,7,12.6) | 12.1 (10,6,13.7) | 12.6 (11,0,14.4) | 12.0 (10,5,13.7) |
|         | Min    | 4.5 (3,8,5.0) | 5.0 (4,3,5.5) | 4.3 (3,6,4.7) | 4.4 (3,7,4.8) | 4.5 (3,8,5.0) | 4.4 (3,8,4.9) |
| Country | Method | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|--------|----------|--------------|------|------|------|------|------|
|         |        | Max      |              |      |      |      |      |      |
| 2b      |        | 9.1 (8.0,10.4) | 9.9 (8.7,11.3) | 8.6 (7.5,9.8) | 9.1 (8.0,10.4) | 9.2 (8.0,10.5) | 8.7 (7.6,9.9) |
|         |        | Min      |              |      |      |      |      |      |
| 3       |        | 4.1 (3.3,4.9) | 4.5 (3.6,5.3) | 3.9 (3.1,4.6) | 4.0 (3.2,4.8) | 4.1 (3.3,4.9) | 4.1 (3.3,4.9) |
|         |        | Max      |              |      |      |      |      |      |

Within each method, the table shows the widest variability observed. This means the minimum adjusted and the maximum crude estimates. The participating centre in Norway could not retrieve incident cases for 2014, and thus incidence could not be estimated for that year. In Portugal, only one of the participating centres reported an extended population, and only for 2018. Plus, incident cases for 2018 could not be retrieved in this centre, so minimum adjusted incidence estimates could not be obtained for Portugal. Instead, the table shows the nearest estimates (maximum adjusted) as minimum values. Values highlighted in bold are the lowest and highest obtained in the sensitivity analyses (as a whole) per country and time period.

Abbreviations: CI, confidence interval; NA, not available; PF-ILD, interstitial lung disease.
| Country | Method | Estimate | Study period | 2014  | 2015  | 2016  | 2017  | 2018  |
|---------|--------|----------|--------------|-------|-------|-------|-------|-------|
|         |        |          |              |       |       |       |       |       |
| Belgium | 1      | Min      | 16.7 (15.0,20.4) | 13.5 (12.0,16.7) | 15.7 (14.0,19.2) | 17.2 (15.4,21.0) | 18.2 (16.3,22.1) | 19.5 (17.5,23.5) |
|         | Max    | 65.3 (59.3,71.3) | 52.4 (47.2,57.6) | 56.2 (51.0,61.5) | 70.1 (63.7,76.5) | 73.8 (67.2,80.5) | 78.0 (71.2,84.8) |
|         | 1b     | Min      | 18.5 (16.7,20.4) | 15.1 (13.5,16.7) | 17.4 (15.7,19.2) | 19.1 (17.2,21.0) | 20.1 (18.1,22.1) | 21.5 (19.4,23.5) |
|         | Max    | 64.6 (58.7,70.6) | 52.4 (47.3,57.6) | 56.4 (51.1,61.7) | 69.0 (62.7,75.3) | 72.3 (65.8,78.9) | 76.4 (69.7,83.2) |
|         | 2      | Min      | 15.6 (13.9,17.3) | 12.6 (11.1,14.1) | 14.6 (13.0,16.3) | 16.0 (14.3,17.8) | 17.0 (15.2,18.8) | 18.2 (16.3,20.1) |
|         | Max    | 60.9 (55.1,66.7) | 48.9 (43.9,53.8) | 52.4 (47.3,57.5) | 65.4 (59.2,71.5) | 68.8 (62.4,75.3) | 72.7 (66.2,79.3) |
|         | 2b     | Min      | 17.7 (15.8,20.4) | 14.4 (12.8,16.7) | 16.6 (14.9,19.2) | 18.2 (16.3,21.0) | 19.1 (17.2,22.1) | 20.4 (18.4,23.5) |
|         | Max    | 60.8 (55.0,66.6) | 49.3 (44.3,54.3) | 53.1 (48.0,58.2) | 64.9 (58.7,71.0) | 68.0 (61.6,74.3) | 71.8 (65.3,78.3) |
|         | 3      | Min      | 17.7 (15.8,19.5) | 14.3 (12.7,15.9) | 16.6 (14.8,18.3) | 18.2 (16.3,20.0) | 19.2 (17.3,21.2) | 20.6 (18.5,22.6) |
|         | Max    | 69.0 (62.8,75.1) | 55.3 (50.0,60.6) | 59.4 (53.9,64.8) | 74.0 (67.5,80.5) | 77.9 (71.1,84.8) | 82.3 (75.3,89.3) |
| Denmark | 1      | Min      | 25.3 (NE)     | 25.2 (NE)     | 27.1 (NE)     | 24.5 (NE)     | 23.2 (NE)     | 26.5 (NE)     |
|         | Max    | 40.4 (38.6,42.3) | 39.9 (38.1,41.8) | 43.3 (41.4,45.2) | 39.3 (37.4,41.1) | 37.1 (35.4,38.9) | 42.6 (40.7,44.5) |
|         | 1b     | Min      | 25.3 (NE)     | 25.2 (NE)     | 27.1 (NE)     | 24.5 (NE)     | 23.1 (NE)     | 26.4 (NE)     |
|         | Max    | 40.4 (38.6,42.3) | 39.9 (38.0,41.7) | 43.3 (41.4,45.2) | 39.2 (37.4,41.1) | 37.1 (35.3,38.9) | 42.6 (40.7,44.5) |
|         | 2      | Min      | 38.7 (NE)     | 38.6 (NE)     | 41.6 (NE)     | 37.6 (NE)     | 35.5 (NE)     | 40.5 (NE)     |
|         | Max    | 62.0 (59.7,64.3) | 61.1 (58.8,63.4) | 66.4 (64.0,68.7) | 60.2 (57.9,62.4) | 56.9 (54.7,59.0) | 65.3 (63.0,67.6) |
|         | 2b     | Min      | 35.1 (NE)     | 35.0 (NE)     | 37.7 (NE)     | 34.0 (NE)     | 32.2 (NE)     | 36.8 (NE)     |
|         | Max    | 56.2 (54.0,58.4) | 55.4 (53.2,57.6) | 60.1 (57.9,62.4) | 54.5 (52.4,56.7) | 51.6 (49.5,53.7) | 59.3 (57.0,61.5) |
|         | 3      | Min      | 29.2 (27.7,30.8) | 28.8 (27.3,30.4) | 31.3 (29.7,32.9) | 28.4 (26.8,29.9) | 26.8 (25.3,28.3) | 30.8 (29.2,32.4) |
|         | Max    | 40.3 (38.5,42.2) | 39.8 (37.9,41.6) | 43.2 (41.3,45.1) | 39.2 (37.3,41.0) | 37.0 (35.2,38.8) | 42.5 (40.6,44.4) |
| Country | Method | Estimate | Study period | 2014        | 2015        | 2016        | 2017        | 2018        |
|---------|--------|----------|--------------|-------------|-------------|-------------|-------------|-------------|
| Finland | 1      | Max      |              | 37.6 (31.5,43.7) | 39.7 (33.4,46.0) | 36.3 (30.4,42.3) | 35.6 (29.7,41.5) | 36.5 (30.6,42.5) | 39.8 (33.5,46.0) |
|         |        | Min      |              | 18.1 (13.9,22.4) | 19.2 (14.8,23.5) | 17.5 (13.4,21.7) | 17.2 (13.1,21.3) | 17.6 (13.5,21.8) | 19.2 (14.9,23.5) |
|         |        | Max      |              | 37.0 (31.0,43.0) | 39.1 (32.9,45.3) | 35.8 (29.8,41.7) | 35.1 (29.2,40.9) | 36.0 (30.0,41.9) | 39.1 (33.0,45.3) |
|         | 1b     | Min      |              | 25.4 (20.4,30.4) | 26.8 (21.6,32.0) | 24.5 (19.6,29.5) | 24.0 (19.2,28.9) | 24.7 (19.8,29.6) | 26.8 (21.7,31.9) |
|         |        | Max      |              | 51.8 (44.7,58.9) | 54.7 (47.3,62.1) | 50.1 (43.0,57.1) | 49.0 (42.1,56.0) | 50.3 (43.3,57.3) | 54.8 (47.5,62.1) |
|         | 2      | Min      |              | 24.5 (19.6,22.4) | 25.9 (20.8,23.5) | 23.7 (18.8,21.7) | 23.2 (18.4,21.3) | 23.8 (19.0,21.8) | 25.9 (20.9,23.5) |
|         |        | Max      |              | 50.0 (43.0,57.0) | 52.8 (45.5,60.0) | 48.3 (41.4,55.2) | 47.3 (40.5,54.1) | 48.6 (41.7,55.4) | 52.8 (45.7,60.0) |
|         | 2b     | Min      |              | 15.3 (11.4,19.1) | 16.1 (12.1,20.1) | 14.8 (10.9,18.6) | 14.5 (10.7,18.2) | 14.8 (11.0,18.6) | 16.1 (12.2,20.1) |
|         |        | Max      |              | 31.1 (25.6,36.7) | 32.9 (27.2,38.6) | 30.1 (24.7,35.6) | 29.5 (24.1,34.9) | 30.3 (24.8,35.7) | 32.9 (27.3,38.6) |
| Greece  | 1      | Min      |              | 5.4 (4.0,15.2)  | 4.3 (3.1,11.7)  | 4.2 (3.0,14.1)  | 5.3 (4.0,15.7)  | 6.2 (4.8,16.7)  | 6.9 (5.4,17.7)  |
|         |        | Max      |              | 21.5 (17.5,25.4) | 17.3 (13.7,20.8) | 16.1 (12.7,19.6) | 21.1 (17.2,25.0) | 25.5 (21.2,29.9) | 27.4 (22.9,31.9) |
|         | 1b     | Min      |              | 13.1 (11.1,15.2) | 9.9 (8.2,11.7)  | 12.1 (10.1,14.1) | 13.6 (11.5,15.7) | 14.5 (12.4,16.7) | 15.5 (13.2,17.7) |
|         |        | Max      |              | 50.7 (44.6,56.7) | 41.5 (36.1,47.0) | 46.1 (40.3,51.9) | 53.1 (46.8,59.3) | 58.0 (51.5,64.5) | 56.4 (49.9,62.8) |
|         | 2      | Min      |              | 6.1 (4.7,7.5)  | 4.8 (3.6,6.1)  | 4.7 (3.5,6.0)  | 6.0 (4.6,7.4)  | 7.0 (5.5,8.5)  | 7.9 (6.3,9.5)  |
|         |        | Max      |              | 24.4 (20.2,28.6) | 19.6 (15.8,23.4) | 18.3 (14.7,22.0) | 24.0 (19.8,28.2) | 29.0 (24.4,33.6) | 31.1 (26.3,35.9) |
|         | 2b     | Min      |              | 14.8 (12.6,15.2) | 11.2 (9.3,11.7) | 13.7 (11.6,14.1) | 15.4 (13.2,15.7) | 16.4 (14.1,16.7) | 17.5 (15.1,17.7) |
|         |        | Max      |              | 57.3 (50.8,63.8) | 47.1 (41.2,52.9) | 52.2 (46.0,58.4) | 60.1 (53.4,66.7) | 65.6 (58.7,72.5) | 63.7 (56.9,70.6) |
|         | 3      | Min      |              | 4.2 (3.0,5.4)  | 3.3 (2.3,4.4)  | 3.3 (2.3,4.3)  | 4.1 (3.0,5.3)  | 4.8 (3.6,6.1)  | 5.5 (4.1,6.8)  |
|         |        | Max      |              | 16.9 (13.4,20.4) | 13.6 (10.4,16.7) | 12.7 (9.6,15.7) | 16.6 (13.1,21.0) | 20.0 (16.2,23.9) | 21.5 (17.5,25.5) |
| Norway  | 1      | Min      |              | 13.1 (11.7,14.2) | 11.0 (9.7,12.1) | 11.7 (10.4,12.8) | 13.8 (12.4,15.0) | 15.3 (13.8,16.5) | 13.4 (12.1,14.6) |
|         |        | Max      |              | 33.3 (30.4,36.3) | 27.5 (24.8,30.3) | 29.9 (27.0,32.8) | 35.7 (32.7,38.8) | 40.3 (37.0,43.5) | 32.7 (30.0,35.5) |
|         | 1b     | Min      |              | 12.9 (11.6,14.2) | 10.8 (9.6,12.1) | 11.6 (10.3,12.8) | 13.6 (12.2,15.0) | 15.1 (13.7,16.5) | 13.3 (12.0,14.6) |
|         |        | Max      |              | 33.1 (30.2,36.1) | 27.4 (24.6,30.1) | 29.7 (26.9,32.6) | 35.5 (32.4,38.6) | 40.0 (36.8,43.3) | 32.6 (29.8,35.3) |
| Country | Method | Estimate | Study period | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------|--------|----------|--------------|------|------|------|------|------|
| 2       | Min    | 15.1 (13.7,16.6) | 12.7 (11.3,14.0) | 13.5 (12.1,14.9) | 15.9 (14.4,17.4) | 17.6 (16.1,19.2) | 15.5 (14.1,16.9) |
|         | Max    | 38.5 (35.4,41.7) | 31.9 (28.9,34.8) | 34.6 (31.5,37.7) | 41.3 (38.0,44.7) | 46.6 (43.1,50.1) | 37.9 (34.9,40.9) |
|         |        | 13.6 (12.3,14.2) | 11.4 (10.1,12.1) | 12.2 (10.8,12.8) | 14.3 (12.9,15.0) | 15.8 (14.3,16.5) | 14.2 (12.8,14.6) |
|         |        | 36.5 (33.5,39.6) | 30.2 (27.3,33.1) | 32.8 (29.8,35.8) | 39.1 (35.9,42.4) | 44.1 (40.7,47.5) | 36.1 (33.2,39.0) |
| 2b      | Min    | 12.8 (11.5,14.2) | 10.8 (9.5,12.0)  | 11.5 (10.2,12.8) | 13.5 (12.1,14.9) | 15.0 (13.6,16.4) | 13.2 (11.9,14.5) |
|         | Max    | 32.7 (29.8,35.6) | 27.0 (24.3,29.8) | 29.4 (26.5,32.2) | 35.1 (32.0,38.2) | 39.6 (36.3,42.8) | 32.1 (29.4,34.9) |
| 3       | Min    | 12.8 (11.5,14.2) | 10.8 (9.5,12.0)  | 11.5 (10.2,12.8) | 13.5 (12.1,14.9) | 15.0 (13.6,16.4) | 13.2 (11.9,14.5) |
|         | Max    | 32.7 (29.8,35.6) | 27.0 (24.3,29.8) | 29.4 (26.5,32.2) | 35.1 (32.0,38.2) | 39.6 (36.3,42.8) | 32.1 (29.4,34.9) |
| Portugal| 1      | Min    | 6.7 (5.3,10.3)  | NA              | NA              | NA              | NA              | 9.1 (7.4,10.3)  |
|         | Max    | 11.3 (9.2,13.4) | 7.0 (5.4,8.6)   | 9.4 (7.5,11.2)  | 10.5 (8.6,12.5) | 12.1 (10.0,14.2) | 19.7 (16.6,22.8) |
| 1b      | Min    | 8.6 (7.0,10.3)  | NA              | NA              | NA              | NA              | 8.6 (7.0,10.3)  | |
|         | Max    | 33.3 (29.7,36.9) | 10.6 (8.6,12.6) | 13.9 (11.6,16.1) | 14.7 (12.4,17.0) | 16.5 (14.0,18.9) | 34.5 (30.3,38.6) |
| 2       | Min    | 6.2 (4.8,7.6)  | NA              | NA              | NA              | NA              | 8.3 (6.7,10.0)  |     |
|         | Max    | 10.4 (8.4,12.3) | 6.4 (4.9,8.0)  | 8.6 (6.8,10.3)  | 9.6 (7.8,11.5)  | 11.1 (9.1,13.1) | 18.1 (15.1,21.1) |
| 2b      | Min    | 7.9 (6.3,10.3)  | NA              | NA              | NA              | NA              | 7.9 (6.3,10.3)  |     |
|         | Max    | 30.9 (27.4,34.3) | 9.9 (8.0,11.8)  | 13.0 (10.8,15.2) | 13.8 (11.6,16.1) | 15.5 (13.1,17.9) | 32.0 (28.0,36.0) |
| 3       | Min    | 8.4 (6.8,10.0)  | NA              | NA              | NA              | NA              | 11.3 (9.4,13.2) |     |
|         | Max    | 14.1 (11.7,16.4) | 8.7 (7.0,10.5)  | 11.7 (9.6,13.7) | 13.1 (10.9,15.3) | 15.1 (12.7,17.4) | 24.5 (21.0,28.0) |
| Overall | 1      | Min    | 14.5 (12.5,18.2) | 13.4 (11.5,16.8) | 14.0 (12.1,17.9) | 14.3 (12.4,18.3) | 14.9 (12.9,18.9) | 15.8 (13.8,19.3) |
|         | Max    | 35.1 (32.0,38.2) | 30.6 (27.8,33.5) | 31.9 (29.0,34.8) | 35.4 (32.3,38.5) | 37.6 (34.4,40.7) | 40.0 (36.8,43.3) |
| 1b      | Min    | 16.1 (14.1,18.2) | 14.8 (12.8,16.8) | 15.8 (13.8,17.9) | 16.2 (14.1,18.3) | 16.8 (14.7,18.9) | 17.2 (15.0,19.3) |
|         | Max    | 40.8 (37.5,44.1) | 35.2 (32.1,38.2) | 37.5 (34.4,40.7) | 41.1 (37.8,44.4) | 43.3 (39.9,46.7) | 46.9 (43.4,50.5) |
| 2       | Min    | 18.3 (16.1,20.5) | 17.3 (15.1,19.5) | 17.9 (15.7,20.1) | 18.0 (15.8,20.2) | 18.5 (16.3,20.8) | 19.8 (17.5,22.2) |
|         | Max    | 41.5 (38.2,44.8) | 37.1 (33.9,40.3) | 38.4 (35.2,41.6) | 41.6 (38.3,44.9) | 43.8 (40.4,47.2) | 46.6 (43.1,50.2) |
|         | Min    | 19.2 (17.0,18.2) | 17.9 (15.7,16.8) | 18.9 (16.7,17.9) | 19.2 (16.9,18.3) | 19.7 (17.4,18.9) | 20.5 (18.1,19.3) |
| Country | Method | Estimate   | Study period | 2014         | 2015         | 2016         | 2017         | 2018         |
|---------|--------|------------|--------------|--------------|--------------|--------------|--------------|--------------|
| 2b      | Max    | 46.4 (42.9,50.0) | 40.8 (37.5,44.1) | 43.3 (39.9,46.7) | 46.6 (43.1,50.2) | 48.9 (45.3,52.5) | 52.6 (48.9,56.4) |
| 3       | Min    | 14.0 (12.4,15.6) | 12.8 (11.2,14.3) | 13.5 (11.9,15.1) | 13.9 (12.2,15.5) | 14.5 (12.8,16.1) | 15.3 (13.6,17.0) |
|         | Max    | 34.2 (31.2,37.3) | 29.6 (26.7,32.4) | 31.1 (28.2,33.9) | 34.6 (31.5,37.6) | 36.6 (33.5,39.8) | 39.3 (36.1,42.6) |

Within each method, the table shows the widest variability observed (minimum adjusted, maximum crude). In Portugal, only one of the participating centres reported an extended population, and only for 2018. Therefore, minimum prevalence estimates could only be obtained for that year. Values highlighted in bold are the lowest and highest obtained in the sensitivity analyses (as a whole) per country and time period.

Abbreviations: CI, confidence interval; NA, not available; NE, not estimable; PF-ILDs, progressive-fibrosing interstitial lung diseases.
References

1. European Commission. Eurostat [Internet]. 2019 [cited 2019 Oct 4]. Available from: https://ec.europa.eu/eurostat/web/population-demography-migration-projections/data/database.

2. Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central Denmark. *Respir Med* 2014; 108: 793–799.

3. Statistics Norway. 04859: Area and population of urban settlements (US) 2000 - 2019 [Internet]. [cited 2020 Sep 17]. Available from: https://www.ssb.no/en/statbank/table/04859/.

4. Statbel. Structure de la population [Internet]. 2019 [cited 2019 Feb 17]. Available from: https://statbel.fgov.be/fr/themes/population/structure-de-la-population.

5. Le Portail des Statistiques Grand-Duché de Luxemburg. Population structure [Internet]. 2020 [cited 2020 Nov 5]. Available from: https://statistiques.public.lu/stat/ReportFolders/ReportFolder.aspx?IF_Language=eng&M ainTheme=2&FldrName=1.